<?xml version='1.0' encoding='UTF-8'?>
<?xml-stylesheet type="text/xsl" href="static/xsl/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-08-02T10:56:19Z</responseDate>
  <request verb="ListRecords" metadataPrefix="oai_dc">https://sonar.ch/oai2d</request>
  <ListRecords>
    <record>
      <header>
        <identifier>oai:sonar.ch:6398</identifier>
        <datestamp>2025-10-24T20:20:26Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Oevermann A</dc:creator>
          <dc:creator>Zurbriggen A</dc:creator>
          <dc:creator>Vandevelde M</dc:creator>
          <dc:date>2010</dc:date>
          <dc:description xml:lang="en">Listeriosis is an emerging zoonotic infection of humans and ruminants worldwide caused by Listeria monocytogenes (LM). In both host species, CNS disease accounts for the high mortality associated with listeriosis and includes rhombencephalitis, whose neuropathology is strikingly similar in humans and ruminants. This review discusses the current knowledge about listeric encephalitis, and involved host and bacterial factors. There is an urgent need to study the molecular mechanisms of neuropathogenesis, which are poorly understood. Such studies will provide a basis for the development of new therapeutic strategies that aim to prevent LM from invading the brain and spread within the CNS.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/6398</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1155/2010/632513</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/20204066</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Interdisciplinary perspectives on infectious diseases. - 2010</dc:source>
          <dc:subject xml:lang="en">Microbiology (medical)</dc:subject>
          <dc:subject xml:lang="en">Microbiology</dc:subject>
          <dc:subject xml:lang="en">Parasitology</dc:subject>
          <dc:subject xml:lang="en">Virology</dc:subject>
          <dc:subject xml:lang="en">Infectious Diseases</dc:subject>
          <dc:title xml:lang="en">Rhombencephalitis Caused by Listeria monocytogenes in Humans and Ruminants: A Zoonosis on the Rise?</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:7092</identifier>
        <datestamp>2025-10-24T20:23:31Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Cimino PJ</dc:creator>
          <dc:creator>Huang L</dc:creator>
          <dc:creator>Du L</dc:creator>
          <dc:creator>Wu Y</dc:creator>
          <dc:creator>Bishop J</dc:creator>
          <dc:creator>Dalsing-Hernandez J</dc:creator>
          <dc:creator>Kotlarczyk K</dc:creator>
          <dc:creator>Gonzales P</dc:creator>
          <dc:creator>Carew J</dc:creator>
          <dc:creator>Nawrocki S</dc:creator>
          <dc:creator>Jordan MA</dc:creator>
          <dc:creator>Wilson L</dc:creator>
          <dc:creator>Lloyd GK</dc:creator>
          <dc:creator>Wirsching HG</dc:creator>
          <dc:date>2019</dc:date>
          <dc:description xml:lang="en">Constitutive activation of Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most common oncogenic event in certain types of human cancer and is associated with poor patient survival. Small molecule signaling inhibitors have improved the clinical outcomes of patients with various cancer types but attempts to target KRAS have been unsuccessful. Plinabulin represents a novel class of agents that inhibit tubulin polymerization with a favorable safety profile in clinical trials. In the present study, the potency of plinabulin to inhibit tubulin polymerization and growth of KRAS-driven cancer cells was characterized. In vivo efficacy of plinabulin was tested in two different mouse models; one being the RCAS/t-va gene transfer system and the other being a xenograft model. In vitro cell culture tubulin polymerization assays were used to complement the mouse models. There was improved survival in a KRAS-driven mouse gene transfer glioma model, but lack of benefit in a similar model, without constitutively active KRAS, which supports the notion of a KRAS-specific effect. This survival benefit was mediated, at least in part, by the ability of plinabulin to inhibit tubulin polymerization and disrupt endosomal recycling. It was proposed a mechanism of compromised endosomal recycling of displaced KRAS through targeting microtubules that yields inhibition of protein kinase B, but not extracellular signal regulated kinase (ERK) signaling, therefore lending rationale to combination treatments of tubulin- and ERK-targeting agents in KRAS-driven cancer.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/7092</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.3892/br.2019.1196</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/30972217</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Biomedical reports. - 2019</dc:source>
          <dc:subject xml:lang="en">Kirsten rat sarcoma viral oncogene homolog</dc:subject>
          <dc:subject xml:lang="en">Plinabulin</dc:subject>
          <dc:subject xml:lang="en">cancer</dc:subject>
          <dc:subject xml:lang="en">endosome</dc:subject>
          <dc:subject xml:lang="en">tubulin</dc:subject>
          <dc:title xml:lang="en">Plinabulin, an inhibitor of tubulin polymerization, targets KRAS signaling through disruption of endosomal recycling.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:7147</identifier>
        <datestamp>2025-10-24T20:23:34Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Moerman F</dc:creator>
          <dc:creator>Fronhofer EA</dc:creator>
          <dc:creator>Wagner A</dc:creator>
          <dc:creator>Altermatt F</dc:creator>
          <dc:date>2020</dc:date>
          <dc:description xml:lang="en">At species' range edges, individuals often face novel environmental conditions that may limit range expansion until populations adapt. The potential to adapt depends on genetic variation upon which selection can act. However, populations at species' range edges are often genetically depauperate. One mechanism increasing genetic variation is reshuffling existing variation through sex. Sex, however, can potentially limit adaptation by breaking up existing beneficial allele combinations (recombination load). The gene swamping hypothesis predicts this is specifically the case when populations expand along an abiotic gradient and asymmetric dispersal leads to numerous maladapted dispersers from the range core swamping the range edge. We used the ciliate Tetrahymena thermophila as a model for testing the gene swamping hypothesis. We performed replicated range expansions in landscapes with or without a pH-gradient, while simultaneously manipulating the occurrence of gene flow and sexual versus asexual reproduction. We show that sex accelerated evolution of local adaptation in the absence of gene flow, but hindered it in the presence of gene flow. However, sex affected adaptation independently of the pH-gradient, indicating that both abiotic gradients and the biotic gradient in population density lead to gene swamping. Overall, our results show that gene swamping alters adaptation in life-history strategies.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/7147</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1098/rsbl.2020.0244</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/32544380</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Biology letters. - 2020</dc:source>
          <dc:subject xml:lang="en">gene flow</dc:subject>
          <dc:subject xml:lang="en">gene swamping</dc:subject>
          <dc:subject xml:lang="en">pH gradient</dc:subject>
          <dc:subject xml:lang="en">range expansion</dc:subject>
          <dc:subject xml:lang="en">sex</dc:subject>
          <dc:subject xml:lang="en">Adaptation, Physiological</dc:subject>
          <dc:subject xml:lang="en">Gene Flow</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Population Density</dc:subject>
          <dc:subject xml:lang="en">Reproduction, Asexual</dc:subject>
          <dc:subject xml:lang="en">Tetrahymena thermophila</dc:subject>
          <dc:title xml:lang="en">Gene swamping alters evolution during range expansions in the protist Tetrahymena thermophila.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:7029</identifier>
        <datestamp>2025-10-24T20:23:39Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Meyer, André N.</dc:creator>
          <dc:date>2018</dc:date>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/7029</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1145/3183440.3183446</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Proceedings of the 40th International Conference on Software Engineering: Companion Proceeedings. - ACM. - 2018</dc:source>
          <dc:title xml:lang="en">Fostering software developers' productivity at work through self-monitoring and goal-setting</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:7013</identifier>
        <datestamp>2025-10-24T20:23:25Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Latshang TD</dc:creator>
          <dc:creator>Tardent RPM</dc:creator>
          <dc:creator>Furian M</dc:creator>
          <dc:creator>Flueck D</dc:creator>
          <dc:creator>Segitz SD</dc:creator>
          <dc:creator>Mueller-Mottet S</dc:creator>
          <dc:creator>Kohler M</dc:creator>
          <dc:creator>Ulrich S</dc:creator>
          <dc:creator>Bloch KE</dc:creator>
          <dc:date>2019</dc:date>
          <dc:description xml:lang="en">Study Objectives
Patients with chronic obstructive pulmonary disease (COPD) have impaired pulmonary gas exchange near sea level. The purpose of the current study was to investigate whether exposure to hypobaric hypoxia during a stay at altitude affects nocturnal oxygen saturation, breathing pattern, and sleep in patients with moderate to severe COPD.


Methods
Thirty-two patients with COPD, median age 67 years, FEV1 59% predicted, PaO2 68 mmHg, living below 800 m, underwent polysomnography and questionnaire evaluations in Zurich (490 m), and in Swiss Alpine villages at 1650 and 2590 m, for two nights each, in random order. Mean nocturnal oxygen saturation (SpO2), the apnea-hypopnea index (AHI), and sleep structure were compared between altitudes.


Results
Polysomnography during the first night at each altitude revealed a reduced SpO2 at 1650 and 2590 m (medians 89% and 85%) compared with 490 m (92%, p &lt;0.05 vs. higher altitudes) and a higher AHI (medians 26.8/hr and 55.7/hr) vs. 490 m (15.4/hr, p &lt;0.05 vs. higher altitudes) due to emergence of frequent central apneas/hypopneas. At 2590 m, sleep efficiency (median 59%) and slow-wave sleep (median 17% of total sleep time) were reduced compared with 490 m (72% and 20%, respectively, p &lt;0.05). In the morning after one night at 2590 m, patients estimated to have spent more time awake (median 110 min) than at 490 m (43 min, p &lt;0.05) and felt slightly less alert.


Conclusions
During a stay at moderate altitude, lowlanders with moderate to severe COPD experience nocturnal hypoxemia that induces central sleep apneas, altered sleep structure, and insomnia. These novel findings help us to counsel patients with COPD planning altitude travel.


Trial Registration
ClinicalTrials.gov: NCT01870830.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/7013</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1093/sleep/zsy203</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/30517695</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Sleep. - 2019</dc:source>
          <dc:subject xml:lang="en">Aged</dc:subject>
          <dc:subject xml:lang="en">Altitude</dc:subject>
          <dc:subject xml:lang="en">Cross-Over Studies</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Hypoxia</dc:subject>
          <dc:subject xml:lang="en">Lung</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Polysomnography</dc:subject>
          <dc:subject xml:lang="en">Pulmonary Disease, Chronic Obstructive</dc:subject>
          <dc:subject xml:lang="en">Pulmonary Gas Exchange</dc:subject>
          <dc:subject xml:lang="en">Respiration</dc:subject>
          <dc:subject xml:lang="en">Sleep</dc:subject>
          <dc:subject xml:lang="en">Sleep Apnea, Obstructive</dc:subject>
          <dc:subject xml:lang="en">Surveys and Questionnaires</dc:subject>
          <dc:subject xml:lang="en">Travel</dc:subject>
          <dc:title xml:lang="en">Sleep and breathing disturbances in patients with chronic obstructive pulmonary disease traveling to altitude: a randomized trial.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:7155</identifier>
        <datestamp>2025-10-24T20:23:35Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Moser, R</dc:creator>
          <dc:creator>Fehr, J</dc:creator>
          <dc:creator>Olgiati, L</dc:creator>
          <dc:creator>Bruijnzeel, PL</dc:creator>
          <dc:description xml:lang="en">&lt;jats:title&gt;Abstract&lt;/jats:title&gt;
               &lt;jats:p&gt;Eosinophils are known to adhere to cytokine-activated endothelium. Whereas transendothelial migration for neutrophils is an inevitable consequence of this endothelial-dependent adherence, this has not yet been shown for eosinophils. By means of human umbilical vein endothelial cells (HUVE) grown to confluence on microporous filters as an in vitro model of leukocytic migration across postcapillary venules, we have characterized the conditions leading to endothelium-driven transmigration of blood eosinophils from normals and from patients with allergic asthma. Freshly isolated eosinophils from nonallergic donors adhered to interleukin-1 (IL-1) and tumor necrosis factor-activated HUVE, but did not penetrate these monolayers. In contrast, eosinophils from allergic asthma patients showed an increased adherence and transmigration capacity. This increased functional competence was not caused by a difference in density phenotype, because the eosinophils from both groups showed a comparable density distribution over discontinuous Percoll gradients. Moreover, no difference existed within one group among eosinophils harvested from the Percoll density bands 1.080, 1.085, and 1.090 g/mL in terms of transendothelial migration. In vitro cultivation of freshly isolated eosinophils from nonallergic individuals in the presence of granulocyte-macrophage colony- stimulating factor (GM-CSF) and IL-3 induced a stepwise decrease of the density distribution over such gradients. In contrast, eosinophils from patients with allergic asthma directly shifted to a final density of 1.075 g/mL within 24 hours of culture. Notwithstanding the kinetics of density changes, eosinophils from nonallergic donors already expressed the capacity to transmigrate IL-1-activated HUVE monolayers 20 hours after cultivation with different combinations of GM-CSF, IL-3, and IL- 5. Inhibition studies with monoclonal antibodies showed that endothelium-driven transmigration of eosinophils predominantly implicates CD11/CD18 structures on the eosinophil surface, whereas no significant inhibition was found with the anti-VLA-4 monoclonal antibody HP2/1. From cytofluorometric studies, we conclude that spontaneous transmigration of eosinophils from allergic asthma patients is not accompanied by quantitative upregulation of these antigens. Taken together, these results allow the conclusion that blood eosinophils from allergic asthma patients have undergone in vivo priming, mimicked in vitro by cytokines such as GM-CSF, IL-3, and IL-5, leading to induction of the capacity to migrate across cytokine- activated HUVE monolayers.&lt;/jats:p&gt;</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/7155</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1182/blood.v79.11.2937.2937</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/issn/0006-4971</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Blood. - American Society of Hematology. - 1992, vol. 79, no. 11, p. 2937-2945</dc:source>
          <dc:subject xml:lang="en">Immunology</dc:subject>
          <dc:subject xml:lang="en">Cell Biology</dc:subject>
          <dc:subject xml:lang="en">Biochemistry</dc:subject>
          <dc:subject xml:lang="en">Hematology</dc:subject>
          <dc:title xml:lang="en">Migration of primed human eosinophils across cytokine-activated endothelial cell monolayers</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:7022</identifier>
        <datestamp>2025-10-24T20:23:38Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Caserza, Lara</dc:creator>
          <dc:creator>Casula, Matteo</dc:creator>
          <dc:creator>Elia, Edorado</dc:creator>
          <dc:creator>Bonaventura, Aldo</dc:creator>
          <dc:creator>Liberale, Luca</dc:creator>
          <dc:creator>Bertolotto, Maria</dc:creator>
          <dc:creator>Artom, Nathan</dc:creator>
          <dc:creator>Minetti, Silvia</dc:creator>
          <dc:creator>Contini, Paola</dc:creator>
          <dc:creator>Verzola, Daniela</dc:creator>
          <dc:creator>Pontremoli, Roberto</dc:creator>
          <dc:creator>Viazzi, Franesca</dc:creator>
          <dc:creator>Viviani, Giorgio L.</dc:creator>
          <dc:creator>Bertolini, Stefano</dc:creator>
          <dc:creator>Pende, Aldo</dc:creator>
          <dc:creator>Pisciotta, Livia</dc:creator>
          <dc:creator>Montecucco, Fabrizio</dc:creator>
          <dc:creator>Carbone, Federico</dc:creator>
          <dc:date>2020</dc:date>
          <dc:identifier>https://sonar.ch/global/documents/7022</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1111/eci.13403</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/issn/0014-2972</dc:relation>
          <dc:source>European Journal of Clinical Investigation. - Wiley. - 2020</dc:source>
          <dc:subject xml:lang="en">Clinical Biochemistry</dc:subject>
          <dc:subject xml:lang="en">Biochemistry</dc:subject>
          <dc:subject xml:lang="en">General Medicine</dc:subject>
          <dc:title xml:lang="en">Serum osteopontin predicts glycaemic profile improvement in metabolic syndrome: A pilot study</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:7088</identifier>
        <datestamp>2025-10-24T20:23:31Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Naef R</dc:creator>
          <dc:creator>Peng-Keller S</dc:creator>
          <dc:creator>Rettke H</dc:creator>
          <dc:creator>Rufer M</dc:creator>
          <dc:creator>Petry H</dc:creator>
          <dc:date>2020</dc:date>
          <dc:description xml:lang="en">BACKGROUND
An in-hospital death is a profound experience for those left behind and has been associated with family members' psychological morbidity. Supporting bereaved family members is an essential part of end-of-life care and includes attentive presence, information-giving, and emotional and practical support. The actual adoption of hospital-based bereavement care, however, remains little understood.


AIM
To investigate hospital-based bereavement care provision and associated barriers.


DESIGN
Cross-sectional survey using an online questionnaire.


SETTING/PARTICIPANTS
Health professionals (n = 196) from two University-affiliated acute and psychiatric hospitals in Switzerland.


RESULTS
The most frequent bereavement services (⩾40%) were viewing the deceased, giving information on available support, and making referrals; the most often named barriers were lack of time and organizational support. Acute care health professionals faced statistically significant more structural barriers (55.1% vs 21.4% lack of time, 47.8% vs 25.9% lack of organizational support) and felt insufficiently trained (38.4% vs 20.7%) compared to mental health professionals (p ⩽ 0.05). Nurses provided more immediate services compared to physicians, such as viewing the deceased (71.3% vs 49.0%) and sending sympathy cards (37.4% vs 16.3%) (p ⩽ 0.01). In contrast, physicians screened more often for complex bereavement disorders (10.2% vs 2.6%) and appraised bereavement care as beyond their role (26.5% vs 7.8%) (p ⩽ 0.05).


CONCLUSION
The study indicates that many barriers to bereavement care exist in hospitals. More research is required to better understand enabling and limiting factors to bereavement care provision. A guideline-driven approach to hospital-based bereavement care that defines best practice and required organizational support seems necessary to ensure needs-based bereavement care.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/7088</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1177/0269216319891070</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/31868555</dc:relation>
          <dc:source>Palliative medicine. - 2020</dc:source>
          <dc:subject xml:lang="en">Bereavement care</dc:subject>
          <dc:subject xml:lang="en">delivery of health care</dc:subject>
          <dc:subject xml:lang="en">hospitals</dc:subject>
          <dc:subject xml:lang="en">professional–family relations</dc:subject>
          <dc:subject xml:lang="en">surveys and questionnaires</dc:subject>
          <dc:title xml:lang="en">Hospital-based bereavement care provision: A cross-sectional survey with health professionals.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:7151</identifier>
        <datestamp>2025-10-24T20:23:34Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Della Chiesa, S.</dc:creator>
          <dc:creator>Bertoldi, G.</dc:creator>
          <dc:creator>Niedrist, G.</dc:creator>
          <dc:creator>Obojes, N.</dc:creator>
          <dc:creator>Endrizzi, S.</dc:creator>
          <dc:creator>Albertson, J. D.</dc:creator>
          <dc:creator>Wohlfahrt, G.</dc:creator>
          <dc:creator>Hörtnagl, L.</dc:creator>
          <dc:creator>Tappeiner, U.</dc:creator>
          <dc:date>2014</dc:date>
          <dc:identifier>https://sonar.ch/global/documents/7151</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1002/eco.1471</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/issn/1936-0584</dc:relation>
          <dc:source>Ecohydrology. - Wiley. - 2014, vol. 7, no. 6, p. 1453-1473</dc:source>
          <dc:subject xml:lang="en">Earth-Surface Processes</dc:subject>
          <dc:subject xml:lang="en">Ecology</dc:subject>
          <dc:subject xml:lang="en">Aquatic Science</dc:subject>
          <dc:subject xml:lang="en">Ecology, Evolution, Behavior and Systematics</dc:subject>
          <dc:title xml:lang="en">Modelling changes in grassland hydrological cycling along an elevational gradient in the Alps</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:7032</identifier>
        <datestamp>2025-10-24T20:23:28Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Dorokhov, A.</dc:creator>
          <dc:creator>Glauser, A.</dc:creator>
          <dc:creator>Musienko, Y.</dc:creator>
          <dc:creator>Regenfus, C.</dc:creator>
          <dc:creator>Reucroft, S.</dc:creator>
          <dc:creator>Swain, J.</dc:creator>
          <dc:date>2009</dc:date>
          <dc:identifier>https://sonar.ch/global/documents/7032</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1080/09500340408235277</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/issn/0950-0340</dc:relation>
          <dc:source>Journal of Modern Optics. - Informa UK Limited. - 2004, vol. 51, no. 9-10, p. 1351-1357</dc:source>
          <dc:subject xml:lang="en">Atomic and Molecular Physics, and Optics</dc:subject>
          <dc:title xml:lang="en">Recent progress on cooled avalanche photodiodes for single photon detection</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:7543</identifier>
        <datestamp>2025-10-24T20:24:59Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Buxton, Meredith Becker</dc:creator>
          <dc:creator>Alexander, Brian Michael</dc:creator>
          <dc:creator>Berry, Donald A.</dc:creator>
          <dc:creator>Cavenee, Webster K.</dc:creator>
          <dc:creator>Colman, Howard</dc:creator>
          <dc:creator>De Groot, John Frederick</dc:creator>
          <dc:creator>Ellingson, Benjamin M.</dc:creator>
          <dc:creator>Gordon, Gary B.</dc:creator>
          <dc:creator>Khasraw, Mustafa</dc:creator>
          <dc:creator>Lassman, Andrew B.</dc:creator>
          <dc:creator>Li, Wenbin</dc:creator>
          <dc:creator>Lim, Michael</dc:creator>
          <dc:creator>Mellinghoff, Ingo K.</dc:creator>
          <dc:creator>Perry, James R.</dc:creator>
          <dc:creator>Sulman, Erik P.</dc:creator>
          <dc:creator>Tanner, Kirk</dc:creator>
          <dc:creator>Weller, Michael</dc:creator>
          <dc:creator>Wen, Patrick Y.</dc:creator>
          <dc:creator>Yung, W. K. Alfred</dc:creator>
          <dc:creator>Cloughesy, Timothy Francis</dc:creator>
          <dc:description xml:lang="en">&lt;jats:p&gt; TPS2579 &lt;/jats:p&gt;&lt;jats:p&gt; Background: Glioblastoma (GBM) is an aggressive brain tumor with few effective therapies and is invariably fatal. Developing new therapies for patients with GBM requires focused interaction between industry, academia, nonprofits, patient advocacy, and health authorities, and novel approaches to clinical trials. Industry is wary of developing drugs for GBM due to the high failure rate and high cost of drug development. GBM Adaptive Global Innovative Learning Environment (GBM AGILE) Trial was designed by over 130 global key opinion leaders in consultation with health authorities to provide an optimal mechanism for phase II/III development in GBM. The Sponsor of GBM AGILE is the Global Coalition for Adaptive Research (GCAR), a non-profit organization. GCAR’s mission is to speed the discovery and development of treatments for patients with rare and deadly diseases by serving as sponsor of innovative trials. Methods: GBM AGILE is an international, seamless phase II/III platform trial designed to evaluate multiple therapies in newly diagnosed and recurrent GBM. Its goals are to identify effective therapies for GBM and match effective therapies with patient subtypes, with data generated to support regulatory filing for new drug applications. Bayesian response adaptive randomization is used within subtypes of the disease to assign participants to investigational arms based on their performance. The primary endpoint is overall survival. The trial is being conducted under a master Investigational New Drug Application/Clinical Trial Agreement and Master Protocol, allowing multiple drugs/drug combinations from different pharmaceutical companies to be evaluated simultaneously and/or over time. The plan is to add experimental therapies as new information is identified and remove therapies as they complete their individual evaluation against a common control. GBM AGILE received IND approval from the FDA in April 2019, enrolling its first patient in June 2019. Site activation is ongoing in the US, with approximately 40 US planned. The trial received CTA approval from Health Canada in January 2020. Expansion to Europe, China, and Australia is also underway. Clinical trial information: NCT03970447 . &lt;/jats:p&gt;</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/7543</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1200/jco.2020.38.15_suppl.tps2579</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/issn/0732-183X</dc:relation>
          <dc:source>Journal of Clinical Oncology. - American Society of Clinical Oncology (ASCO). - 2020, vol. 38, no. 15_suppl, p. TPS2579-TPS2579</dc:source>
          <dc:subject xml:lang="en">Cancer Research</dc:subject>
          <dc:subject xml:lang="en">Oncology</dc:subject>
          <dc:title xml:lang="en">GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:7458</identifier>
        <datestamp>2025-10-24T20:24:56Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Zimmermann, M</dc:creator>
          <dc:creator>Valcanaia, A</dc:creator>
          <dc:creator>Neiva, G</dc:creator>
          <dc:creator>Mehl, A</dc:creator>
          <dc:creator>Fasbinder, D</dc:creator>
          <dc:description xml:lang="en">&lt;jats:title&gt;ABSTRACT&lt;/jats:title&gt;
               &lt;jats:sec&gt;
                  &lt;jats:title&gt;Objective:&lt;/jats:title&gt;
                  &lt;jats:p&gt;CAM fabrication is an important step within the CAD/CAM process. The internal fit of restorations is influenced by the accuracy of the subtractive CAM procedure. Little is known about how CAM strategies might influence the fit of CAD/CAM fabricated restorations. The aim of this study was to three-dimensionally evaluate the fit of CAD/CAM fabricated zirconia-reinforced lithium silicate ceramic partial crowns fabricated with three different CAM strategies. The null hypothesis was that different CAM strategies did not influence the fitting accuracy of CAD/CAM fabricated zirconia-reinforced lithium silicate ceramic partial crowns.&lt;/jats:p&gt;
               &lt;/jats:sec&gt;
               &lt;jats:sec&gt;
                  &lt;jats:title&gt;Methods and Materials:&lt;/jats:title&gt;
                  &lt;jats:p&gt;Preparation for a partial crown was performed on a maxillary right first molar on a typodont. A chairside CAD/CAM system with the intraoral scanning device CEREC Omnicam (Dentsply Sirona, York, PA, USA) and the 3+1 axis milling unit CEREC MCXL was used. There were three groups with different CAM strategies: step bur 12 (12), step bur 12S (12S), and two step-mode (12TWO). The zirconia-reinforced lithium silicate ceramic Celtra Duo (Dentsply Sirona) was used as the CAD/CAM material. A new 3D method for evaluating the fit was applied, consisting of the quadrant scan with the intraoral scanning device CEREC Omnicam. The scan of the PVS material adherent to the preparation and the preparation scan were matched, and the difference analysis was performed with special software OraCheck (Cyfex AG, Zurich, Switzerland). Three areas were selected for analysis: margin (MA), axial (AX), and occlusal (OC). Statistical analysis was performed using 80% percentile, one-way ANOVA, and the post hoc Scheffé test with α=0.05.&lt;/jats:p&gt;
               &lt;/jats:sec&gt;
               &lt;jats:sec&gt;
                  &lt;jats:title&gt;Results:&lt;/jats:title&gt;
                  &lt;jats:p&gt;Statistically significant differences were found both within and between the test groups. The aspect axial fit results varied from 90.5 ± 20.1 μm for the two-step milling mode (12TWO_AX) to 122.8 ± 12.2 μm for the milling with step bur 12S (12S_AX). The worst result in all groups was found for the aspect occlusal fit with the highest value for group 12S of 222.8 ± 35.6 μm. Group two-step milling mode (12TWO) performed statistically significantly better from groups 12 and 12S for the occlusal fit (p&amp;amp;lt;0.05). Deviation patterns were visually analyzed with a color-coded scheme for each restoration.&lt;/jats:p&gt;
               &lt;/jats:sec&gt;
               &lt;jats:sec&gt;
                  &lt;jats:title&gt;Conclusions:&lt;/jats:title&gt;
                  &lt;jats:p&gt;CAM strategy influenced the internal adaptation of zirconia-reinforced lithium silicate partial crowns fabricated with a chairside CAD/CAM system. Sensible selection of specific areas of internal adaptation and fit is an important factor for evaluating the CAM accuracy of CAD/CAM systems.&lt;/jats:p&gt;
               &lt;/jats:sec&gt;</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/7458</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.2341/17-130-l</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/issn/0361-7734</dc:relation>
          <dc:source>Operative Dentistry. - Operative Dentistry. - 2018, vol. 43, no. 5, p. 530-538</dc:source>
          <dc:subject xml:lang="en">General Dentistry</dc:subject>
          <dc:title xml:lang="en">Influence of Different CAM Strategies on the Fit of Partial Crown Restorations: A Digital Three-dimensional Evaluation</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:7383</identifier>
        <datestamp>2025-10-24T20:25:08Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Frossard CP</dc:creator>
          <dc:creator>Lazarevic V</dc:creator>
          <dc:creator>Gaïa N</dc:creator>
          <dc:creator>Leo S</dc:creator>
          <dc:creator>Doras C</dc:creator>
          <dc:creator>Habre W</dc:creator>
          <dc:creator>Schrenzel J</dc:creator>
          <dc:creator>Burger D</dc:creator>
          <dc:creator>Eigenmann PA</dc:creator>
          <dc:date>2017</dc:date>
          <dc:description xml:lang="en">BACKGROUND
Being born and raised in a farm provides a long-lasting protection for allergies. The microbial environment provided by farm animals is crucial to induce this protective effect, although underlying immune mechanisms remain elusive.


OBJECTIVE
To establish a mouse model of global exposure to the farming environment and to study immunologic changes linked to protection of allergy.


METHODS
Mice colonies were bred in parallel in a farm cowshed and the university animal facility (AF). Mice from both locations were subjected to a skin contact allergy model. Peripheral blood cells and cell cytokine production were assessed in both populations. In addition, the gut microbiome at various ages was characterized.


RESULTS
Mice born in the farm were less prone to develop allergy than mice bred in the AF. Mice transfers between the AF and the farm showed a better protection when mice were moved to the farm early in life. As compared to AF-bred mice, farm mice displayed early immune activation with higher CD4+ T cell population, in particular CD4+ CD25+ FoxP3- (activated cells). The cytokine profile of mice from the farm was skewed towards an IL-17 and IL-22 secreting cell profile accompanied by increased IL-10 secretion. These differences were mostly seen within a specific age window between birth and 8 weeks of age. Microbiome analysis showed differences between 4 and 20 weeks old mice and between farm and AF mice with an increased number of Murine mastadenovirus B in young farm mice exclusively.


CONCLUSION
The farming environment provides a strong, allergy protective IL-22 stimulus and generates activated CD4+ T cells. Exposure to the farm environment early in their life may also provide a better protection for contact skin allergy. Whether a viral trigger might decisively influence protection for allergies remains to be determined.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/7383</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1111/cea.12905</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/28198584</dc:relation>
          <dc:source>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. - 2017</dc:source>
          <dc:subject xml:lang="en">Mastadenoviruses</dc:subject>
          <dc:subject xml:lang="en">T cell tolerance</dc:subject>
          <dc:subject xml:lang="en">allergy</dc:subject>
          <dc:subject xml:lang="en">farming environment</dc:subject>
          <dc:subject xml:lang="en">gut microbiome</dc:subject>
          <dc:subject xml:lang="en">Allergens</dc:subject>
          <dc:subject xml:lang="en">Animals</dc:subject>
          <dc:subject xml:lang="en">CD4-Positive T-Lymphocytes</dc:subject>
          <dc:subject xml:lang="en">Dermatitis, Allergic Contact</dc:subject>
          <dc:subject xml:lang="en">Farms</dc:subject>
          <dc:subject xml:lang="en">Gastrointestinal Microbiome</dc:subject>
          <dc:subject xml:lang="en">Lymphocyte Activation</dc:subject>
          <dc:subject xml:lang="en">Mice</dc:subject>
          <dc:subject xml:lang="en">Mice, Inbred BALB C</dc:subject>
          <dc:title xml:lang="en">The farming environment protects mice from allergen-induced skin contact hypersensitivity.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:7419</identifier>
        <datestamp>2025-10-24T20:25:11Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Xiang, Yu-Tao</dc:creator>
          <dc:creator>Wang, Chuan-Yue</dc:creator>
          <dc:creator>Si, Tian-Mei</dc:creator>
          <dc:creator>Lee, Edwin Ho Ming</dc:creator>
          <dc:creator>He, Yan-Ling</dc:creator>
          <dc:creator>Ungvari, Gabor S.</dc:creator>
          <dc:creator>Chiu, Helen F.K.</dc:creator>
          <dc:creator>Yang, Shu-Yu</dc:creator>
          <dc:creator>Chong, Mian-Yoon</dc:creator>
          <dc:creator>Shinfuku, Naotaka</dc:creator>
          <dc:creator>Tan, Chay Hoon</dc:creator>
          <dc:creator>Kua, Ee Heok</dc:creator>
          <dc:creator>Fujii, Senta</dc:creator>
          <dc:creator>Sim, Kang</dc:creator>
          <dc:creator>Yong, KH</dc:creator>
          <dc:creator>Trivedi, Jitendra Kumar</dc:creator>
          <dc:creator>Chung, Eun Kee</dc:creator>
          <dc:creator>Udomratn, Pichet</dc:creator>
          <dc:creator>Chee, Kok-Yoon</dc:creator>
          <dc:creator>Sartorius, Norman</dc:creator>
          <dc:date>2011</dc:date>
          <dc:identifier>https://sonar.ch/global/documents/7419</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.3109/00048674.2010.538839</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/issn/0004-8674</dc:relation>
          <dc:source>Australian &amp; New Zealand Journal of Psychiatry. - SAGE Publications. - 2011, vol. 45, no. 3, p. 193-198</dc:source>
          <dc:subject xml:lang="en">Psychiatry and Mental health</dc:subject>
          <dc:subject xml:lang="en">General Medicine</dc:subject>
          <dc:title xml:lang="en">Sex Differences in Use of Psychotropic Drugs and Drug-Induced Side Effects in Schizophrenia Patients: Findings of the Research on Asia Psychotropic Prescription (REAP) Studies</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:7427</identifier>
        <datestamp>2025-10-24T20:25:12Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Ghattas MA</dc:creator>
          <dc:creator>Eissa NA</dc:creator>
          <dc:creator>Tessaro F</dc:creator>
          <dc:creator>Perozzo R</dc:creator>
          <dc:creator>Scapozza L</dc:creator>
          <dc:creator>Obaid D</dc:creator>
          <dc:creator>Atatreh N</dc:creator>
          <dc:date>2019</dc:date>
          <dc:description xml:lang="en">The need for new antibacterial agents is increasingly becoming of great importance as bacterial resistance to current drugs is quickly spreading. Enoyl-acyl carrier protein reductases (FabI) are important enzymes for fatty acid biosynthesis in bacteria and other micro-organisms. In this project, we conducted structure-based virtual screening against the FabI enzyme, and accordingly, 37 compounds were selected for experimental testing. Interestingly, five compounds were able to demonstrate antimicrobial effect with variable inhibition activity against various strains of bacteria and fungi. Minimum inhibitory concentrations of the active compounds were determined and showed to be in low to medium micromolar range. Subsequently, enzyme inhibition assay was carried out for our five antimicrobial hits to confirm their biological target and determine their IC50 values. Three of these tested compounds exhibited inhibition activity for the FabI enzyme where our best hit MN02 had an IC50 value of 7.8 μM. Furthermore, MN02 is a small bisphenolic compound that is predicted to have all required features to firmly bind with the target enzyme. To sum up, hits discovered in this work can act as a good starting point for the future development of new and potent antimicrobial agents.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/7427</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1111/cbdd.13536</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/31063658</dc:relation>
          <dc:source>Chemical biology &amp; drug design. - 2019</dc:source>
          <dc:subject xml:lang="en">FabI</dc:subject>
          <dc:subject xml:lang="en">antimicrobial agents</dc:subject>
          <dc:subject xml:lang="en">bacterial resistance</dc:subject>
          <dc:subject xml:lang="en">bisphenol</dc:subject>
          <dc:subject xml:lang="en">dichlorophen</dc:subject>
          <dc:subject xml:lang="en">diphenylmethane</dc:subject>
          <dc:subject xml:lang="en">docking</dc:subject>
          <dc:subject xml:lang="en">drug discovery</dc:subject>
          <dc:subject xml:lang="en">enoyl-acyl carrier protein reductase</dc:subject>
          <dc:subject xml:lang="en">Anti-Bacterial Agents</dc:subject>
          <dc:subject xml:lang="en">Bacteria</dc:subject>
          <dc:subject xml:lang="en">Bacterial Proteins</dc:subject>
          <dc:subject xml:lang="en">Drug Design</dc:subject>
          <dc:subject xml:lang="en">Enoyl-(Acyl-Carrier-Protein) Reductase (NADH)</dc:subject>
          <dc:subject xml:lang="en">Enzyme Inhibitors</dc:subject>
          <dc:title xml:lang="en">Structure-based drug design and in vitro testing reveal new inhibitors of enoyl-acyl carrier protein reductases.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:7425</identifier>
        <datestamp>2025-10-24T20:25:12Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Lietti, D.</dc:creator>
          <dc:creator>Berra, A.</dc:creator>
          <dc:creator>Bolognini, D.</dc:creator>
          <dc:creator>Hasan, S.</dc:creator>
          <dc:creator>Mattera, A.</dc:creator>
          <dc:creator>Prest, M.</dc:creator>
          <dc:creator>Blondel, A.</dc:creator>
          <dc:creator>Cadoux, F.</dc:creator>
          <dc:creator>Graulich, J. S.</dc:creator>
          <dc:creator>Masciocchi, F.</dc:creator>
          <dc:creator>Wisting, H.</dc:creator>
          <dc:creator>Giannini, G.</dc:creator>
          <dc:creator>Iugovaz, D.</dc:creator>
          <dc:creator>Reia, S.</dc:creator>
          <dc:creator>Mascagna, V.</dc:creator>
          <dc:creator>Vallazza, E.</dc:creator>
          <dc:date>2011</dc:date>
          <dc:identifier>https://sonar.ch/global/documents/7425</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1142/9789814307529_0076</dc:relation>
          <dc:source>Astroparticle, Particle and Space Physics, Detectors and Medical Physics Applications. - WORLD SCIENTIFIC. - 2010</dc:source>
          <dc:title xml:lang="en">Performance of the readout electronics chain of the MICE Electron Muon Ranger</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:7382</identifier>
        <datestamp>2025-10-24T20:25:08Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Gabbiani, Giulio</dc:creator>
          <dc:identifier>https://sonar.ch/global/documents/7382</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.3410/f.1028987.342461</dc:relation>
          <dc:source>Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature. - Faculty Opinions Ltd. - 2005</dc:source>
          <dc:title xml:lang="en">Faculty Opinions recommendation of Mechanical force mobilizes zyxin from focal adhesions to actin filaments and regulates cytoskeletal reinforcement.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:7326</identifier>
        <datestamp>2025-10-24T20:25:00Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Schmid, Bernhard</dc:creator>
          <dc:identifier>https://sonar.ch/global/documents/7326</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.3410/f.734845003.793563176</dc:relation>
          <dc:source>Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature. - Faculty Opinions Ltd. - 2019</dc:source>
          <dc:title xml:lang="en">Faculty Opinions recommendation of How to analyse plant phenotypic plasticity in response to a changing climate.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:7355</identifier>
        <datestamp>2025-10-24T20:25:01Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Watanabe, Reika</dc:creator>
          <dc:creator>Castillon, Guillaume</dc:creator>
          <dc:identifier>https://sonar.ch/global/documents/7355</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.3410/f.1127070.15768203</dc:relation>
          <dc:source>Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature. - Faculty Opinions Ltd. - 2012</dc:source>
          <dc:title xml:lang="en">Faculty Opinions recommendation of Regulation of T cell receptor activation by dynamic membrane binding of the CD3epsilon cytoplasmic tyrosine-based motif.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:7509</identifier>
        <datestamp>2025-10-24T20:25:15Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>ARZY, SHAHAR</dc:creator>
          <dc:creator>LANDIS, THEODOR</dc:creator>
          <dc:creator>BLANKE, OLAF</dc:creator>
          <dc:date>2012</dc:date>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/7509</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1142/9789812701596_0027</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Endophysics, Time, Quantum and the Subjective. - WORLD SCIENTIFIC. - 2005</dc:source>
          <dc:title xml:lang="en">OUT-OF-BODY, OUT-OF-TIME. ABNORMAL UNITY OF BODY AND SELF IN SPACE AND TIME</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:7481</identifier>
        <datestamp>2025-10-24T20:25:14Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Kashaev, Rinat M.</dc:creator>
          <dc:creator>Sergeev, Sergey M.</dc:creator>
          <dc:date>2018</dc:date>
          <dc:description xml:lang="en">&lt;jats:p&gt; Motivated by applications for non-perturbative topological strings in toric Calabi–Yau manifolds, we discuss the spectral problem for a pair of commuting modular conjugate (in the sense of Faddeev) Harper type operators, corresponding to a special case of the quantized mirror curve of local [Formula: see text] and complex values of Planck’s constant. We illustrate our analytical results by numerical calculations. &lt;/jats:p&gt;&lt;jats:p&gt; In memory of Ludwig Faddeev &lt;/jats:p&gt;</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/7481</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1142/s0129055x18400093</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/issn/0129-055X</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Reviews in Mathematical Physics. - World Scientific Pub Co Pte Lt. - 2018, vol. 30, no. 07, p. 1840009</dc:source>
          <dc:title xml:lang="en">Spectral Equations for the Modular Oscillator</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:7428</identifier>
        <datestamp>2025-10-24T20:25:12Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Tignino, Mara</dc:creator>
          <dc:creator>Stephan, Raya Marina</dc:creator>
          <dc:creator>Martin-Nagle, Renée</dc:creator>
          <dc:creator>McIntyre, Owen</dc:creator>
          <dc:date>2019</dc:date>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/7428</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1080/02508060.2019.1600250</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/issn/0250-8060</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Water International. - Informa UK Limited. - 2019, vol. 44, no. 3, p. 255-257</dc:source>
          <dc:title xml:lang="en">Bridging science and policy: legal perspectives</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:7542</identifier>
        <datestamp>2025-10-24T20:25:19Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Lima WC</dc:creator>
          <dc:creator>Gasteiger E</dc:creator>
          <dc:creator>Marcatili P</dc:creator>
          <dc:creator>Duek P</dc:creator>
          <dc:creator>Bairoch A</dc:creator>
          <dc:creator>Cosson P</dc:creator>
          <dc:date>2020</dc:date>
          <dc:description xml:lang="en">The ABCD (for AntiBodies Chemically Defined) database is a repository of sequenced antibodies, integrating curated information about the antibody and its antigen with cross-links to standardized databases of chemical and protein entities. It is freely available to the academic community, accessible through the ExPASy server (https://web.expasy.org/abcd/). The ABCD database aims at helping to improve reproducibility in academic research by providing a unique, unambiguous identifier associated to each antibody sequence. It also allows to determine rapidly if a sequenced antibody is available for a given antigen.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/7542</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1093/nar/gkz714</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/31410491</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Nucleic acids research. - 2020</dc:source>
          <dc:subject xml:lang="en">Amino Acid Sequence</dc:subject>
          <dc:subject xml:lang="en">Antibodies</dc:subject>
          <dc:subject xml:lang="en">Antigens</dc:subject>
          <dc:subject xml:lang="en">Databases, Protein</dc:subject>
          <dc:title xml:lang="en">The ABCD database: a repository for chemically defined antibodies.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:7454</identifier>
        <datestamp>2025-10-24T20:25:31Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Schmid, Bernhard</dc:creator>
          <dc:creator>Zeller, Simon L</dc:creator>
          <dc:identifier>https://sonar.ch/global/documents/7454</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.3410/f.9175956.9813054</dc:relation>
          <dc:source>Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature. - Faculty Opinions Ltd. - 2011</dc:source>
          <dc:title xml:lang="en">Faculty Opinions recommendation of Natural and within-farmland biodiversity enhances crop productivity.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:7415</identifier>
        <datestamp>2025-10-24T20:25:26Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Jäncke, Lutz</dc:creator>
          <dc:identifier>https://sonar.ch/global/documents/7415</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.3410/f.726256421.793517690</dc:relation>
          <dc:source>Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature. - Faculty Opinions Ltd. - 2016</dc:source>
          <dc:title xml:lang="en">Faculty Opinions recommendation of Right hemisphere structures predict poststroke speech fluency.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:7397</identifier>
        <datestamp>2025-10-24T20:25:22Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Stieger, Bruno</dc:creator>
          <dc:identifier>https://sonar.ch/global/documents/7397</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.3410/f.733253114.793551355</dc:relation>
          <dc:source>Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature. - Faculty Opinions Ltd. - 2018</dc:source>
          <dc:title xml:lang="en">Faculty Opinions recommendation of A multi-center preclinical study of gadoxetate DCE-MRI in rats as a biomarker of drug induced inhibition of liver transporter function.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:7526</identifier>
        <datestamp>2025-10-24T20:25:18Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Drugowitsch, Jan</dc:creator>
          <dc:creator>DeAngelis, Gregory C</dc:creator>
          <dc:creator>Angelaki, Dora E</dc:creator>
          <dc:creator>Pouget, Alexandre</dc:creator>
          <dc:identifier>https://sonar.ch/global/documents/7526</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.7554/elife.06678.007</dc:relation>
          <dc:title xml:lang="en">Author response: Tuning the speed-accuracy trade-off to maximize reward rate in multisensory decision-making</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:7420</identifier>
        <datestamp>2025-10-24T20:25:27Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Stieger, Bruno</dc:creator>
          <dc:identifier>https://sonar.ch/global/documents/7420</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.3410/f.725251883.793501969</dc:relation>
          <dc:source>Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature. - Faculty Opinions Ltd. - 2014</dc:source>
          <dc:title xml:lang="en">Faculty Opinions recommendation of Autotaxin activity has a high accuracy to diagnose intrahepatic cholestasis of pregnancy.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:7772</identifier>
        <datestamp>2025-10-24T20:26:40Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Brousse, Olivier</dc:creator>
          <dc:creator>Guillot, Jérémie</dc:creator>
          <dc:creator>Sassatelli, Gilles</dc:creator>
          <dc:creator>Gil, Thierry</dc:creator>
          <dc:creator>Grize, François</dc:creator>
          <dc:creator>Robert, Michel</dc:creator>
          <dc:date>2011</dc:date>
          <dc:description xml:lang="en">&lt;jats:p&gt; Ubiquitous computing is now the new computing trend, such systems that interact with their environment require self-adaptability. Bioinspiration is a natural candidate to provide the capability to handle complex and changing scenarios. This paper presents a programming framework dedicated to pervasive platforms programming. This bioinspired and agentoriented framework has been developed within the frame of the PERPLEXUS European project that is intended to provide support for bioinspiration-driven system adaptability. This framework enables the platform to adapt itself to application requirements at high-level while using hardware acceleration at node level. The resulting programming solution has been used to program three collaborative robotic applications in which robots learn tasks and evolve for achieving a better adaptation to their environment. &lt;/jats:p&gt;</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/7772</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1155/2012/193864</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/issn/1550-1477</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>International Journal of Distributed Sensor Networks. - SAGE Publications. - 2011, vol. 8, no. 1, p. 193864</dc:source>
          <dc:subject xml:lang="en">General Engineering</dc:subject>
          <dc:subject xml:lang="en">Computer Networks and Communications</dc:subject>
          <dc:title xml:lang="en">A Mobile Computing Framework for Pervasive Adaptive Platforms</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:7760</identifier>
        <datestamp>2025-10-24T20:26:39Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Minnig K</dc:creator>
          <dc:creator>Lazarevic V</dc:creator>
          <dc:creator>Soldo B</dc:creator>
          <dc:creator>Mauël C</dc:creator>
          <dc:date>2005</dc:date>
          <dc:description xml:lang="en">The expression of the Bacillus subtilis W23 tar genes specifying the biosynthesis of the major wall teichoic acid, the poly(ribitol phosphate), was studied under phosphate limitation using lacZ reporter fusions. Three different regulation patterns can be deduced from these beta-galactosidase activity data: (i) tarD and tarL gene expression is downregulated under phosphate starvation; (ii) tarA and, to a minor extent, tarB expression after an initial decrease unexpectedly increases; and (iii) tarO is not influenced by phosphate concentration. To dissect the tarA regulatory pattern, its two promoters were analysed under phosphate limitation: The P(tarA)-ext promoter is repressed under phosphate starvation by the PhoPR two-component system, whereas, under the same conditions, the P(tarA)-int promoter is upregulated by the action of an extracytoplasmic function (ECF) sigma factor, sigma(M). In contrast to strain 168, sigma(M) is activated in strain W23 in phosphate-depleted conditions, a phenomenon indirectly dependent on PhoPR, the two-component regulatory system responsible for the adaptation to phosphate starvation. These results provide further evidence for the role of sigma(M) in cell-wall stress response, and suggest that impairment of cell-wall structure is the signal activating this ECF sigma factor.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/7760</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1099/mic.0.28021-0</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/16151214</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Microbiology (Reading, England). - 2005</dc:source>
          <dc:subject xml:lang="en">Bacillus subtilis</dc:subject>
          <dc:subject xml:lang="en">Bacterial Proteins</dc:subject>
          <dc:subject xml:lang="en">Cell Wall</dc:subject>
          <dc:subject xml:lang="en">Gene Expression Regulation, Bacterial</dc:subject>
          <dc:subject xml:lang="en">Molecular Sequence Data</dc:subject>
          <dc:subject xml:lang="en">Phosphates</dc:subject>
          <dc:subject xml:lang="en">Sigma Factor</dc:subject>
          <dc:subject xml:lang="en">Teichoic Acids</dc:subject>
          <dc:subject xml:lang="en">Transcription, Genetic</dc:subject>
          <dc:title xml:lang="en">Analysis of teichoic acid biosynthesis regulation reveals that the extracytoplasmic function sigma factor sigmaM is induced by phosphate depletion in Bacillus subtilis W23.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:7804</identifier>
        <datestamp>2025-10-24T20:26:51Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Fahrni S</dc:creator>
          <dc:creator>Campana L</dc:creator>
          <dc:creator>Dominguez A</dc:creator>
          <dc:creator>Uldin T</dc:creator>
          <dc:creator>Dedouit F</dc:creator>
          <dc:creator>Delémont O</dc:creator>
          <dc:creator>Grabherr S</dc:creator>
          <dc:date>2017</dc:date>
          <dc:description xml:lang="en">Three-dimensional surface scanning (3DSS) and multi-detector computed tomography (MDCT) are two techniques that are used in legal medicine for digitalizing objects, a body or body parts such as bones. While these techniques are more and more commonly employed, surprisingly little information is known about the quality rendering of digitalized three-dimensional (3D) models provided by each of them. This paper presents findings related to the measurement precision of 3D models obtained through observation of a study case, where a fractured skull reconstructed by an anthropologist was digitalized using both post-mortem imaging methods. Computed tomography (CT) scans were performed using an 8-row MDCT unit with two different slice thicknesses. The variability of 3D CT models superimposition allowed to assess the reproducibility and robustness of this digitalization technique. Furthermore, two 3D surface scans were done using a professional high resolution 3D digitizer. The comparison of 3D CT-scans with 3D surface scans by superimposition demonstrated several regions with significant differences in topology (average difference between +1.45 and -1.22 mm). When comparing the reproducibility between these two digitalizing techniques, it appeared that MDCT 3D models led in general to greater variability for measurement precision between scanned surfaces. Also, the reproducibility was better achieved with the 3D surface digitizer, showing 3D models with fewer and less pronounced differences (from +0.32 to -0.31 mm). These experiments suggest that MDCT provides less reproducible body models than 3D surface scanning. But further studies must be undertaken in order to corroborate this first impression, and possibly explain the reason for these findings.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/7804</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1080/20961790.2017.1334353</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/30483625</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Forensic sciences research. - 2017</dc:source>
          <dc:subject xml:lang="en">3D surface scanning</dc:subject>
          <dc:subject xml:lang="en">Forensic imaging</dc:subject>
          <dc:subject xml:lang="en">anthropology</dc:subject>
          <dc:subject xml:lang="en">multi-detector computed tomography (MDCT)</dc:subject>
          <dc:title xml:lang="en">CT-scan vs. 3D surface scanning of a skull: first considerations regarding reproducibility issues.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:7942</identifier>
        <datestamp>2025-10-24T20:26:46Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Di Gioia, Giuseppe</dc:creator>
          <dc:creator>Soto Flores, Nina</dc:creator>
          <dc:creator>Franco, Danilo</dc:creator>
          <dc:creator>Colaiori, Iginio</dc:creator>
          <dc:creator>Sonck, Jeroen</dc:creator>
          <dc:creator>Gigante, Carlo</dc:creator>
          <dc:creator>Kodeboina, Monika</dc:creator>
          <dc:creator>Bartunek, Jozef</dc:creator>
          <dc:creator>Vanderheyden, Marc</dc:creator>
          <dc:creator>Van Praet, Frank</dc:creator>
          <dc:creator>Casselman, Filip</dc:creator>
          <dc:creator>Degriek, Ivan</dc:creator>
          <dc:creator>Stockman, Bernard</dc:creator>
          <dc:creator>Barbato, Emanuele</dc:creator>
          <dc:creator>Collet, Carlos</dc:creator>
          <dc:creator>De Bruyne, Bernard</dc:creator>
          <dc:description xml:lang="en">&lt;jats:sec&gt;
            &lt;jats:title&gt;Background:&lt;/jats:title&gt;
            &lt;jats:p&gt;In diabetic patients with multivessel coronary artery disease, coronary artery bypass grafting (CABG) has shown long-term benefits over percutaneous coronary intervention (PCI). Physiology-guided PCI has shown to improve clinical outcomes in multivessel coronary artery disease, though its impact in diabetic patients has never been investigated. We evaluated long-term clinical outcomes of diabetic patients with multivessel coronary artery disease treated with fractional flow reserve (FFR)–guided PCI compared with CABG.&lt;/jats:p&gt;
          &lt;/jats:sec&gt;
          &lt;jats:sec&gt;
            &lt;jats:title&gt;Methods:&lt;/jats:title&gt;
            &lt;jats:p&gt;From 2010 to 2018, 4622 diabetic patients undergoing coronary angiography were screened for inclusion. The inclusion criterion was the presence of at least 2-vessel disease defined as with diameter stenosis ≥50%, in which at least 1 intermediate stenosis (diameter stenosis, 30%–70%) was treated or deferred according to FFR. Inverse probability of treatment weighting analysis was used to account for baseline differences with a contemporary cohort of patients treated with CABG. The primary end point was major adverse cardiovascular and cerebrovascular events, defined as all-cause death, myocardial infarction, revascularization, or stroke.&lt;/jats:p&gt;
          &lt;/jats:sec&gt;
          &lt;jats:sec&gt;
            &lt;jats:title&gt;Results:&lt;/jats:title&gt;
            &lt;jats:p&gt;
              A total of 418 patients were included in the analysis. Among them, 209 patients underwent CABG and 209 FFR-guided PCI. At 5 years, the incidence of major adverse cardiovascular and cerebrovascular events was higher in the FFR-guided PCI versus the CABG group (44.5% versus 31.9%; hazard ratio, 1.60 [95% CI, 1.15–2.22];
              &lt;jats:italic&gt;P&lt;/jats:italic&gt;
              =0.005). No difference was found in the composite of all-cause death, myocardial infarction, or stroke (28.8% versus 27.5%; hazard ratio, 1.05 [95% CI, 0.72–1.53];
              &lt;jats:italic&gt;P&lt;/jats:italic&gt;
              =0.81). Repeat revascularization was more frequent with FFR-guided PCI (24.9% versus 8.2%; hazard ratio, 3.51 [95% CI, 1.93–6.40];
              &lt;jats:italic&gt;P&lt;/jats:italic&gt;
              &amp;lt;0.001).
            &lt;/jats:p&gt;
          &lt;/jats:sec&gt;
          &lt;jats:sec&gt;
            &lt;jats:title&gt;Conclusions:&lt;/jats:title&gt;
            &lt;jats:p&gt;In diabetic patients with multivessel coronary artery disease, CABG was associated with a lower rate of major adverse cardiovascular and cerebrovascular events compared with FFR-guided PCI, driven by a higher rate of repeat revascularization. At 5-year follow-up, no difference was observed in the composite of all-cause death, myocardial infarction, or stroke between CABG and FFR-guided PCI.&lt;/jats:p&gt;
          &lt;/jats:sec&gt;
          &lt;jats:sec&gt;
            &lt;jats:title&gt;Graphic Abstract:&lt;/jats:title&gt;
            &lt;jats:p&gt;
              A
              &lt;jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="graphic abstract"&gt;graphic abstract&lt;/jats:ext-link&gt;
              is available for this article.
            &lt;/jats:p&gt;
          &lt;/jats:sec&gt;</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/7942</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1161/circinterventions.120.009157</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/issn/1941-7640</dc:relation>
          <dc:source>Circulation: Cardiovascular Interventions. - Ovid Technologies (Wolters Kluwer Health). - 2020, vol. 13, no. 10</dc:source>
          <dc:subject xml:lang="en">Cardiology and Cardiovascular Medicine</dc:subject>
          <dc:title xml:lang="en">Coronary Artery Bypass Grafting or Fractional Flow Reserve–Guided Percutaneous Coronary Intervention in Diabetic Patients With Multivessel Disease</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:7788</identifier>
        <datestamp>2025-10-24T20:26:50Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Peciu-Florianu, Iulia</dc:creator>
          <dc:creator>Chittur Viswanathan, Gopalakrishnan</dc:creator>
          <dc:creator>Barges-Coll, Juan</dc:creator>
          <dc:creator>Castillo-Velázquez, Gabriel A.</dc:creator>
          <dc:creator>Zambelli, Pierre-Yves</dc:creator>
          <dc:creator>Duff, John M.</dc:creator>
          <dc:description xml:lang="en">&lt;jats:p&gt;Osteoblastoma is a rare, benign, osteoid-producing, and slow-growing primary bone tumor, typically arising in long bones or in the spine, with a slight male predominance. This report describes the surgical treatment of a giant C-1 (atlantal) osteoblastoma diagnosed in a young male patient with neurofibromatosis Type 1. The authors describe the clinical presentation, the surgical procedure for complete excision and stabilization, and results as of the 1-year follow-up. They detail a bilateral occipitoaxial spinal interarticular stabilization technique that they used after complete tumor excision. To the best of their knowledge, this is the first case of bilateral C-1 lateral mass reconstruction by this technique to be reported in the literature.&lt;/jats:p&gt;</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/7788</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.3171/2016.8.spine16319</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/issn/1547-5654</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Journal of Neurosurgery: Spine. - Journal of Neurosurgery Publishing Group (JNSPG). - 2017, vol. 26, no. 3, p. 307-312</dc:source>
          <dc:subject xml:lang="en">General Medicine</dc:subject>
          <dc:title xml:lang="en">Bilateral C-1 lateral mass reconstruction following radical resection of a giant osteoblastoma of the atlas: case report</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:7834</identifier>
        <datestamp>2025-10-24T20:26:42Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Taffin H</dc:creator>
          <dc:creator>Maurey H</dc:creator>
          <dc:creator>Ozanne A</dc:creator>
          <dc:creator>Durand P</dc:creator>
          <dc:creator>Husson B</dc:creator>
          <dc:creator>Knebel JF</dc:creator>
          <dc:creator>Adamsbaum C</dc:creator>
          <dc:creator>Deiva K</dc:creator>
          <dc:creator>Saliou G</dc:creator>
          <dc:date>2020</dc:date>
          <dc:description xml:lang="en">AIM
To describe the long-term outcomes of children by the time they reached school age with vein of Galen aneurysmal malformation (VGAM).


METHOD
This was a retrospective observational study on a consecutive cohort of patients with VGAM. We included patients with at least one Francophone parent, aged between 6 and 11 years at the time of long-term evaluation. The neurological outcome was assessed with the King's Outcome Scale for Childhood Injury score and eight neurological and behavioural items from the Rivermead Postconcussion Symptoms questionnaire.


RESULTS
All 52 patients (17 females, 32 males [data missing for n=3]) with at least one Francophone parent (5 fetuses and 47 children) were included. At the long-term evaluation time-point, 33 patients were alive and 19 patients had died. Risk of postnatal death was associated with severe neonatal cardiac failure (p=0.007) or isosystemic or suprasystemic pulmonary hypertension (p=0.014). Among survivors, 19 had a good outcome with normal schooling and 14 had a poor outcome. Moreover, among the good outcome patients, a large proportion had neurodevelopmental alterations.


INTERPRETATION
Long-term outcome of patients with VGAM appears to be less favourable than outcome described at the short- and medium-term, even in the absence of encephalomalacia at birth. Even patients with good outcome often have neuropsychological disorders that may have repercussions on learning and requiring appropriate rehabilitation or medical management.


WHAT THIS PAPER ADDS
Long-term outcome appears to be less favourable than described at short- and medium-term follow-up. Even patients with good outcome at these time-points often have minor neuropsychological disorders.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/7834</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1111/dmcn.14392</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/31713850</dc:relation>
          <dc:source>Developmental medicine and child neurology. - 2020</dc:source>
          <dc:subject xml:lang="en">Age Factors</dc:subject>
          <dc:subject xml:lang="en">Child</dc:subject>
          <dc:subject xml:lang="en">Embolization, Therapeutic</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Neurodevelopmental Disorders</dc:subject>
          <dc:subject xml:lang="en">Prognosis</dc:subject>
          <dc:subject xml:lang="en">Retrospective Studies</dc:subject>
          <dc:subject xml:lang="en">Survival Rate</dc:subject>
          <dc:subject xml:lang="en">Vein of Galen Malformations</dc:subject>
          <dc:title xml:lang="en">Long-term outcome of vein of Galen malformation.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:7741</identifier>
        <datestamp>2025-10-24T20:26:37Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>De Vries AM</dc:creator>
          <dc:creator>de Roten Y</dc:creator>
          <dc:creator>Meystre C</dc:creator>
          <dc:creator>Passchier J</dc:creator>
          <dc:creator>Despland JN</dc:creator>
          <dc:creator>Stiefel F</dc:creator>
          <dc:date>2014</dc:date>
          <dc:description xml:lang="en">OBJECTIVE
The aim of this study was to review the literature on clinician characteristics influencing patient-clinician communication or patient outcome in oncology.


METHODS
Studies investigating the association of clinician characteristics with quality of communication and with outcome for adult cancer patients were systematically searched in MEDLINE, PSYINFO, PUBMED, EMBASE, CINHAL, Web of Science and The Cochrane Library up to November 2012. We used the preferred reporting items for systematic reviews and meta-analyses statement to guide our review. Articles were extracted independently by two of the authors using predefined criteria.


RESULTS
Twenty seven articles met the inclusion criteria. Clinician characteristics included a variety of sociodemographic, relational, and personal characteristics. A positive impact on quality of communication and/or patient outcome was reported for communication skills training, an external locus of control, empathy, a socioemotional approach, shared decision-making style, higher anxiety, and defensiveness. A negative impact was reported for increased level of fatigue and burnout and expression of worry. Professional experience of clinicians was not related to communication and/or to patient outcome, and divergent results were reported for clinician gender, age, stress, posture, and confidence or self-efficacy.


CONCLUSIONS
Various clinician characteristics have different effects on quality of communication and/or patient outcome. Research is needed to investigate the pathways leading to effective communication between clinicians and patients.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/7741</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1002/pon.3445</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/24243790</dc:relation>
          <dc:source>Psycho-oncology. - 2014</dc:source>
          <dc:subject xml:lang="en">cancer</dc:subject>
          <dc:subject xml:lang="en">clinician characteristics</dc:subject>
          <dc:subject xml:lang="en">communication</dc:subject>
          <dc:subject xml:lang="en">oncology</dc:subject>
          <dc:subject xml:lang="en">patient outcome</dc:subject>
          <dc:subject xml:lang="en">Age Factors</dc:subject>
          <dc:subject xml:lang="en">Burnout, Professional</dc:subject>
          <dc:subject xml:lang="en">Communication</dc:subject>
          <dc:subject xml:lang="en">Decision Making</dc:subject>
          <dc:subject xml:lang="en">Empathy</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Internal-External Control</dc:subject>
          <dc:subject xml:lang="en">Medical Oncology</dc:subject>
          <dc:subject xml:lang="en">Neoplasms</dc:subject>
          <dc:subject xml:lang="en">Patient Participation</dc:subject>
          <dc:subject xml:lang="en">Physician-Patient Relations</dc:subject>
          <dc:subject xml:lang="en">Treatment Outcome</dc:subject>
          <dc:title xml:lang="en">Clinician characteristics, communication, and patient outcome in oncology: a systematic review.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:7912</identifier>
        <datestamp>2025-10-24T20:26:44Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Conus P</dc:creator>
          <dc:creator>Macneil C</dc:creator>
          <dc:creator>McGorry PD</dc:creator>
          <dc:date>2014</dc:date>
          <dc:description xml:lang="en">OBJECTIVES
Early intervention and preventive strategies have become major targets of research and service development in psychiatry over the last few years. Compared to schizophrenia, bipolar disorder (BD) has received limited attention in this regard. In this paper, we review the available literature in order to explore the public health significance of BD and the extent to which this may justify the development of early intervention strategies for this disorder.


METHODS
The main computerized psychiatric literature databases were accessed. This included Medline and PsychInfo, using the following keywords: bipolar, early intervention, staging model, burden, caregiver, public health, and manic depression.


RESULTS
BD is often recurrent and has an impact that goes well beyond symptomatic pathology. The burden it incurs is linked not only to its cardinal clinical features, but also to cognitive dysfunction, poor functional outcome, poor physical health, high rate of comorbidities, and suicide. At a societal level, BD induces enormous direct and indirect costs and has a major impact on caregivers. The available literature reveals a usually long delay between illness onset and the start of treatment, and the absence of specific guidelines for the treatment of the early phase of BD.


CONCLUSIONS
Considering the major impact of BD on patients and society, there is an urgent need for the development of early intervention strategies aimed at earlier detection and more specific treatment of the early phase of the disorder.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/7912</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1111/bdi.12137</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/24127825</dc:relation>
          <dc:source>Bipolar disorders. - 2014</dc:source>
          <dc:subject xml:lang="en">bipolar disorder</dc:subject>
          <dc:subject xml:lang="en">burden</dc:subject>
          <dc:subject xml:lang="en">early intervention</dc:subject>
          <dc:subject xml:lang="en">public health</dc:subject>
          <dc:subject xml:lang="en">Biomedical Research</dc:subject>
          <dc:subject xml:lang="en">Bipolar Disorder</dc:subject>
          <dc:subject xml:lang="en">Early Intervention, Educational</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Public Health</dc:subject>
          <dc:title xml:lang="en">Public health significance of bipolar disorder: implications for early intervention and prevention.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:7756</identifier>
        <datestamp>2025-10-24T20:26:39Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Roulin, Nicolas</dc:creator>
          <dc:creator>Krings, Franciska</dc:creator>
          <dc:date>2016</dc:date>
          <dc:identifier>https://sonar.ch/global/documents/7756</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1111/apps.12072</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/issn/0269-994X</dc:relation>
          <dc:source>Applied Psychology. - Wiley. - 2016, vol. 65, no. 4, p. 643-670</dc:source>
          <dc:title xml:lang="en">When Winning is Everything: The Relationship between Competitive Worldviews and Job Applicant Faking</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:8644</identifier>
        <datestamp>2025-10-24T20:30:59Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Sadallah S</dc:creator>
          <dc:creator>Schmied L</dc:creator>
          <dc:creator>Eken C</dc:creator>
          <dc:creator>Charoudeh HN</dc:creator>
          <dc:creator>Amicarella F</dc:creator>
          <dc:creator>Schifferli JA</dc:creator>
          <dc:date>2016</dc:date>
          <dc:description xml:lang="en">Platelet (PLT) transfusions are potentially life saving for individuals with low PLT numbers; however, previous work revealed that PLT transfusions are associated with increased infection risk. During storage, PLT intended for transfusion continuously shed ectosomes (Ecto) from their surface, which express immunomodulatory molecules like phosphatidylserine or TGF-β1. Recently, PLT-Ecto were shown to reduce proinflammatory cytokine release by macrophages and to favor the differentiation of naive T cells toward regulatory T cells. Whether PLT-Ecto modify NK cells remains unclear. We exposed purified NK cells and full PBMCs from healthy donors to PLT-Ecto. We found a reduced expression of several activating surface receptors (NKG2D, NKp30, and DNAM-1) and decreased NK cell function, as measured by CD107a expression and IFN-γ production. Pretreatment of PLT-Ecto with anti-TGF-β1 neutralizing Ab restored surface receptor expression and NK cell function. We further observed a TGF-β1-mediated upregulation of miR-183, which, in turn, reduced DAP12, an important protein for stabilization and downstream signaling of several activating NK cell receptors. Again, these effects could antagonized, in part, when PLT-Ecto were preincubated with anti-TGF-β1 Ab. Erythrocyte Ecto did not affect NK cells. Polymorphonuclear cell Ecto expressed MHC class I and inhibited NK cell function. In addition, they induced the secretion of TGF-β1 by NK cells, which participated in an auto/paracrine manner in the suppressive activity of polymorphonuclear cell-derived Ecto. In sum, our study showed that PLT-Ecto could inhibit NK cell effector function in a TGF-β1-dependent manner, suggesting that recipients of PLT transfusions may experience reduced NK cell function.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/8644</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.4049/jimmunol.1502658</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/27448586</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Journal of immunology (Baltimore, Md. : 1950). - 2016</dc:source>
          <dc:subject xml:lang="en">Adaptor Proteins, Signal Transducing</dc:subject>
          <dc:subject xml:lang="en">Antigens, Differentiation, T-Lymphocyte</dc:subject>
          <dc:subject xml:lang="en">Blood Platelets</dc:subject>
          <dc:subject xml:lang="en">Cell-Derived Microparticles</dc:subject>
          <dc:subject xml:lang="en">GPI-Linked Proteins</dc:subject>
          <dc:subject xml:lang="en">Genes, MHC Class I</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Intercellular Signaling Peptides and Proteins</dc:subject>
          <dc:subject xml:lang="en">Interferon-gamma</dc:subject>
          <dc:subject xml:lang="en">Killer Cells, Natural</dc:subject>
          <dc:subject xml:lang="en">Lysosomal-Associated Membrane Protein 1</dc:subject>
          <dc:subject xml:lang="en">Membrane Proteins</dc:subject>
          <dc:subject xml:lang="en">MicroRNAs</dc:subject>
          <dc:subject xml:lang="en">Monocytes</dc:subject>
          <dc:subject xml:lang="en">Natural Cytotoxicity Triggering Receptor 3</dc:subject>
          <dc:subject xml:lang="en">Neutrophils</dc:subject>
          <dc:subject xml:lang="en">Phosphatidylserines</dc:subject>
          <dc:subject xml:lang="en">Receptors, Natural Killer Cell</dc:subject>
          <dc:subject xml:lang="en">Transforming Growth Factor beta</dc:subject>
          <dc:title xml:lang="en">Platelet-Derived Ectosomes Reduce NK Cell Function.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:8756</identifier>
        <datestamp>2025-10-24T20:31:06Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Farrera P</dc:creator>
          <dc:creator>Heinze G</dc:creator>
          <dc:creator>Albrecht B</dc:creator>
          <dc:creator>Ho M</dc:creator>
          <dc:creator>Chávez M</dc:creator>
          <dc:creator>Teo C</dc:creator>
          <dc:creator>Sangouard N</dc:creator>
          <dc:creator>de Riedmatten H</dc:creator>
          <dc:date>2016</dc:date>
          <dc:description xml:lang="en">The generation of ultra-narrowband, pure and storable single photons with widely tunable wave shape is an enabling step toward hybrid quantum networks requiring interconnection of remote disparate quantum systems. It allows interaction of quantum light with several material systems, including photonic quantum memories, single trapped ions and opto-mechanical systems. Previous approaches have offered a limited tuning range of the photon duration of at most one order of magnitude. Here we report on a heralded single photon source with controllable emission time based on a cold atomic ensemble, which can generate photons with temporal durations varying over three orders of magnitude up to 10 μs without a significant change of the readout efficiency. We prove the nonclassicality of the emitted photons, show that they are emitted in a pure state, and demonstrate that ultra-long photons with nonstandard wave shape can be generated, which are ideally suited for several quantum information tasks.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/8756</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1038/ncomms13556</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/27886166</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Nature communications. - 2016</dc:source>
          <dc:title xml:lang="en">Generation of single photons with highly tunable wave shape from a cold atomic ensemble.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:8742</identifier>
        <datestamp>2025-10-24T20:31:04Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Sharma N</dc:creator>
          <dc:creator>Naraev BG</dc:creator>
          <dc:creator>Engelman EG</dc:creator>
          <dc:creator>Zimmerman MB</dc:creator>
          <dc:creator>Bushnell DL</dc:creator>
          <dc:creator>OʼDorisio TM</dc:creator>
          <dc:creator>OʼDorisio MS</dc:creator>
          <dc:creator>Menda Y</dc:creator>
          <dc:creator>Müller-Brand J</dc:creator>
          <dc:creator>Howe JR</dc:creator>
          <dc:creator>Halfdanarson TR</dc:creator>
          <dc:date>2017</dc:date>
          <dc:description xml:lang="en">OBJECTIVES
The objective of this study was to describe the outcomes of patients in the University of Iowa Neuroendocrine Tumor (NET) Database treated with peptide receptor radionuclide therapy (PRRT).


METHODS
One hundred thirty-five patients from the University of Iowa NET Database who received PRRT were analyzed, their characteristics were described, and survival was calculated.


RESULTS
The median age at diagnosis was 51 years, and 64% were men. The primary tumor was located in the small bowel (SBNET) in 37.8%, in the pancreas (PNET) in 26.0%, in the lung in 13.3%, in unknown primary in 9.6%, and in other sites in 13.3%. A radiographic response of any magnitude was observed in 65.8%, 11.1% had a mixed response, and 15.4% showed progression. The overall survival (OS) from the first PRRT was 40 months, and the median time to progression was 23.9 months. Higher pretreatment chromogranin A and pancreastatin levels predicted inferior OS.


CONCLUSIONS
Peptide receptor radionuclide therapy resulted in a relatively long OS and time to progression in heavily pretreated North American patients with advanced NETs. Elevated pretreatment chromogranin A and pancreastatin predicted shorter OS after therapy. Peptide receptor radionuclide therapy is a valuable treatment option in patients with advanced NETs, especially SBNETS.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/8742</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1097/MPA.0000000000000734</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/27759712</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Pancreas. - 2017</dc:source>
          <dc:subject xml:lang="en">Adolescent</dc:subject>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Aged</dc:subject>
          <dc:subject xml:lang="en">Cohort Studies</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Iowa</dc:subject>
          <dc:subject xml:lang="en">Kaplan-Meier Estimate</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Neoplasm Metastasis</dc:subject>
          <dc:subject xml:lang="en">Neuroendocrine Tumors</dc:subject>
          <dc:subject xml:lang="en">Octreotide</dc:subject>
          <dc:subject xml:lang="en">Radiopharmaceuticals</dc:subject>
          <dc:subject xml:lang="en">Young Adult</dc:subject>
          <dc:title xml:lang="en">Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:8654</identifier>
        <datestamp>2025-10-24T20:30:59Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Marsano A</dc:creator>
          <dc:creator>Medeiros da Cunha CM</dc:creator>
          <dc:creator>Ghanaati S</dc:creator>
          <dc:creator>Gueven S</dc:creator>
          <dc:creator>Centola M</dc:creator>
          <dc:creator>Tsaryk R</dc:creator>
          <dc:creator>Barbeck M</dc:creator>
          <dc:creator>Stuedle C</dc:creator>
          <dc:creator>Barbero A</dc:creator>
          <dc:creator>Helmrich U</dc:creator>
          <dc:creator>Schaeren S</dc:creator>
          <dc:creator>Kirkpatrick JC</dc:creator>
          <dc:creator>Banfi A</dc:creator>
          <dc:creator>Martin I</dc:creator>
          <dc:date>2016</dc:date>
          <dc:description xml:lang="en">: Chondrogenic differentiation of bone marrow-derived mesenchymal stromal/stem cells (MSCs) can be induced by presenting morphogenetic factors or soluble signals but typically suffers from limited efficiency, reproducibility across primary batches, and maintenance of phenotypic stability. Considering the avascular and hypoxic milieu of articular cartilage, we hypothesized that sole inhibition of angiogenesis can provide physiological cues to direct in vivo differentiation of uncommitted MSCs to stable cartilage formation. Human MSCs were retrovirally transduced to express a decoy soluble vascular endothelial growth factor (VEGF) receptor-2 (sFlk1), which efficiently sequesters endogenous VEGF in vivo, seeded on collagen sponges and immediately implanted ectopically in nude mice. Although naïve cells formed vascularized fibrous tissue, sFlk1-MSCs abolished vascular ingrowth into engineered constructs, which efficiently and reproducibly developed into hyaline cartilage. The generated cartilage was phenotypically stable and showed no sign of hypertrophic evolution up to 12 weeks. In vitro analyses indicated that spontaneous chondrogenic differentiation by blockade of angiogenesis was related to the generation of a hypoxic environment, in turn activating the transforming growth factor-β pathway. These findings suggest that VEGF blockade is a robust strategy to enhance cartilage repair by endogenous or grafted mesenchymal progenitors. This article outlines the general paradigm of controlling the fate of implanted stem/progenitor cells by engineering their ability to establish specific microenvironmental conditions rather than directly providing individual morphogenic cues.


SIGNIFICANCE
Chondrogenic differentiation of mesenchymal stromal/stem cells (MSCs) is typically targeted by morphogen delivery, which is often associated with limited efficiency, stability, and robustness. This article proposes a strategy to engineer MSCs with the capacity to establish specific microenvironmental conditions, supporting their own targeted differentiation program. Sole blockade of angiogenesis mediated by transduction for sFlk-1, without delivery of additional morphogens, is sufficient for inducing MSC chondrogenic differentiation. The findings represent a relevant step forward in the field because the method allowed reducing interdonor variability in MSC differentiation efficiency and, importantly, onset of a stable, nonhypertrophic chondrocyte phenotype.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/8654</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.5966/sctm.2015-0321</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/27460852</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Stem cells translational medicine. - 2016</dc:source>
          <dc:subject xml:lang="en">Chondrogenesis</dc:subject>
          <dc:subject xml:lang="en">Hypoxia</dc:subject>
          <dc:subject xml:lang="en">Mesenchymal stromal/stem cells</dc:subject>
          <dc:subject xml:lang="en">Vascular endothelial growth factor blockade</dc:subject>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Bone Marrow Cells</dc:subject>
          <dc:subject xml:lang="en">Cell Differentiation</dc:subject>
          <dc:subject xml:lang="en">Cell Proliferation</dc:subject>
          <dc:subject xml:lang="en">Chondrogenesis</dc:subject>
          <dc:subject xml:lang="en">Endothelial Cells</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Hypertrophy</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Mesenchymal Stem Cells</dc:subject>
          <dc:subject xml:lang="en">Neovascularization, Physiologic</dc:subject>
          <dc:subject xml:lang="en">Oxygen</dc:subject>
          <dc:subject xml:lang="en">Signal Transduction</dc:subject>
          <dc:subject xml:lang="en">Transduction, Genetic</dc:subject>
          <dc:subject xml:lang="en">Transforming Growth Factor beta</dc:subject>
          <dc:subject xml:lang="en">Vascular Endothelial Growth Factor A</dc:subject>
          <dc:subject xml:lang="en">Vascular Endothelial Growth Factor Receptor-2</dc:subject>
          <dc:subject xml:lang="en">Young Adult</dc:subject>
          <dc:title xml:lang="en">Spontaneous In Vivo Chondrogenesis of Bone Marrow-Derived Mesenchymal Progenitor Cells by Blocking Vascular Endothelial Growth Factor Signaling.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:8630</identifier>
        <datestamp>2025-10-24T20:30:58Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Shaw D</dc:creator>
          <dc:date>2016</dc:date>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/8630</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1007/s11673-016-9734-0</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/27379649</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Journal of bioethical inquiry. - 2016</dc:source>
          <dc:subject xml:lang="en">Authorship</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Publishing</dc:subject>
          <dc:title xml:lang="en">The Virus of Vagueness in Authorship.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:8704</identifier>
        <datestamp>2025-10-24T20:31:01Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Aeschbacher S</dc:creator>
          <dc:creator>Bossard M</dc:creator>
          <dc:creator>Schoen T</dc:creator>
          <dc:creator>Schmidlin D</dc:creator>
          <dc:creator>Muff C</dc:creator>
          <dc:creator>Maseli A</dc:creator>
          <dc:creator>Leuppi JD</dc:creator>
          <dc:creator>Miedinger D</dc:creator>
          <dc:creator>Probst-Hensch NM</dc:creator>
          <dc:creator>Schmidt-Trucksäss A</dc:creator>
          <dc:creator>Risch M</dc:creator>
          <dc:creator>Risch L</dc:creator>
          <dc:creator>Conen D</dc:creator>
          <dc:date>2016</dc:date>
          <dc:description xml:lang="en">Obstructive sleep apnea seems to have an important influence on the autonomic nervous system. In this study, we assessed the relations of sleep apnea-related parameters with 24-hour heart rate variability (HRV) in a large population of young and healthy adults. Participants aged 25 to 41 years with a body mass index &lt;35 kg/m(2) and without known obstructive sleep apnea were included in a prospective population-based cohort study. HRV was assessed using 24-hour electrocardiographic monitoring. The SD of all normal RR intervals (SDNN) was used as the main HRV variable. Apnea-Hypopnea Index (AHI) and oxygen desaturation index (ODI) were obtained from nighttime pulse oximetry with nasal airflow measurements. We defined sleep-related breathing disorders as an AHI ≥5 or an ODI ≥5. Multivariable regression models were constructed to assess the relation of HRV with either AHI or ODI. Median age of the 1,255 participants was 37 years, 47% were men, and 9.6% had an AHI ≥5. Linear inverse associations of SDNN across AHI and ODI groups were found (p for trend = 0.006 and 0.0004, respectively). The β coefficients (95% CI) for the relation between SDNN and elevated AHI were -0.20 (-0.40 to -0.11), p = 0.04 and -0.29 (-0.47 to -0.11), p = 0.002 for elevated ODI. After adjustment for 24-hour heart rate, the same β coefficients (95% CI) were -0.06 (-0.22 to 0.11), p = 0.51 and -0.14 (-0.30 to 0.01), p = 0.07, respectively. In conclusion, even early stages of sleep-related breathing disorders are inversely associated with HRV in young and healthy adults, suggesting that they are tightly linked with autonomic dysfunction. However, HRV and 24-hour heart rate seem to have common information.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/8704</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.amjcard.2016.06.032</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/27553103</dc:relation>
          <dc:source>The American journal of cardiology. - 2016</dc:source>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Autonomic Nervous System</dc:subject>
          <dc:subject xml:lang="en">Blood Pressure</dc:subject>
          <dc:subject xml:lang="en">Body Mass Index</dc:subject>
          <dc:subject xml:lang="en">Cohort Studies</dc:subject>
          <dc:subject xml:lang="en">Electrocardiography, Ambulatory</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Heart Rate</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Linear Models</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Multivariate Analysis</dc:subject>
          <dc:subject xml:lang="en">Obesity</dc:subject>
          <dc:subject xml:lang="en">Overweight</dc:subject>
          <dc:subject xml:lang="en">Oximetry</dc:subject>
          <dc:subject xml:lang="en">Prospective Studies</dc:subject>
          <dc:subject xml:lang="en">Pulmonary Ventilation</dc:subject>
          <dc:subject xml:lang="en">Sex Factors</dc:subject>
          <dc:subject xml:lang="en">Sleep Apnea, Obstructive</dc:subject>
          <dc:title xml:lang="en">Heart Rate Variability and Sleep-Related Breathing Disorders in the General Population.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:8767</identifier>
        <datestamp>2025-10-24T20:31:07Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Eppler E</dc:creator>
          <dc:creator>Müller-Gerbl M</dc:creator>
          <dc:creator>Maly IP</dc:creator>
          <dc:date>2017</dc:date>
          <dc:description xml:lang="en">The tight junction protein claudin-3 is overexpressed in diverse epithelial tumours and is associated with increased survival, progression and motility of tumour cells. Claudin-3 expression profiles are being increasingly used for diagnostic and prognostic tumour classification. Claudin-3 has been identified as a receptor for Clostridium perfringens enterotoxin, which is under consideration for selective lysis of claudin-3-expressing tumours, particularly brain metastases, and other translational medicine uses. However, the localization of claudin-3 in the brain has not been completely elucidated. While claudin-3 in brain tissue adjacent to claudin-3-expressing metastases had been excluded and low or undetectable levels proposed in the CNS, under physiological conditions, in adult human, rat and mouse brains, claudin-3 was exclusively found in choroid plexus epithelium where it is considered an integral component of the blood-cerebrospinal-fluid barrier. We report here the pronounced presence of claudin-3 not only in the nasal region (as described for rat), but also in the mouse olfactory bulb and nerve using immunohistochemistry and Western blot. Claudin-3 was present in the fila olfactoria from the epithelium to the olfactory nerve and in the main and accessory olfactory bulb. We propose that the abundant presence of claudin-3 in the olfactory system, particularly in nerve fibres and the olfactory bulb cone, which we present here, may play a role at the interface of the central and peripheral nervous system, both as barrier and for axonal growth and communication. Thus, claudin-3 should be considered and further explored with regards to treatment approaches addressing the olfactory bulb and nasal region.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/8767</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.14670/HH-11-854</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/27943232</dc:relation>
          <dc:source>Histology and histopathology. - 2017</dc:source>
          <dc:subject xml:lang="en">Animals</dc:subject>
          <dc:subject xml:lang="en">Axons</dc:subject>
          <dc:subject xml:lang="en">Blood-Brain Barrier</dc:subject>
          <dc:subject xml:lang="en">Claudin-1</dc:subject>
          <dc:subject xml:lang="en">Claudin-2</dc:subject>
          <dc:subject xml:lang="en">Claudin-3</dc:subject>
          <dc:subject xml:lang="en">Claudin-4</dc:subject>
          <dc:subject xml:lang="en">Claudin-5</dc:subject>
          <dc:subject xml:lang="en">Enterotoxins</dc:subject>
          <dc:subject xml:lang="en">Epithelium</dc:subject>
          <dc:subject xml:lang="en">Gene Expression Regulation</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Mice</dc:subject>
          <dc:subject xml:lang="en">Mice, Inbred C57BL</dc:subject>
          <dc:subject xml:lang="en">Nasal Mucosa</dc:subject>
          <dc:subject xml:lang="en">Neurons</dc:subject>
          <dc:subject xml:lang="en">Olfactory Bulb</dc:subject>
          <dc:subject xml:lang="en">Olfactory Nerve</dc:subject>
          <dc:subject xml:lang="en">Smell</dc:subject>
          <dc:subject xml:lang="en">Tight Junctions</dc:subject>
          <dc:subject xml:lang="en">Tissue Distribution</dc:subject>
          <dc:title xml:lang="en">Distinct presence of the tight junction protein claudin-3 in olfactory bulb and fila olfactoria of the mouse.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:8744</identifier>
        <datestamp>2025-10-24T20:31:04Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Broder UN</dc:creator>
          <dc:creator>Jaeger T</dc:creator>
          <dc:creator>Jenal U</dc:creator>
          <dc:date>2016</dc:date>
          <dc:description xml:lang="en">Virulence of pathogenic bacteria is a tightly controlled process to facilitate invasion and survival in host tissues. Although pathways controlling virulence have been defined in detail, signals modulating these processes are poorly understood. The opportunistic pathogen Pseudomonas aeruginosa causes acute and chronic infections in humans. Disease progression is typically associated with a loss of acute virulence and the emergence of biofilms and chronic behaviour. The acute-to-chronic switch is governed by the global Gac/Rsm pathway. Using a newly developed acute-chronic dual reporter system we show that calcium stimulates the Gac/Rsm pathway via the Gac-associated hybrid histidine kinase LadS. We show that calcium binds to the periplasmic DISMED2 sensor domain of LadS to activate its kinase activity. Activation of the Gac/Rsm pathway by calcium leads to a switch to the chronic program and confers drug tolerance by reducing P. aeruginosa growth rate. Clinical isolates from cystic fibrosis airways retain their calcium response during chronic infections. Our data imply that calcium sensing evolved as an adaptation to the opportunistic lifestyle of P. aeruginosa and that calcium serves as a host signal to balance acute-to-chronic behaviour during infections. Establishing calcium signalling in host-pathogen interaction adds to growing evidence indicating key roles for calcium in bacterial signalling.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/8744</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1038/nmicrobiol.2016.184</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/27775685</dc:relation>
          <dc:source>Nature microbiology. - 2016</dc:source>
          <dc:subject xml:lang="en">Calcium</dc:subject>
          <dc:subject xml:lang="en">Calcium Signaling</dc:subject>
          <dc:subject xml:lang="en">Cystic Fibrosis</dc:subject>
          <dc:subject xml:lang="en">Gene Expression Regulation, Bacterial</dc:subject>
          <dc:subject xml:lang="en">Host-Pathogen Interactions</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Phosphotransferases</dc:subject>
          <dc:subject xml:lang="en">Pseudomonas Infections</dc:subject>
          <dc:subject xml:lang="en">Pseudomonas aeruginosa</dc:subject>
          <dc:subject xml:lang="en">Virulence</dc:subject>
          <dc:title xml:lang="en">LadS is a calcium-responsive kinase that induces acute-to-chronic virulence switch in Pseudomonas aeruginosa.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:8696</identifier>
        <datestamp>2025-10-24T20:31:00Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Zimmermann P</dc:creator>
          <dc:creator>Tebruegge M</dc:creator>
          <dc:creator>Curtis N</dc:creator>
          <dc:creator>Ritz N</dc:creator>
          <dc:date>2016</dc:date>
          <dc:identifier>https://sonar.ch/global/documents/8696</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jinf.2016.07.017</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/27506394</dc:relation>
          <dc:source>The Journal of infection. - 2016</dc:source>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Lymphadenitis</dc:subject>
          <dc:subject xml:lang="en">Mycobacterium Infections, Nontuberculous</dc:subject>
          <dc:subject xml:lang="en">Neck</dc:subject>
          <dc:subject xml:lang="en">Nontuberculous Mycobacteria</dc:subject>
          <dc:subject xml:lang="en">Tuberculosis, Lymph Node</dc:subject>
          <dc:title xml:lang="en">A personalised approach is needed for the management of non-tuberculous mycobacterial cervicofacial lymphadenitis.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:8934</identifier>
        <datestamp>2025-10-24T20:31:35Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Straface A</dc:creator>
          <dc:creator>Rupp L</dc:creator>
          <dc:creator>Gintaute A</dc:creator>
          <dc:creator>Fischer J</dc:creator>
          <dc:creator>Zitzmann NU</dc:creator>
          <dc:creator>Rohr N</dc:creator>
          <dc:date>2019</dc:date>
          <dc:description xml:lang="en">BACKGROUND
The required pretreatment of CAD/CAM ceramic materials before resin composite cement application varies among studies. The aim of the present study was to evaluate the effect of hydrofluoric acid concentration and etching time on the shear bond strength (SBS) of two adhesive and two self-adhesive resin composite cements to different CAD/CAM ceramic materials.


METHODS
SBS of two adhesive (Panavia V5, Kuraray, [PV5]; Vita Adiva F-Cem, Vita Zahnfabrik, [VAF]) and two self-adhesive (RelyX Unicem 2 Automix, 3 M Espe, [RUN]; Vita Adiva S-Cem, Vita, [VAS]) cements to four different CAD/CAM materials (Vitablocs Mark II, Vita, [VM]; Vita Enamic, Vita, [VE]; e.max CAD, Ivoclar Vivadent, [EC]; Vita Suprinity PC, Vita, [VS]) was measured. The effect of the surface pretreatment by using two different hydrofluoric acid products (HF5% Vita Ceramics Etch, Vita and HF9% buffered, Ultradent Porcelain Etch, Ultradent Products) were assessed at etching times of 0 s, 5 s, 15 s, 30s and 60s for each cement and restorative material combination (n = 10 per group, total n = 1440).


RESULTS
Significant effects were found for the etching time and cement for all materials with highest shear bond strength for etching times of 60s = 30s = 15 s ≥ 5 s &gt; 0 s and for RUN&gt;PV5 = VAF &gt; VAS (p &lt; 0.05). Etching with HF5% for 5 s to 15 s resulted in higher SBS values, while no differences were observed between HF5% and HF9% buffered when the substrates were etched for 30s to 60s (p &lt; 0.05).


CONCLUSIONS
Within the limitations of this study the recommended surface pretreatment of silicate ceramics is HF etching with concentrations of 5% or 9% for 15 s to 60s to achieve highest shear bond strength while the glassy matrix is sufficiently dissolved. The tested resin composite cements can be applied with all tested materials and suggested for clinical application.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/8934</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1186/s13005-019-0206-8</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/31395069</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Head &amp; face medicine. - 2019</dc:source>
          <dc:subject xml:lang="en">CAD/CAM</dc:subject>
          <dc:subject xml:lang="en">Ceramic</dc:subject>
          <dc:subject xml:lang="en">HF concentration</dc:subject>
          <dc:subject xml:lang="en">HF etching time</dc:subject>
          <dc:subject xml:lang="en">Shear bond strength</dc:subject>
          <dc:subject xml:lang="en">Ceramics</dc:subject>
          <dc:subject xml:lang="en">Computer-Aided Design</dc:subject>
          <dc:subject xml:lang="en">Dental Bonding</dc:subject>
          <dc:subject xml:lang="en">Dental Materials</dc:subject>
          <dc:subject xml:lang="en">Materials Testing</dc:subject>
          <dc:subject xml:lang="en">Resin Cements</dc:subject>
          <dc:subject xml:lang="en">Shear Strength</dc:subject>
          <dc:subject xml:lang="en">Surface Properties</dc:subject>
          <dc:title xml:lang="en">HF etching of CAD/CAM materials: influence of HF concentration and etching time on shear bond strength.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:8915</identifier>
        <datestamp>2025-10-24T20:31:34Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Choi J</dc:creator>
          <dc:creator>Hwang JH</dc:creator>
          <dc:creator>Lim H</dc:creator>
          <dc:creator>Joo H</dc:creator>
          <dc:creator>Yang HS</dc:creator>
          <dc:creator>Lee YH</dc:creator>
          <dc:creator>Eeftens M</dc:creator>
          <dc:creator>Struchen B</dc:creator>
          <dc:creator>Röösli M</dc:creator>
          <dc:creator>Lee AK</dc:creator>
          <dc:creator>Choi HD</dc:creator>
          <dc:creator>Kwon JH</dc:creator>
          <dc:creator>Ha M</dc:creator>
          <dc:date>2018</dc:date>
          <dc:description xml:lang="en">We aimed to assess the personal radiofrequency electromagnetic field (RF-EMF) exposure levels of children and adults through their activities, with consideration to the body shadowing effect. We recruited 50 child-adult pairs, living in Seoul, Cheonan, and Ulsan, South Korea. RF-EMF measurements were performed between September and December 2016, using a portable exposure meter tailored to capture 14 Korean radiofrequency (RF) bands ranging from 87.5 to 5875MHz. The participants carried the device for 48h and kept a time-activity diary using a smartphone application in flight mode. To enhance accuracy of the exposure assessment, the body shadowing effect was compensated during the statistical analysis with the measured RF-EMF exposure. The compensation was conducted using the hybrid model that represents the decrease of the exposure level due to the body shadowing effect. A generalized linear mixed model was used to compare the RF-EMF exposure levels by subjects and activities. The arithmetic (geometric) means of the total power density were 174.9 (36.6) μW/m2 for all participants, 226.9 (44.6) for fathers, 245.4 (44.8) for mothers, and 116.2 (30.1) for children. By compensating for the body shadowing effect, the total RF-EMF exposure increased marginally, approximately 1.4 times. Each frequency band contribution to total RF-EMF exposure consisted of 76.7%, 2.4%, 9.9%, 5.0%, 3.3%, and 2.6% for downlink, uplink, WiFi, FM Radio, TV, and WiBro bands, respectively. Among the three regions, total RF-EMF exposure was highest in Seoul, and among the activities, it was highest in the metro, followed by foot/bicycle, bus/car, and outside. The contribution of base-station exposure to total RF-EMF exposure was the highest both in parents and children. Total and base-station RF-EMF exposure levels in Korea were higher than those reported in European countries.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/8915</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.scitotenv.2018.01.318</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/30857115</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>The Science of the total environment. - 2018</dc:source>
          <dc:subject xml:lang="en">Body shadowing effect</dc:subject>
          <dc:subject xml:lang="en">Exposure assessment</dc:subject>
          <dc:subject xml:lang="en">Mobile phone base-station</dc:subject>
          <dc:subject xml:lang="en">Portable exposure meter (PEM)</dc:subject>
          <dc:subject xml:lang="en">Radiofrequency electromagnetic fields (RF-EMF)</dc:subject>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Cell Phone</dc:subject>
          <dc:subject xml:lang="en">Child</dc:subject>
          <dc:subject xml:lang="en">Electromagnetic Fields</dc:subject>
          <dc:subject xml:lang="en">Environmental Exposure</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Linear Models</dc:subject>
          <dc:subject xml:lang="en">Radio Waves</dc:subject>
          <dc:subject xml:lang="en">Republic of Korea</dc:subject>
          <dc:subject xml:lang="en">Seoul</dc:subject>
          <dc:subject xml:lang="en">Smartphone</dc:subject>
          <dc:title xml:lang="en">Assessment of radiofrequency electromagnetic field exposure from personal measurements considering the body shadowing effect in Korean children and parents.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:8891</identifier>
        <datestamp>2025-10-24T20:31:48Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Munsch M</dc:creator>
          <dc:creator>Kuhlmann AV</dc:creator>
          <dc:creator>Cadeddu D</dc:creator>
          <dc:creator>Gérard JM</dc:creator>
          <dc:creator>Claudon J</dc:creator>
          <dc:creator>Poggio M</dc:creator>
          <dc:creator>Warburton RJ</dc:creator>
          <dc:date>2017</dc:date>
          <dc:description xml:lang="en">Coupling a microscopic mechanical resonator to a nanoscale quantum system enables control of the mechanical resonator via the quantum system and vice-versa. The coupling is usually achieved through functionalization of the mechanical resonator, but this results in additional mass and dissipation channels. An alternative is an intrinsic coupling based on strain. Here we employ a monolithic semiconductor system: the nanoscale quantum system is a semiconductor quantum dot (QD) located inside a nanowire. We demonstrate the resonant optical driving of the QD transition in such a structure. The noise spectrum of the resonance fluorescence signal, recorded in the single-photon counting regime, reveals a coupling to mechanical modes of different types. We measure a sensitivity to displacement of 65 fm/[Formula: see text] limited by charge noise in the device. Finally, we use thermal excitation of the different modes to determine the location of the QD within the trumpet, and calculate the contribution of the Brownian motion to the dephasing of the emitter.Resonant driving of a nanoscale quantum system coupled to a microscopic mechanical resonator may have uses in precision sensing and quantum information. The authors realize this by tailoring the geometry of a semiconductor nanowire embedding a quantum dot, detecting sub-picometre displacements.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/8891</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1038/s41467-017-00097-3</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/28710414</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Nature communications. - 2017</dc:source>
          <dc:title xml:lang="en">Resonant driving of a single photon emitter embedded in a mechanical oscillator.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:8805</identifier>
        <datestamp>2025-10-24T20:31:29Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Ortega Sanchez G</dc:creator>
          <dc:creator>Jahn K</dc:creator>
          <dc:creator>Savic S</dc:creator>
          <dc:creator>Zippelius A</dc:creator>
          <dc:creator>Läubli H</dc:creator>
          <dc:date>2018</dc:date>
          <dc:description xml:lang="en">BACKGROUND
The development of pulmonary immune-related adverse events (irAEs) in patients undergoing PD-(L)1 targeted checkpoint inhibitors are rare, but may be life-threatening. While many published articles and guidelines are focusing on the presentation and upfront treatment of pulmonary irAEs, the strategy in patients with late-onset pneumonia that are resistant to commonly used immunosuppressive drugs remains unclear.


CASE PRESENTATION
Here, we report the successful treatment of a mycophenolate-resistant organizing pneumonia (OP) with infliximab in a patient with metastatic melanoma after PD-1 blockade. The patient received two years of PD-1 targeted immunotherapy when he developed multiple nodular lung lesions mimicking a metastatic progression. However, wedge resection of these lesions showed defined areas of OP, which responded well to corticosteroids. Upon tapering, new foci of OP developed which were resistant to high-dose steroids and mycophenolate treatment. The TNFα antagonist infliximab led to a rapid and durable regression of the inflammatory lesions.


CONCLUSION
This case describes a not well-studied situation, in which a mycophenolate-resistant PD-1 blocker-associated pneumonitis was successfully treated with a TNFα neutralizing antibody. The outcome of this case suggests that infliximab might be the preferable option compared to classical immunosuppressants in the case of steroid-resistant/-dependent late onset pulmonary irAEs.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/8805</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1186/s40425-018-0400-4</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/30176946</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Journal for immunotherapy of cancer. - 2018</dc:source>
          <dc:subject xml:lang="en">Cancer immunotherapy</dc:subject>
          <dc:subject xml:lang="en">Immune checkpoint inhibitor</dc:subject>
          <dc:subject xml:lang="en">Immune-related adverse event</dc:subject>
          <dc:subject xml:lang="en">Lung</dc:subject>
          <dc:subject xml:lang="en">Pneumonitis</dc:subject>
          <dc:subject xml:lang="en">Aged</dc:subject>
          <dc:subject xml:lang="en">Antibodies, Monoclonal, Humanized</dc:subject>
          <dc:subject xml:lang="en">Antineoplastic Agents</dc:subject>
          <dc:subject xml:lang="en">Antineoplastic Agents, Immunological</dc:subject>
          <dc:subject xml:lang="en">CTLA-4 Antigen</dc:subject>
          <dc:subject xml:lang="en">Drug Resistance, Neoplasm</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Immunosuppressive Agents</dc:subject>
          <dc:subject xml:lang="en">Infliximab</dc:subject>
          <dc:subject xml:lang="en">Ipilimumab</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Melanoma</dc:subject>
          <dc:subject xml:lang="en">Mycophenolic Acid</dc:subject>
          <dc:subject xml:lang="en">Pneumonia</dc:subject>
          <dc:subject xml:lang="en">Programmed Cell Death 1 Receptor</dc:subject>
          <dc:subject xml:lang="en">Tumor Necrosis Factor-alpha</dc:subject>
          <dc:title xml:lang="en">Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:8897</identifier>
        <datestamp>2025-10-24T20:31:49Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Krähenmann R</dc:creator>
          <dc:creator>Küchenhoff B</dc:creator>
          <dc:creator>Böker H</dc:creator>
          <dc:creator>Schick M</dc:creator>
          <dc:date>2010</dc:date>
          <dc:description xml:lang="en">OBJECTIVE
The case of a schizoaffective patient suffering from a malignant catatonic syndrome following combined lithium-risperidone therapy is explored.


METHOD
A case report and relevant deliberations regarding pathophysiology of the catatonic dilemma are discussed.


CONCLUSIONS
There are two critical transitions in the development of a malignant catatonic syndrome. Dopaminergic system and psychopharmacological factors are supposed to play a key role. However, other neurotransmitter systems and the individual predisposition must be considered.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/8897</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1055/s-0030-1248498</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/20803411</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Psychiatrische Praxis. - 2010</dc:source>
          <dc:subject xml:lang="en">Antimanic Agents</dc:subject>
          <dc:subject xml:lang="en">Antipsychotic Agents</dc:subject>
          <dc:subject xml:lang="en">Brain</dc:subject>
          <dc:subject xml:lang="en">Catatonia</dc:subject>
          <dc:subject xml:lang="en">Clozapine</dc:subject>
          <dc:subject xml:lang="en">Diagnosis, Differential</dc:subject>
          <dc:subject xml:lang="en">Dopamine</dc:subject>
          <dc:subject xml:lang="en">Dose-Response Relationship, Drug</dc:subject>
          <dc:subject xml:lang="en">Drug Interactions</dc:subject>
          <dc:subject xml:lang="en">Drug Therapy, Combination</dc:subject>
          <dc:subject xml:lang="en">Electroencephalography</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Hypnotics and Sedatives</dc:subject>
          <dc:subject xml:lang="en">Lithium Carbonate</dc:subject>
          <dc:subject xml:lang="en">Long-Term Care</dc:subject>
          <dc:subject xml:lang="en">Lorazepam</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Psychotic Disorders</dc:subject>
          <dc:subject xml:lang="en">Risperidone</dc:subject>
          <dc:subject xml:lang="en">Serotonin</dc:subject>
          <dc:title xml:lang="en">[Catatonic dilemma in a schizoaffective patient with combined lithium-risperidone administration].</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:8987</identifier>
        <datestamp>2025-10-24T20:31:53Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Gerber M</dc:creator>
          <dc:creator>Minghetti A</dc:creator>
          <dc:creator>Beck J</dc:creator>
          <dc:creator>Zahner L</dc:creator>
          <dc:creator>Donath L</dc:creator>
          <dc:date>2019</dc:date>
          <dc:description xml:lang="en">Major depressive disorder (MDD) is one of the most burdensome disorders worldwide. While exercise training in patients with MDD contributes to clinically relevant improvements in cardiorespiratory fitness, whether and to what degree changes in cardiorespiratory fitness impact depressive symptom severity has not yet been addressed systematically in prior research. The purpose of our study was threefold. Firstly, to examine whether baseline levels and improvements in objectively assessed VO2max and subjectively perceived fitness predicted endpoint levels and change in depressive symptoms, wellbeing and sleep. Secondly, to determine whether exercise modality (sprint interval training [SIT]) versus continuous aerobic exercise training [CAT]) predicted depressive symptoms, wellbeing and sleep. Thirdly, whether the affective responses during and following exercise predicted depressive symptoms, wellbeing and sleep. All measurements were taken in a sample of inpatients diagnosed with MDD. The sample consisted of 53 participants (41 women and 12 men, Mage = 36.3 years, SD = 11.3) with unipolar depression who were randomly assigned to SIT and CAT. Data were assessed at baseline and after four weeks of exercise training (including three weekly 35 min sessions). Multiple linear regression analyses showed that improvements in VO2max were associated with fewer depressive symptoms, better mental wellbeing, and better sleep after completion of the intervention. Additionally, improvements in perceived fitness were associated with fewer dysfunctional sleep-related cognitions and higher mental toughness post-intervention. Improvements in VO2max and perceived fitness were also associated with favorable changes in depressive symptoms, mental wellbeing, and sleep. More research is needed to find out which fitness tests are most time- and cost-efficient in a clinical setting and most acceptable for psychiatric patients.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/8987</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jpsychires.2019.03.011</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/30903972</dc:relation>
          <dc:source>Journal of psychiatric research. - 2019</dc:source>
          <dc:subject xml:lang="en">Exercise training</dc:subject>
          <dc:subject xml:lang="en">Fitness</dc:subject>
          <dc:subject xml:lang="en">Inpatients</dc:subject>
          <dc:subject xml:lang="en">Major depression</dc:subject>
          <dc:subject xml:lang="en">Sleep</dc:subject>
          <dc:subject xml:lang="en">Wellbeing</dc:subject>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Depressive Disorder, Major</dc:subject>
          <dc:subject xml:lang="en">Exercise</dc:subject>
          <dc:subject xml:lang="en">Exercise Therapy</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Physical Fitness</dc:subject>
          <dc:subject xml:lang="en">Psychiatric Status Rating Scales</dc:subject>
          <dc:subject xml:lang="en">Severity of Illness Index</dc:subject>
          <dc:subject xml:lang="en">Sleep Wake Disorders</dc:subject>
          <dc:subject xml:lang="en">Switzerland</dc:subject>
          <dc:title xml:lang="en">Is improved fitness following a 12-week exercise program associated with decreased symptom severity, better wellbeing, and fewer sleep complaints in patients with major depressive disorders? A secondary analysis of a randomized controlled trial.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:8803</identifier>
        <datestamp>2025-10-24T20:31:41Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Feng S</dc:creator>
          <dc:creator>Zhang B</dc:creator>
          <dc:creator>Kappos EA</dc:creator>
          <dc:creator>Tremp M</dc:creator>
          <dc:creator>Yang C</dc:creator>
          <dc:date>2017</dc:date>
          <dc:description xml:lang="en">BACKGROUND
Nipple reconstruction is an important last step in the process of autologous or implant-based breast reconstruction. A multitude of techniques have been described, among others the S-flap. To prevent nipple retraction after surgery, we modified the originally described method by Cronin.


METHODS
By adding an S-shaped incision line, the flap can be transposed with less tension and sutured on top of the new nipple along a curved line. Furthermore, two small triangular flaps were inserted at the base for reinforcement and reduced linear contraction. Assessment was completed by measuring nipple diameter and projection with a caliper.


RESULTS
A total of 16 patients underwent the technique, of whom 11 could be followed after 3 and 6 months. Overall patient satisfaction with the aesthetic result was high, and we observed no infection or necrosis. Nipples were stable in size and shape at 6 months. Although reduction of 68% in projection and 31% in diameter was observed, the nipples remained pleasantly similar to the contralateral non-operated side.


CONCLUSIONS
The modified S-flap is a simple and reliable technique for moderate-sized nipple reconstruction. By providing more tissue at the base, size and projection remain stable and durable. Moreover, by a modified linear incision line at the base, tension and subsequent scar contraction is minimal.


LEVEL OF EVIDENCE IV
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/8803</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1007/s00266-017-0789-z</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/28233130</dc:relation>
          <dc:source>Aesthetic plastic surgery. - 2017</dc:source>
          <dc:subject xml:lang="en">Breast surgery</dc:subject>
          <dc:subject xml:lang="en">Nipple reconstruction</dc:subject>
          <dc:subject xml:lang="en">Outcome</dc:subject>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Breast Neoplasms</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Mammaplasty</dc:subject>
          <dc:subject xml:lang="en">Mastectomy</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Nipples</dc:subject>
          <dc:subject xml:lang="en">Surgical Flaps</dc:subject>
          <dc:subject xml:lang="en">Suture Techniques</dc:subject>
          <dc:title xml:lang="en">Modified S-Flap for Nipple Reconstruction.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:8832</identifier>
        <datestamp>2025-10-24T20:31:44Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Prêtre V</dc:creator>
          <dc:creator>Wicki A</dc:creator>
          <dc:date>2018</dc:date>
          <dc:description xml:lang="en">AGC kinases have been identified to contribute to cancer development and progression. Currently, most AGC inhibitors in clinical development are Akt inhibitors such as MK-2206 or GDC-0068, which are known to promote cell growth arrest and to sensitize cancer cells to radiotherapy. Response rates in clinical trials with single agent Akt inhibitors are typically low. The observed adverse events are within the expected limits for compounds inhibiting the PI3K-mTOR axis. Preclinical and early clinical data for combination therapies are accumulating. Based on these data, several Akt inhibitors are about to enter phase 3 trials. Besides drugs that target Akt, p70S6K inhibitors have entered clinical development. Again, the response rates were rather low. In addition, relevant toxicities were identified, including a risk for coagulopathies with these compounds. Multi-AGC kinase inhibitors are also in early clinical development but the data is not sufficient yet to draw conclusions regarding their efficacy and side-effect profile. PKC inhibitors have been tested in the phase 3 setting but were found to lack efficacy. More trials with isoform-specific PKC inhibitors are expected. Taken together, therapies with AGC kinase inhibitors as single agents are unlikely to meet success. However, combination therapies and a precise stratification of patients according to the activation of signaling axes may increase the probability to see relevant efficacy with these compounds. The emergence of onco-immunotherapies holds some new challenges for these agents.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/8832</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.semcancer.2017.04.011</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/28473255</dc:relation>
          <dc:source>Seminars in cancer biology. - 2018</dc:source>
          <dc:subject xml:lang="en">AGC kinases</dc:subject>
          <dc:subject xml:lang="en">Akt</dc:subject>
          <dc:subject xml:lang="en">Biomarkers</dc:subject>
          <dc:subject xml:lang="en">Inhibitors</dc:subject>
          <dc:subject xml:lang="en">Therapy</dc:subject>
          <dc:subject xml:lang="en">Biomarkers, Tumor</dc:subject>
          <dc:subject xml:lang="en">Clinical Trials as Topic</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Molecular Targeted Therapy</dc:subject>
          <dc:subject xml:lang="en">Neoplasms</dc:subject>
          <dc:subject xml:lang="en">Protein Kinase Inhibitors</dc:subject>
          <dc:subject xml:lang="en">Protein-Serine-Threonine Kinases</dc:subject>
          <dc:subject xml:lang="en">Proto-Oncogene Proteins c-akt</dc:subject>
          <dc:title xml:lang="en">Inhibition of Akt and other AGC kinases: A target for clinical cancer therapy?</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:8844</identifier>
        <datestamp>2025-10-24T20:31:46Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Oranges CM</dc:creator>
          <dc:creator>Tremp M</dc:creator>
          <dc:creator>di Summa PG</dc:creator>
          <dc:creator>Schaefer DJ</dc:creator>
          <dc:creator>Kalbermatten DF</dc:creator>
          <dc:date>2017</dc:date>
          <dc:identifier>https://sonar.ch/global/documents/8844</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.bjps.2017.05.030</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/28601601</dc:relation>
          <dc:source>Journal of plastic, reconstructive &amp; aesthetic surgery : JPRAS. - 2017</dc:source>
          <dc:subject xml:lang="en">Buttocks</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Injections, Intramuscular</dc:subject>
          <dc:subject xml:lang="en">Prostheses and Implants</dc:subject>
          <dc:subject xml:lang="en">Reconstructive Surgical Procedures</dc:subject>
          <dc:title xml:lang="en">Commentary on "Does intramuscular gluteal augmentation using implants affect sensitivity in the buttocks?"</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:9956</identifier>
        <datestamp>2025-10-24T20:36:03Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Garrard, Rodney</dc:creator>
          <dc:creator>Kohler, Thomas</dc:creator>
          <dc:creator>Price, Martin F.</dc:creator>
          <dc:creator>Byers, Alton C.</dc:creator>
          <dc:creator>Sherpa, Ang Rita</dc:creator>
          <dc:creator>Maharjan, Gyanu Raja</dc:creator>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/9956</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1659/mrd-journal-d-15-00005.1</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/issn/0276-4741</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Mountain Research and Development. - International Mountain Society (IMS) and United Nations University. - 2016, vol. 36, no. 3, p. 299</dc:source>
          <dc:title xml:lang="en">Land Use and Land Cover Change in Sagarmatha National Park, a World Heritage Site in the Himalayas of Eastern Nepal</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:9925</identifier>
        <datestamp>2025-10-24T20:35:59Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Christen, Elisabeth</dc:creator>
          <dc:creator>Francois, Joseph</dc:creator>
          <dc:date>2015</dc:date>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/9925</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1111/twec.12330</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/issn/0378-5920</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>The World Economy. - Wiley. - 2015, vol. 40, no. 3, p. 517-531</dc:source>
          <dc:title xml:lang="en">Modes of Supply for US Exports of Services</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:9751</identifier>
        <datestamp>2025-10-24T20:35:53Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Kusejko K</dc:creator>
          <dc:creator>Salazar-Vizcaya L</dc:creator>
          <dc:creator>Braun DL</dc:creator>
          <dc:creator>Tarr PE</dc:creator>
          <dc:creator>Bernasconi E</dc:creator>
          <dc:creator>Doco-Lecompte T</dc:creator>
          <dc:creator>Cavassini M</dc:creator>
          <dc:creator>Schmid P</dc:creator>
          <dc:creator>Du Pasquier R</dc:creator>
          <dc:creator>Hauser C</dc:creator>
          <dc:creator>Günthard HF</dc:creator>
          <dc:creator>Kouyos RD</dc:creator>
          <dc:date>2020</dc:date>
          <dc:description xml:lang="en">BACKGROUND
Self-reported neurocognitive impairment (SRNI) in people living with human immunodeficiency virus type 1 (HIV-1) infection is frequent. We use longitudinal information on SRNI in the Swiss HIV Cohort Study (SHCS) to identify and characterize groups of patients with persisting SRNI over time.


METHODS
We included all SHCS patients who were assessed for SRNI during at least 5 visits spanning at least 2.5 years in 2013-2017. We first compared patients with SRNI to those without SRNI over the whole study period. Second, we used a hierarchical cluster algorithm to identify groups of patients with similar changes of SRNI over time. In both analyses, we studied clinical and demographic factors potentially influencing SRNI.


RESULTS
In total, 79 683 questionnaires of 11 029 patients contained information about SRNI, and 8545 of 11 029 (77.5%) patients had longitudinal information. The overall percentage of patients with SRNI decreased from 19.6% in 2013 to 10.7% in 2017. Compared to patients in the cluster with low-level SRNI over time, patients in the cluster with high-level persisting SRNI more often had a prior opportunistic infection of the central nervous system (CNS) (odds ratio [OR], 3.7; P &lt; .001), imperfect adherence to antiretroviral therapy (ART) (OR, 2.8; P &lt; .001), and depression (OR, 1.9; P &lt; .001).


CONCLUSIONS
Although overall SRNI is decreasing in the SHCS, there is a group of patients with persisting SRNI over time. Past opportunistic infections of the CNS, imperfect adherence to ART, and depression were associated most with persisting SRNI. Patients with these characteristics should be preferentially tested for neurocognitive impairment.Although overall self-reported neurocognitive impairment (SRNI) is decreasing in the Swiss HIV Cohort Study, there is a group of patients with persisting SRNI over time, characterized by more past opportunistic infections of the central nervous system, imperfect adherence to antiretroviral therapy, and depression.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/9751</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1093/cid/ciz868</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/31504323</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. - 2020</dc:source>
          <dc:subject xml:lang="en">HIV</dc:subject>
          <dc:subject xml:lang="en">self-reported neurocognitive impairment</dc:subject>
          <dc:title xml:lang="en">Self-reported Neurocognitive Impairment in People Living With Human Immunodeficiency Virus (HIV): Characterizing Clusters of Patients With Similar Changes in Self-reported Neurocognitive Impairment, 2013-2017, in the Swiss HIV Cohort Study.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:9942</identifier>
        <datestamp>2025-10-24T20:36:01Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Nguyen DP</dc:creator>
          <dc:creator>Hnilicka S</dc:creator>
          <dc:creator>Kiss B</dc:creator>
          <dc:creator>Seiler R</dc:creator>
          <dc:creator>Thalmann GN</dc:creator>
          <dc:creator>Roth B</dc:creator>
          <dc:date>2015</dc:date>
          <dc:description xml:lang="en">PURPOSE
Management of ureteral stones remains controversial. To determine whether optimizing the extracorporeal shock wave lithotripsy delivery rate would improve the treatment of solitary ureteral stones we compared the outcomes of 2 delivery rates in a prospective randomized trial.


MATERIALS AND METHODS
From July 2010 to October 2012, 254 consecutive patients were randomized to extracorporeal shock wave lithotripsy at a shock wave delivery rate of 60 and 90 pulses per minute in 130 and 124, respectively. The primary study end point was the stone-free rate at 3-month followup. Secondary end points were stone disintegration, treatment time, complications and the rate of secondary treatments. Descriptive statistics were used to compare end points between the 2 groups. The adjusted OR and 95% CI were calculated to assess predictors of success.


RESULTS
The stone-free rate at 3 months was significantly higher in patients who underwent extracorporeal shock wave lithotripsy at a shock wave delivery rate of 90 pulses per minute than in those who received 60 pulses per minute (91% vs 80%, p = 0.01). Patients with proximal (100% vs 83%, p = 0.005) and mid ureteral stones (96% vs 73%, p = 0.03) accounted for the observed difference but not those with distal ureteral stones (81% vs 80%, p = 0.9, respectively). Treatment time, complications and the rate of secondary treatments were comparable between the 2 groups. On multivariable analysis the shock wave delivery rate of 90 pulses per minute, proximal stone location, stone density, stone size and an absent indwelling Double-J® stent were independent predictors of success.


CONCLUSIONS
Optimizing the extracorporeal shock wave lithotripsy delivery rate can achieve excellent results for ureteral stones.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/9942</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.juro.2015.01.110</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/25661296</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>The Journal of urology. - 2015</dc:source>
          <dc:subject xml:lang="en">calculi</dc:subject>
          <dc:subject xml:lang="en">high-energy shock waves</dc:subject>
          <dc:subject xml:lang="en">lithotripsy</dc:subject>
          <dc:subject xml:lang="en">outcome and process assessment</dc:subject>
          <dc:subject xml:lang="en">ureter</dc:subject>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Aged</dc:subject>
          <dc:subject xml:lang="en">Disease Management</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Follow-Up Studies</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Lithotripsy</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Prospective Studies</dc:subject>
          <dc:subject xml:lang="en">Reproducibility of Results</dc:subject>
          <dc:subject xml:lang="en">Treatment Outcome</dc:subject>
          <dc:subject xml:lang="en">Ureteral Calculi</dc:subject>
          <dc:title xml:lang="en">Optimization of Extracorporeal Shock Wave Lithotripsy Delivery Rates Achieves Excellent Outcomes for Ureteral Stones: Results of a Prospective Randomized Trial.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:9783</identifier>
        <datestamp>2025-10-24T20:35:50Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Matteodo M</dc:creator>
          <dc:creator>Ammann K</dc:creator>
          <dc:creator>Verrecchia EP</dc:creator>
          <dc:creator>Vittoz P</dc:creator>
          <dc:date>2016</dc:date>
          <dc:description xml:lang="en">While the upward shift of plant species has been observed on many alpine and nival summits, the reaction of the subalpine and lower alpine plant communities to the current warming and lower snow precipitation has been little investigated so far. To this aim, 63 old, exhaustive plant inventories, distributed along a subalpine-alpine elevation gradient of the Swiss Alps and covering different plant community types (acidic and calcareous grasslands; windy ridges; snowbeds), were revisited after 25-50 years. Old and recent inventories were compared in terms of species diversity with Simpson diversity and Bray-Curtis dissimilarity indices, and in terms of community composition with principal component analysis. Changes in ecological conditions were inferred from the ecological indicator values. The alpha-diversity increased in every plant community, likely because of the arrival of new species. As observed on mountain summits, the new species led to a homogenization of community compositions. The grasslands were quite stable in terms of species composition, whatever the bedrock type. Indeed, the newly arrived species were part of the typical species pool of the colonized community. In contrast, snowbed communities showed pronounced vegetation changes and a clear shift toward dryer conditions and shorter snow cover, evidenced by their colonization by species from surrounding grasslands. Longer growing seasons allow alpine grassland species, which are taller and hence more competitive, to colonize the snowbeds. This study showed that subalpine-alpine plant communities reacted differently to the ongoing climate changes. Lower snow/rain ratio and longer growing seasons seem to have a higher impact than warming, at least on plant communities dependent on long snow cover. Consequently, they are the most vulnerable to climate change and their persistence in the near future is seriously threatened. Subalpine and alpine grasslands are more stable, and, until now, they do not seem to be affected by a warmer climate.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/9783</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1002/ece3.2354</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/28725374</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Ecology and evolution. - 2016</dc:source>
          <dc:subject xml:lang="en">Colonization</dc:subject>
          <dc:subject xml:lang="en">Switzerland</dc:subject>
          <dc:subject xml:lang="en">cover changes</dc:subject>
          <dc:subject xml:lang="en">diversity</dc:subject>
          <dc:subject xml:lang="en">ecological indicator values</dc:subject>
          <dc:subject xml:lang="en">grasslands</dc:subject>
          <dc:subject xml:lang="en">homogenization</dc:subject>
          <dc:subject xml:lang="en">resurvey study</dc:subject>
          <dc:subject xml:lang="en">semipermanent plot</dc:subject>
          <dc:subject xml:lang="en">snowmelt</dc:subject>
          <dc:title xml:lang="en">Snowbeds are more affected than other subalpine-alpine plant communities by climate change in the Swiss Alps.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:9782</identifier>
        <datestamp>2025-10-24T20:35:50Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Grosse Holtforth M</dc:creator>
          <dc:creator>Krieger T</dc:creator>
          <dc:creator>Zimmermann J</dc:creator>
          <dc:creator>Altenstein-Yamanaka D</dc:creator>
          <dc:creator>Dörig N</dc:creator>
          <dc:creator>Meisch L</dc:creator>
          <dc:creator>Hayes AM</dc:creator>
          <dc:date>2019</dc:date>
          <dc:description xml:lang="en">BACKGROUND
Emotional processing (EP) is hypothesized to be a key mechanism of change in psychotherapy that may enhance its long-term efficacy. To study the effects of fostering EP in psychotherapy for depression, this randomized-controlled clinical trial compares the efficacy and pattern of change of a cognitive-behavioral therapy that integrates emotion-focused techniques within an exposure framework (Exposure-Based Cognitive Therapy for depression; EBCT-R) to a standard cognitive-behavioral therapy (CBT).


METHODS
One hundred and forty-nine depressed outpatients were randomized to a maximum of 22 sessions of manualized EBCT-R (N = 77) or CBT (N = 72). Primary outcomes were self-reported and clinician-rated depressive symptoms at posttreatment and 12-month follow-up. Secondary outcomes were self-esteem, interpersonal problems, and avoidance thoughts and behaviors.


RESULTS
Depressive symptoms improved significantly over therapy in both treatments, with large within-group effect sizes for CBT (d = -1.95) and EBCT-R (d = -1.77). The pattern of depression change during treatment did not differ between treatments. Symptom relief lasted over 12 months and did not differ between EBCT-R and CBT.


CONCLUSIONS
Results suggest that both treatments produced significant short- and long-term improvement in depression symptoms, but the integration of emotion-focused techniques within an exposure framework did not have added benefit.


TRIAL REGISTRATION
ClinicalTrials.gov Identifier: NCT01012856 Clinical or methodological significance of this article: This trial compares cognitive-behavioral therapy (CBT) with a similarly structured CBT that was designed to foster emotional processing by integrating emotion-focused techniques within an exposure framework. Results indicate that this form of assimilative integration did not improve outcomes at 12-month follow-up.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/9782</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1080/10503307.2017.1397796</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/29130400</dc:relation>
          <dc:source>Psychotherapy research : journal of the Society for Psychotherapy Research. - 2019</dc:source>
          <dc:subject xml:lang="en">Depressionen</dc:subject>
          <dc:subject xml:lang="en">Veränderungsmechanismen</dc:subject>
          <dc:subject xml:lang="en">cognitive–behavioral therapy</dc:subject>
          <dc:subject xml:lang="en">depression</dc:subject>
          <dc:subject xml:lang="en">depressione</dc:subject>
          <dc:subject xml:lang="en">depressão</dc:subject>
          <dc:subject xml:lang="en">emotional processing</dc:subject>
          <dc:subject xml:lang="en">emotionale Verarbeitung</dc:subject>
          <dc:subject xml:lang="en">expositionsbasierte kognitive Therapie</dc:subject>
          <dc:subject xml:lang="en">exposure-based cognitive therapy</dc:subject>
          <dc:subject xml:lang="en">kognitive Verhaltenstherapie</dc:subject>
          <dc:subject xml:lang="en">mecanismos de mudança</dc:subject>
          <dc:subject xml:lang="en">meccanismi di cambiamento</dc:subject>
          <dc:subject xml:lang="en">mechanisms of change</dc:subject>
          <dc:subject xml:lang="en">processamento delle emozioni</dc:subject>
          <dc:subject xml:lang="en">processamento emocional</dc:subject>
          <dc:subject xml:lang="en">terapia cognitiva basata sull'esposizione</dc:subject>
          <dc:subject xml:lang="en">terapia cognitiva baseada em exposição</dc:subject>
          <dc:subject xml:lang="en">terapia cognitiva comportamental</dc:subject>
          <dc:subject xml:lang="en">terapia cognitivo-comportamentale</dc:subject>
          <dc:subject xml:lang="en">情緒歷程</dc:subject>
          <dc:subject xml:lang="en">憂鬱症</dc:subject>
          <dc:subject xml:lang="en">改變機制</dc:subject>
          <dc:subject xml:lang="en">暴露為基礎的認知治療</dc:subject>
          <dc:subject xml:lang="en">認知行為治療</dc:subject>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Cognitive Behavioral Therapy</dc:subject>
          <dc:subject xml:lang="en">Depression</dc:subject>
          <dc:subject xml:lang="en">Depressive Disorder</dc:subject>
          <dc:subject xml:lang="en">Emotions</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Follow-Up Studies</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Implosive Therapy</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Outcome Assessment, Health Care</dc:subject>
          <dc:subject xml:lang="en">Psychotherapeutic Processes</dc:subject>
          <dc:title xml:lang="en">A randomized-controlled trial of cognitive-behavioral therapy for depression with integrated techniques from emotion-focused and exposure therapies.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:9838</identifier>
        <datestamp>2025-10-24T20:36:07Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Denenberg, Sagi</dc:creator>
          <dc:creator>Dubé, Maya Bräm</dc:creator>
          <dc:date>2018</dc:date>
          <dc:description xml:lang="en">&lt;jats:sec&gt;&lt;jats:title&gt;Practical relevance:&lt;/jats:title&gt;&lt;jats:p&gt; When a cat is presented for evaluation of a problem behaviour, it is likely that the cat’s wellbeing is negatively affected by the condition. In addition, the owners and any other animals around the cat may also be experiencing negative consequences. When managing these cases, it is important to consider all options (including behaviour modification, environmental changes, medications) that can help to reach an optimal solution. Medication cannot teach the cat how to behave or change a particular behaviour; it can, however, reduce arousal, excitability, reactivity and anxiety. &lt;/jats:p&gt;&lt;/jats:sec&gt;&lt;jats:sec&gt;&lt;jats:title&gt;Rationale:&lt;/jats:title&gt;&lt;jats:p&gt; The rationale for using psychoactive medications in behavioural medicine, or veterinary psychiatry, is to increase the wellbeing of the animal and to aid the owner and practitioner in managing problem behaviours. Medications should always be used as an adjunct to behavioural and environmental modification. &lt;/jats:p&gt;&lt;/jats:sec&gt;&lt;jats:sec&gt;&lt;jats:title&gt;Clinical challenges:&lt;/jats:title&gt;&lt;jats:p&gt; Many psychoactive medications cannot be used in the face of certain physical illnesses or concurrently with other medications. Some medications may also have side effects, not be effective at the recommended dose or have a paradoxical effect. Furthermore, success is reliant on the owner being able to administer the medication. &lt;/jats:p&gt;&lt;/jats:sec&gt;&lt;jats:sec&gt;&lt;jats:title&gt;Aims:&lt;/jats:title&gt;&lt;jats:p&gt; This article aims to guide practitioners by discussing questions such as how to choose the appropriate medication, how to dose it and how long to use it. The psychoactive medications most commonly used in feline medicine are reviewed, as well as some that are newer or less common. &lt;/jats:p&gt;&lt;/jats:sec&gt;&lt;jats:sec&gt;&lt;jats:title&gt;Evidence base:&lt;/jats:title&gt;&lt;jats:p&gt; Data for the use of medications in cats is limited, with just a small number of clinical-, species- and problem-directed studies available, and a few more case series and case reports. Where feline-specific research is not available, the authors have drawn upon research published in other species, such as humans, dogs and rats, as well as anecdotal reports and expert opinions. &lt;/jats:p&gt;&lt;/jats:sec&gt;</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/9838</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1177/1098612x18806760</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/issn/1098-612X</dc:relation>
          <dc:source>Journal of Feline Medicine and Surgery. - SAGE Publications. - 2018, vol. 20, no. 11, p. 1034-1045</dc:source>
          <dc:subject xml:lang="en">Small Animals</dc:subject>
          <dc:title xml:lang="en">Tools for managing feline problem behaviours: Psychoactive medications</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:9841</identifier>
        <datestamp>2025-10-24T20:35:55Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Bayer, Stefan</dc:creator>
          <dc:creator>Komor, Nathalie</dc:creator>
          <dc:creator>Kramer, Annina</dc:creator>
          <dc:creator>Albrecht, Dominic</dc:creator>
          <dc:creator>Mericske-Stern, Regina</dc:creator>
          <dc:creator>Enkling, Norbert</dc:creator>
          <dc:date>2011</dc:date>
          <dc:identifier>https://sonar.ch/global/documents/9841</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1111/j.1600-0501.2011.02312.x</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/issn/0905-7161</dc:relation>
          <dc:source>Clinical Oral Implants Research. - Wiley. - 2011, vol. 23, no. 12, p. 1377-1384</dc:source>
          <dc:subject xml:lang="en">Oral Surgery</dc:subject>
          <dc:title xml:lang="en">Retention force of plastic clips on implant bars: a randomized controlled trial</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:9831</identifier>
        <datestamp>2025-10-24T20:36:06Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Pfäffli, Matthias</dc:creator>
          <dc:creator>Oswald, Franz</dc:creator>
          <dc:creator>Weinmann, Wolfgang</dc:creator>
          <dc:date>2013</dc:date>
          <dc:identifier>https://sonar.ch/global/documents/9831</dc:identifier>
          <dc:language>ger</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.4414/smf.2013.01491</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/issn/1424-4020</dc:relation>
          <dc:source>Swiss Medical Forum ‒ Schweizerisches Medizin-Forum. - EMH Swiss Medical Publishers, Ltd.. - 2013, vol. 13, no. 16</dc:source>
          <dc:title xml:lang="de">Urinschnelltests (Immunoassays) auf Drogen und Medikamente</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:10375</identifier>
        <datestamp>2025-10-24T20:38:17Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Imprialou M</dc:creator>
          <dc:creator>Kahles A</dc:creator>
          <dc:creator>Steffen JG</dc:creator>
          <dc:creator>Osborne EJ</dc:creator>
          <dc:creator>Gan X</dc:creator>
          <dc:creator>Lempe J</dc:creator>
          <dc:creator>Bhomra A</dc:creator>
          <dc:creator>Belfield E</dc:creator>
          <dc:creator>Visscher A</dc:creator>
          <dc:creator>Greenhalgh R</dc:creator>
          <dc:creator>Harberd NP</dc:creator>
          <dc:creator>Goram R</dc:creator>
          <dc:creator>Hein J</dc:creator>
          <dc:creator>Robert-Seilaniantz A</dc:creator>
          <dc:creator>Jones J</dc:creator>
          <dc:creator>Stegle O</dc:creator>
          <dc:creator>Kover P</dc:creator>
          <dc:creator>Tsiantis M</dc:creator>
          <dc:creator>Nordborg M</dc:creator>
          <dc:creator>Rätsch G</dc:creator>
          <dc:creator>Clark RM</dc:creator>
          <dc:creator>Mott R</dc:creator>
          <dc:date>2017</dc:date>
          <dc:description xml:lang="en">To understand the population genetics of structural variants and their effects on phenotypes, we developed an approach to mapping structural variants that segregate in a population sequenced at low coverage. We avoid calling structural variants directly. Instead, the evidence for a potential structural variant at a locus is indicated by variation in the counts of short-reads that map anomalously to that locus. These structural variant traits are treated as quantitative traits and mapped genetically, analogously to a gene expression study. Association between a structural variant trait at one locus, and genotypes at a distant locus indicate the origin and target of a transposition. Using ultra-low-coverage (0.3×) population sequence data from 488 recombinant inbred Arabidopsis thaliana genomes, we identified 6502 segregating structural variants. Remarkably, 25% of these were transpositions. While many structural variants cannot be delineated precisely, we validated 83% of 44 predicted transposition breakpoints by polymerase chain reaction. We show that specific structural variants may be causative for quantitative trait loci for germination and resistance to infection by the fungus Albugo laibachii, isolate Nc14. Further we show that the phenotypic heritability attributable to read-mapping anomalies differs from, and, in the case of time to germination and bolting, exceeds that due to standard genetic variation. Genes within structural variants are also more likely to be silenced or dysregulated. This approach complements the prevalent strategy of structural variant discovery in fewer individuals sequenced at high coverage. It is generally applicable to large populations sequenced at low-coverage, and is particularly suited to mapping transpositions.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/10375</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1534/genetics.116.192823</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/28179367</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Genetics. - 2017</dc:source>
          <dc:subject xml:lang="en">Arabidopsis</dc:subject>
          <dc:subject xml:lang="en">heritability</dc:subject>
          <dc:subject xml:lang="en">low-coverage sequencing</dc:subject>
          <dc:subject xml:lang="en">quantitative trait locus</dc:subject>
          <dc:subject xml:lang="en">structural variation</dc:subject>
          <dc:subject xml:lang="en">Arabidopsis</dc:subject>
          <dc:subject xml:lang="en">Genomic Structural Variation</dc:subject>
          <dc:subject xml:lang="en">Phenotype</dc:subject>
          <dc:subject xml:lang="en">Plant Immunity</dc:subject>
          <dc:subject xml:lang="en">Quantitative Trait Loci</dc:subject>
          <dc:subject xml:lang="en">Quantitative Trait, Heritable</dc:subject>
          <dc:title xml:lang="en">Genomic Rearrangements in Arabidopsis Considered as Quantitative Traits.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:10384</identifier>
        <datestamp>2025-10-24T20:38:18Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Khrameeva E</dc:creator>
          <dc:creator>Kurochkin I</dc:creator>
          <dc:creator>Han D</dc:creator>
          <dc:creator>Guijarro P</dc:creator>
          <dc:creator>Kanton S</dc:creator>
          <dc:creator>Santel M</dc:creator>
          <dc:creator>Qian Z</dc:creator>
          <dc:creator>Rong S</dc:creator>
          <dc:creator>Mazin P</dc:creator>
          <dc:creator>Sabirov M</dc:creator>
          <dc:creator>Bulat M</dc:creator>
          <dc:creator>Efimova O</dc:creator>
          <dc:creator>Tkachev A</dc:creator>
          <dc:creator>Guo S</dc:creator>
          <dc:creator>Sherwood CC</dc:creator>
          <dc:creator>Camp JG</dc:creator>
          <dc:creator>Pääbo S</dc:creator>
          <dc:creator>Treutlein B</dc:creator>
          <dc:creator>Khaitovich P</dc:creator>
          <dc:date>2020</dc:date>
          <dc:description xml:lang="en">Identification of gene expression traits unique to the human brain sheds light on the molecular mechanisms underlying human evolution. Here, we searched for uniquely human gene expression traits by analyzing 422 brain samples from humans, chimpanzees, bonobos, and macaques representing 33 anatomical regions, as well as 88,047 cell nuclei composing three of these regions. Among 33 regions, cerebral cortex areas, hypothalamus, and cerebellar gray and white matter evolved rapidly in humans. At the cellular level, astrocytes and oligodendrocyte progenitors displayed more differences in the human evolutionary lineage than the neurons. Comparison of the bulk tissue and single-nuclei sequencing revealed that conventional RNA sequencing did not detect up to two-thirds of cell-type-specific evolutionary differences.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/10384</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1101/gr.256958.119</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/32424074</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Genome research. - 2020</dc:source>
          <dc:subject xml:lang="en">Genetics(clinical)</dc:subject>
          <dc:subject xml:lang="en">Genetics</dc:subject>
          <dc:title xml:lang="en">Single-cell-resolution transcriptome map of human, chimpanzee, bonobo, and macaque brains.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:10253</identifier>
        <datestamp>2025-10-24T20:38:09Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Retel C</dc:creator>
          <dc:creator>Märkle H</dc:creator>
          <dc:creator>Becks L</dc:creator>
          <dc:creator>Feulner PGD</dc:creator>
          <dc:date>2019</dc:date>
          <dc:description xml:lang="en">The contemporary genomic diversity of viruses is a result of the continuous and dynamic interaction of past ecological and evolutionary processes. Thus, genome sequences of viruses can be a valuable source of information about these processes. In this review, we first describe the relevant processes shaping viral genomic variation, with a focus on the role of host⁻virus coevolution and its potential to give rise to eco-evolutionary feedback loops. We further give a brief overview of available methodology designed to extract information about these processes from genomic data. Short generation times and small genomes make viruses ideal model systems to study the joint effect of complex coevolutionary and eco-evolutionary interactions on genetic evolution. This complexity, together with the diverse array of lifetime and reproductive strategies in viruses ask for extensions of existing inference methods, for example by integrating multiple information sources. Such integration can broaden the applicability of genetic inference methods and thus further improve our understanding of the role viruses play in biological communities.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/10253</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.3390/v11030220</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/30841497</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Viruses. - 2019</dc:source>
          <dc:subject xml:lang="en">eco-evolutionary feedback</dc:subject>
          <dc:subject xml:lang="en">genetic diversity</dc:subject>
          <dc:subject xml:lang="en">host–virus coevolution</dc:subject>
          <dc:subject xml:lang="en">viral population genetics</dc:subject>
          <dc:subject xml:lang="en">Ecosystem</dc:subject>
          <dc:subject xml:lang="en">Evolution, Molecular</dc:subject>
          <dc:subject xml:lang="en">Genetic Variation</dc:subject>
          <dc:subject xml:lang="en">Genomics</dc:subject>
          <dc:subject xml:lang="en">Host Microbial Interactions</dc:subject>
          <dc:subject xml:lang="en">Models, Biological</dc:subject>
          <dc:subject xml:lang="en">Viruses</dc:subject>
          <dc:title xml:lang="en">Ecological and Evolutionary Processes Shaping Viral Genetic Diversity.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:10228</identifier>
        <datestamp>2025-10-24T20:38:07Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Bürkli A</dc:creator>
          <dc:creator>Sieber N</dc:creator>
          <dc:creator>Seppälä K</dc:creator>
          <dc:creator>Jokela J</dc:creator>
          <dc:date>2017</dc:date>
          <dc:description xml:lang="en">The rate of self-fertilization (that is, selfing) is a key evolutionary parameter in hermaphroditic species, yet obtaining accurate estimates of selfing rates in natural populations can be technically challenging. Most published estimates are derived from population-level heterozygote deficiency (that is, FIS) or identity disequilibria (for example, the software RMES (robust multilocus estimate of selfing)). These indirect methods can be applied to population genetic survey data, whereas direct methods using progeny arrays require much larger data sets that are often difficult to collect in natural populations or even require captive breeding. Unfortunately, indirect methods rely on assumptions that can be problematic, such as negating biparental inbreeding, inbreeding disequilibrium and (for FIS) the presence of null alleles. The performance of indirect estimates against progeny-array estimates is still largely unknown. Here we used both direct progeny-array and indirect population-level methods to estimate the selfing rate in a single natural population of the simultaneously hermaphroditic freshwater snail Radix balthica throughout its reproductive lifespan using 10 highly polymorphic microsatellites. We found that even though progeny arrays (n=1034 field-collected embryos from 60 families) did not reveal a single selfed embryo, FIS-based selfing rates (n=316 adults) were significantly positive in all 6 sequential population samples. Including a locus with a high frequency of null alleles further biased FIS-based estimates. Conversely, RMES-based estimates were very similar to progeny-array estimates and proved insensitive to null alleles. The assumptions made by RMES were thus either met or irrelevant in this particular population, making RMES a valid, cost-efficient alternative to progeny arrays.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/10228</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1038/hdy.2017.1</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/28177324</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Heredity. - 2017</dc:source>
          <dc:subject xml:lang="en">Alleles</dc:subject>
          <dc:subject xml:lang="en">Animals</dc:subject>
          <dc:subject xml:lang="en">Fresh Water</dc:subject>
          <dc:subject xml:lang="en">Genetics, Population</dc:subject>
          <dc:subject xml:lang="en">Inbreeding</dc:subject>
          <dc:subject xml:lang="en">Microsatellite Repeats</dc:subject>
          <dc:subject xml:lang="en">Models, Biological</dc:subject>
          <dc:subject xml:lang="en">Ovum</dc:subject>
          <dc:subject xml:lang="en">Self-Fertilization</dc:subject>
          <dc:subject xml:lang="en">Snails</dc:subject>
          <dc:title xml:lang="en">Comparing direct and indirect selfing rate estimates: when are population-structure estimates reliable?</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:10241</identifier>
        <datestamp>2025-10-24T20:38:20Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Carpov S</dc:creator>
          <dc:creator>Gama N</dc:creator>
          <dc:creator>Georgieva M</dc:creator>
          <dc:creator>Troncoso-Pastoriza JR</dc:creator>
          <dc:date>2020</dc:date>
          <dc:description xml:lang="en">BACKGROUND
Privacy-preserving computations on genomic data, and more generally on medical data, is a critical path technology for innovative, life-saving research to positively and equally impact the global population. It enables medical research algorithms to be securely deployed in the cloud because operations on encrypted genomic databases are conducted without revealing any individual genomes. Methods for secure computation have shown significant performance improvements over the last several years. However, it is still challenging to apply them on large biomedical datasets.


METHODS
The HE Track of iDash 2018 competition focused on solving an important problem in practical machine learning scenarios, where a data analyst that has trained a regression model (both linear and logistic) with a certain set of features, attempts to find all features in an encrypted database that will improve the quality of the model. Our solution is based on the hybrid framework Chimera that allows for switching between different families of fully homomorphic schemes, namely TFHE and HEAAN.


RESULTS
Our solution is one of the finalist of Track 2 of iDash 2018 competition. Among the submitted solutions, ours is the only bootstrapped approach that can be applied for different sets of parameters without re-encrypting the genomic database, making it practical for real-world applications.


CONCLUSIONS
This is the first step towards the more general feature selection problem across large encrypted databases.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/10241</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1186/s12920-020-0723-0</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/32693814</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>BMC medical genomics. - 2020</dc:source>
          <dc:subject xml:lang="en">Fully homomorphic encryption</dc:subject>
          <dc:subject xml:lang="en">Genome privacy</dc:subject>
          <dc:subject xml:lang="en">Genome-wide association study</dc:subject>
          <dc:subject xml:lang="en">Logistic regression</dc:subject>
          <dc:title xml:lang="en">Privacy-preserving semi-parallel logistic regression training with fully homomorphic encryption.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:10278</identifier>
        <datestamp>2025-10-24T20:38:11Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Gilarranz LJ</dc:creator>
          <dc:date>2020</dc:date>
          <dc:description xml:lang="en">Landscape's spatial structure has vast implications for the dynamics and distribution of species populations and ecological communities. However, the characterization of the structure of spatial networks has not received nearly as much attention as networks of species interactions counterparts. Recent experiments show the dynamical implications of modularity to buffer perturbations, and theory shows that several other processes might be impacted if spatial networks were modular, from disease transmission to gene flow. Yet the question is, are spatial networks actually modular? Even though some case studies have found modular structures, we lack a general answer to that question. Here, I show that modularity is a naturally emergent property of spatial networks. This finding is further reinforced by analyzing real patchy habitats. Furthermore, I show that there is no need for any other biological process other than dispersal in order to generate a significantly modular spatial network. Modularity is explained by the spatial heterogeneity in the density of habitat fragments. The fact that spatial networks are intrinsically modular might have direct consequences for population and evolutionary dynamics. Modules define the spatial limits of populations and the role each habitat fragment plays in ecological dynamics; they become the relevant scale at which a multitude of processes occur.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/10278</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1038/s41598-020-65669-8</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/32457480</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Scientific reports. - 2020</dc:source>
          <dc:subject xml:lang="en">Multidisciplinary</dc:subject>
          <dc:title xml:lang="en">Generic Emergence of Modularity in Spatial Networks.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:10303</identifier>
        <datestamp>2025-10-24T20:38:12Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Bolli M</dc:creator>
          <dc:creator>Micura R</dc:creator>
          <dc:creator>Eschenmoser A</dc:creator>
          <dc:date>1997</dc:date>
          <dc:description xml:lang="en">BACKGROUND
Why did Nature choose furanosyl-RNA and not pyranosyl-RNA as her molecular genetic system? An experimental approach to this problem is the systematic comparison of the two isomeric oligonucleotide systems with respect to the chemical properties that are fundamental to the biological role of RNA, such as base pairing and nonenzymic replication. Pyranosyl-RNA has been found to be not only a stronger, but also a more selective pairing system than natural RNA; both form hairpin structures with comparable ease. Base sequences of pyranosyl-RNA can be copied by template-controlled replicative ligation of short activated oligomers (e.g. tetramer-2',3'-cyclophosphates) under mild and potentially natural conditions. The copying proceeds with high regioselectivity as well as chiroselectivity: homochiral template sequences mediate the formation of the correct (4'--&gt;2')-phosphodiester junction between homochiral tetramer units provided they have the same sense of chirality as the template. How could homochiral template sequences assemble themselves in the first place?


RESULTS
Higher oligomers of pyranosyl-RNA can self-assemble in dilute solutions under mild conditions by ligative oligomerization of tetramer-2',3'-cyclophosphates containing hemi self-complementary base sequences. The only side reaction that effectively competes with ligation is hydrolytic deactivation of 2',3'-cyclophosphate end groups. The ligation reaction is highly chiroselective; it is slower by at least two orders of magnitude when one of the (D)-ribopyranosyl units of a homochiral (D)-tetramer-2',3'-cyclophosphate is replaced by a corresponding (L)-unit, except when the (L)-unit is at the 4' end of the tetramer and carries a purine, when the oligomerization rate can be approximately 10% of that shown for a homochiral isomer. The oligomerization of homochiral tetramers is not, or only weakly, inhibited by the presence of the non-oligomerizing diastereomers.


CONCLUSIONS
Available data on the chiroselective self-directed oligomerization of tetramer-2',3'-cyclophosphates allow us to extrapolate that sets of tetramers with different but mutually fitting base sequences can be expected to co-oligomerize stochastically and generate sequence libraries consisting of predominantly homochiral (D)- and (L)-oligomers, starting from the racemic mixture of tetramers containing all possible diastereomers. Such a capability of an oligonucleotide system deserves special attention in the context of the problem of the origin of biomolecular homochirality: breaking molecular mirror symmetry by de-racemization is an intrinsic property of such a system whenever the constitutional complexity of the products of co-oligomerization exceeds a critical level.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/10303</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/s1074-5521(97)90074-0</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/9195870</dc:relation>
          <dc:source>Chemistry &amp; biology. - 1997</dc:source>
          <dc:subject xml:lang="en">Biopolymers</dc:subject>
          <dc:subject xml:lang="en">Chromatography, High Pressure Liquid</dc:subject>
          <dc:subject xml:lang="en">Molecular Structure</dc:subject>
          <dc:subject xml:lang="en">Nucleic Acid Conformation</dc:subject>
          <dc:subject xml:lang="en">Oligoribonucleotides</dc:subject>
          <dc:subject xml:lang="en">RNA</dc:subject>
          <dc:subject xml:lang="en">Ribose</dc:subject>
          <dc:subject xml:lang="en">Stereoisomerism</dc:subject>
          <dc:title xml:lang="en">Pyranosyl-RNA: chiroselective self-assembly of base sequences by ligative oligomerization of tetranucleotide-2',3'-cyclophosphates (with a commentary concerning the origin of biomolecular homochirality).</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:10305</identifier>
        <datestamp>2025-10-24T20:38:12Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Panke S</dc:creator>
          <dc:creator>Wubbolts MG</dc:creator>
          <dc:creator>Schmid A</dc:creator>
          <dc:creator>Witholt B</dc:creator>
          <dc:date>2000</dc:date>
          <dc:description xml:lang="en">A whole cell biocatalytic process was developed to enable the efficient oxidation of styrene to chiral (S)-styrene oxide with an enantiomeric excess better than 99%. Recombinant Escherichia coli cells were employed to express the genes styAB encoding the styrene monooxygenase of Pseudomonas sp. strain VLB120 from an expression plasmid utilizing the alk regulatory system of P. oleovorans GPo1. The strains reached specific activities of up to 70 U* (g cell dry weight)(-1) in shake-flask experiments with glucose as the carbon source. An efficient two-liquid phase fed-batch process was established for the production of (S)-styrene oxide with hexadecane as an apolar carrier solvent and a nutrient feed consisting of glucose, magnesium sulfate, and yeast extract. Engineering of the phase fraction and the composition of organic phase and feed led to a 2-L scale process with maximal volumetric productivities of 2.2 g (S)-styrene oxide per liter liquid volume per hour. This optimized process was based completely on defined medium and used bis(2-ethylhexyl)phthalate as the apolar carrier solvent, which together with substrate and inducer consisted of 50% of the total liquid volume. Using this system, we were able to produce per liter liquid volume 11 g of enantiopure (S)-styrene oxide in 10 h.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/10305</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1002/(sici)1097-0290(20000705)69:1&lt;91::aid-bit11&gt;3.0.co;2-x</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/10820335</dc:relation>
          <dc:source>Biotechnology and bioengineering. - 2000</dc:source>
          <dc:subject xml:lang="en">Base Sequence</dc:subject>
          <dc:subject xml:lang="en">DNA Primers</dc:subject>
          <dc:subject xml:lang="en">Epoxy Compounds</dc:subject>
          <dc:subject xml:lang="en">Escherichia coli</dc:subject>
          <dc:subject xml:lang="en">Fermentation</dc:subject>
          <dc:subject xml:lang="en">Oxygenases</dc:subject>
          <dc:subject xml:lang="en">Recombination, Genetic</dc:subject>
          <dc:subject xml:lang="en">Stereoisomerism</dc:subject>
          <dc:title xml:lang="en">Production of enantiopure styrene oxide by recombinant Escherichia coli synthesizing a two-component styrene monooxygenase.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:10338</identifier>
        <datestamp>2025-10-24T20:38:14Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Klein C</dc:creator>
          <dc:creator>Nazeeruddin MK</dc:creator>
          <dc:creator>Di Censo D</dc:creator>
          <dc:creator>Liska P</dc:creator>
          <dc:creator>Grätzel M</dc:creator>
          <dc:date>2004</dc:date>
          <dc:description xml:lang="en">Amphiphilic ligands 4,4'-bis(1-adamantyl-aminocarbonyl)-2,2'-bipyridine (L(1)), 4,4'-bis[5-[N-[2-(3beta-cholest-5-en-3-ylcarbamate-N-yl)ethyl]aminocarbonyl]]-2,2'-bipyridine (L(2)), 4,4'-bis[5-[N-[2-(3beta-cholest-5-en-3-ylcarbamate-N-yl)propyl]aminocarbonyl]]-2,2'-bipyridine (L(3)), and 4,4'-bis(dodecan-12-ol)-2,2'-bipyridine (L(4)) and their heteroleptic ruthenium(II) complexes of the type [Ru(II)LL(1)(NCS)(2)] (5), [Ru(II)LL(2)(NCS)(2)] (6), [Ru(II)LL(3)(NCS)(2)] (7), and [Ru(II)LL(4)(NCS)(2)] (8) (where L = 4,4'-bis(carboxylic acid)-2,2'-bipyridine) have been synthesized starting from dichloro(p-cymene)ruthenium(II) dimer. All the ligands and the complexes were characterized by analytical, spectroscopic, and electrochemical techniques. The performance of these complexes as charge-transfer photosensitizers in nanocrystalline TiO(2)-based solar cells was studied. When complexes 5-8 anchored onto a 12 + 4 microm thick nanocrystalline TiO(2) films, very efficient sensitization was achieved (85 +/- 5% incident photon-to-current efficiencies in the visible region, using an electrolyte consisting of 0.6 M butylmethylimidazolium iodide, 0.05 M I(2), 0.1 M LiI, and 0.5 M tert-butyl pyridine in 1:1 acetonitrile + valeronitrile). Under standard AM 1.5 sunlight, the complex 8 yielded a short-circuit photocurrent density of 17 +/- 0.5 mA/cm(2), the open-circuit voltage was 720 +/- 50 mV, and the fill factor was 0.72 +/- 0.05, corresponding to an overall conversion efficiency of 8.8 +/- 0.5%.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/10338</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1021/ic049906m</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/15236533</dc:relation>
          <dc:source>Inorganic chemistry. - 2004</dc:source>
          <dc:title xml:lang="en">Amphiphilic ruthenium sensitizers and their applications in dye-sensitized solar cells.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:11513</identifier>
        <datestamp>2025-10-24T20:43:35Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Reding D</dc:creator>
          <dc:creator>Pestalozzi BC</dc:creator>
          <dc:creator>Breitenstein S</dc:creator>
          <dc:creator>Stupp R</dc:creator>
          <dc:creator>Clavien PA</dc:creator>
          <dc:creator>Slankamenac K</dc:creator>
          <dc:creator>Samaras P</dc:creator>
          <dc:date>2017</dc:date>
          <dc:description xml:lang="en">OBJECTIVES
To report survival following different operative strategies and perioperative chemotherapy in patients with synchronous colorectal liver metastases in a tertiary academic referral centre.


METHODS
We performed a retrospective analysis, based on a prospective database, of patients who presented with synchronous colorectal liver metastases. Follow-up data were obtained from medical records, letters or telephone contacts. The main endpoint was overall survival. An additional event of interest was postoperative mortality according to treatment strategy. Predefined variables were analysed to identify associated risk factors.


RESULTS
Overall, 109 patients undergoing liver resection for synchronous colorectal liver metastases between 2000 and 2010 were identified. The majority of patients had resection of the primary tumour first (n = 82), the classic approach; notably fewer were treated according to a combined (n = 20) or a reverse "liver first" strategy (n = 7). Most patients (92%) received preoperative, interval and/or postoperative chemotherapy. Median overall survival of the entire population was 33.6 months (interquartile range [IQR] 11-92.7 months). Patients undergoing classic surgery had a median overall survival of 40.3 months (IQR 14.9-96.6 months). The 3-year survival rates of the three patient groups were 53% in the classic, 47% in the combined and 58% in the reverse group. The lowest rate of 180-day mortality (9%) was after the classic surgical approach. On a multivariate Cox proportional hazards regression analysis, patient age &gt;60 years (hazard ratio [HR] 2.1, 95% confidence interval [CI] 1.1-3.9; p = 0.018), R2-status (HR 2.08, 95% CI 1.03-4.2; p = 0.040), and &gt;4 liver metastases (HR 2.4, 95% CI 1.2-4.6; p = 0.011) were associated significantly with worse overall survival.


CONCLUSIONS
In patients undergoing surgical resection for synchronous colorectal liver metastases, promising survival rates could be achieved, irrespective of the chosen surgical strategy. The presence of five or more liver metastases, patient age over 60 years and R2-status were found to be adverse risk factors.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/11513</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.4414/smw.2017.14486</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/28871569</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Swiss medical weekly. - 2017</dc:source>
          <dc:subject xml:lang="en">Antibodies, Monoclonal</dc:subject>
          <dc:subject xml:lang="en">Chemotherapy, Adjuvant</dc:subject>
          <dc:subject xml:lang="en">Colorectal Neoplasms</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Hepatectomy</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Liver</dc:subject>
          <dc:subject xml:lang="en">Liver Neoplasms</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Retrospective Studies</dc:subject>
          <dc:subject xml:lang="en">Survival Rate</dc:subject>
          <dc:subject xml:lang="en">Treatment Outcome</dc:subject>
          <dc:title xml:lang="en">Treatment strategies and outcome of surgery for synchronous colorectal liver metastases.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:11514</identifier>
        <datestamp>2025-10-24T20:43:44Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Rauscher, T.</dc:creator>
          <dc:creator>Nishimura, N.</dc:creator>
          <dc:creator>Cescutti, G.</dc:creator>
          <dc:creator>Hirschi, R.</dc:creator>
          <dc:creator>Murphy, A. St. J.</dc:creator>
          <dc:creator>Travaglio, C.</dc:creator>
          <dc:date>2020</dc:date>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/11514</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.7566/jpscp.32.010061</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Proceedings of 13th International Conference on Nucleus-Nucleus Collisions. - Journal of the Physical Society of Japan. - 2020</dc:source>
          <dc:title xml:lang="en">Impact of Uncertainties in Nuclear Reaction Cross Sections on p Nucleosynthesis in Thermonuclear Supernovae</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:11496</identifier>
        <datestamp>2025-10-24T20:43:33Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Linnebank M</dc:creator>
          <dc:creator>McDougall CG</dc:creator>
          <dc:creator>Krueger S</dc:creator>
          <dc:creator>Biskup S</dc:creator>
          <dc:creator>Neumann M</dc:creator>
          <dc:creator>Weller M</dc:creator>
          <dc:creator>Valavanis A</dc:creator>
          <dc:creator>Prudlo J</dc:creator>
          <dc:date>2016</dc:date>
          <dc:description xml:lang="en">Previous case studies reported nine patients with cerebral arteriovenous malformations (AVM) who developed amyotrophic lateral sclerosis (ALS) after AVM embolisation. Here, we describe three novel cases of ALS which developed 13-34 years after treatment, including embolisation, of cerebral AVM. This study provides further arguments supporting the thesis that embolisation of cerebral AVM might influence the risk of later ALS development.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/11496</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.4414/smw.2016.14361</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/27878793</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Swiss medical weekly. - 2016</dc:source>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Amyotrophic Lateral Sclerosis</dc:subject>
          <dc:subject xml:lang="en">Embolization, Therapeutic</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Intracranial Arteriovenous Malformations</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Risk Factors</dc:subject>
          <dc:subject xml:lang="en">Time Factors</dc:subject>
          <dc:title xml:lang="en">Novel cases of amyotrophic lateral sclerosis after treatment of cerebral arteriovenous malformationss.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:11525</identifier>
        <datestamp>2025-10-24T20:43:44Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Imlay H</dc:creator>
          <dc:creator>Xie H</dc:creator>
          <dc:creator>Leisenring WM</dc:creator>
          <dc:creator>Duke ER</dc:creator>
          <dc:creator>Kimball LE</dc:creator>
          <dc:creator>Huang ML</dc:creator>
          <dc:creator>Pergam SA</dc:creator>
          <dc:creator>Hill JA</dc:creator>
          <dc:creator>Jerome KR</dc:creator>
          <dc:creator>Milano F</dc:creator>
          <dc:creator>Nichols WG</dc:creator>
          <dc:creator>Pang PS</dc:creator>
          <dc:creator>Hirsch HH</dc:creator>
          <dc:creator>Limaye AP</dc:creator>
          <dc:creator>Boeckh M</dc:creator>
          <dc:date>2020</dc:date>
          <dc:description xml:lang="en">BK polyomavirus (BKPyV) has been associated with hemorrhagic cystitis (HC) after allogeneic hematopoietic cell transplantation (HCT), but the natural history of HC and factors associated with the clinical course are incompletely understood. We retrospectively analyzed allogeneic HCT patients transplanted from 2007-2017 who presented after platelet engraftment or after day 28 post-HCT with BKPyV-associated HC (BKPyV-HC), which was defined as a positive urine BKPyV PCR, ≥1 plasma BKPyV viral load result, and macroscopic hematuria (Bedi grade ≥2). Factors associated with resolution of macroscopic hematuria and resolution of all cystitis symptoms within 90 days after HC diagnosis were investigated in multivariable models. In 128 patients with BKPyV-HC, the median times from diagnosis to resolution of all symptoms, macroscopic hematuria, and urinary clots (present in 55% [71/128]) were 24 days (15-44), 17 days (10-30), and 14 days (5-26), respectively. Ninety percent of patients had BKPyV viremia at the onset of HC with a median viral load of 1850 copies/mL (interquartile range, 240-8550). In multivariable models, high plasma viral load (≥10 000 copies/mL) and cytopenias at the beginning of BKPyV-HC were significantly associated with longer macroscopic hematuria and cystitis symptoms. Use of cidofovir was not associated with shorter duration of illness. In conclusion, BKPyV-HC after allogeneic HCT is characterized by prolonged and severe symptoms and requires improved management strategies. High-grade viremia and cytopenias were associated with a longer duration of BKPyV-associated HC. Accurate descriptions of disease and factors associated with prolonged recovery will inform end points of future clinical trials.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/11525</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1182/bloodadvances.2019000802</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/32074279</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Blood advances. - 2020</dc:source>
          <dc:title xml:lang="en">Presentation of BK polyomavirus-associated hemorrhagic cystitis after allogeneic hematopoietic cell transplantation.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:11553</identifier>
        <datestamp>2025-10-24T20:43:42Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Bauer DE</dc:creator>
          <dc:creator>Hingsammer A</dc:creator>
          <dc:creator>Ernstbrunner L</dc:creator>
          <dc:creator>Aichmair A</dc:creator>
          <dc:creator>Rosskopf AB</dc:creator>
          <dc:creator>Eckers F</dc:creator>
          <dc:creator>Wieser K</dc:creator>
          <dc:creator>Fucentese SF</dc:creator>
          <dc:date>2018</dc:date>
          <dc:description xml:lang="en">PURPOSE
Injection drug users are at high risk for both infection with blood-borne pathogens, namely, human immune deficiency virus (HIV), hepatitis-B, -C virus, various bacterial infections, as well as early primary and secondary joint degeneration. When total knee arthroplasty (TKA) is anticipated the risk of septic complications is a major concern. The purpose of this study was to assess the clinical and radiographic outcome of patients with a history of intravenous drug use after total knee arthroplasty. The primary outcome was revision rate. Secondary outcomes were the Western Ontario and McMaster Universities Arthritis Index (WOMAC), Knee Society Score (KSS) and radiographic loosening.


METHODS
We retrospectively reviewed the records of 1,692 TKA performed or revised in our institution. Data of 18 TKA in 12 patients (11 male, 1 female; average age 42, range 23-62 years) with a history of intravenous opioid abuse were available for final analysis.


RESULTS
The mean follow up was 125 (range 25-238) months. Seven patients required revision surgery due to periprosthetic joint infection after 62 months (range 5-159): one two staged revision, three arthrodesis and three amputations. The median prosthesis survival was 101 (95%-CI 48-154) months.


CONCLUSION
Total knee arthroplasty in patients with a history of intravenous drug abuse is associated with major complications, including above-the-knee amputation. If permanent abstinence from intravenous drug abuse is doubtful, other therapeutic options including primary arthrodesis should be considered.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/11553</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1007/s00264-017-3655-3</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/29032478</dc:relation>
          <dc:source>International orthopaedics. - 2018</dc:source>
          <dc:subject xml:lang="en">Drug</dc:subject>
          <dc:subject xml:lang="en">Intravenous</dc:subject>
          <dc:subject xml:lang="en">Periprosthetic joint infection (PJI)</dc:subject>
          <dc:subject xml:lang="en">Risk factor</dc:subject>
          <dc:subject xml:lang="en">Total knee arthroplasty (TKA)</dc:subject>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Amputation</dc:subject>
          <dc:subject xml:lang="en">Arthrodesis</dc:subject>
          <dc:subject xml:lang="en">Arthroplasty, Replacement, Knee</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Follow-Up Studies</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Knee Joint</dc:subject>
          <dc:subject xml:lang="en">Knee Prosthesis</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Opioid-Related Disorders</dc:subject>
          <dc:subject xml:lang="en">Prosthesis Failure</dc:subject>
          <dc:subject xml:lang="en">Prosthesis-Related Infections</dc:subject>
          <dc:subject xml:lang="en">Reoperation</dc:subject>
          <dc:subject xml:lang="en">Retrospective Studies</dc:subject>
          <dc:subject xml:lang="en">Risk Factors</dc:subject>
          <dc:subject xml:lang="en">Survival Analysis</dc:subject>
          <dc:subject xml:lang="en">Treatment Outcome</dc:subject>
          <dc:subject xml:lang="en">Young Adult</dc:subject>
          <dc:title xml:lang="en">Total knee arthroplasty in patients with a history of illicit intravenous drug abuse.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:11534</identifier>
        <datestamp>2025-10-24T20:43:38Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Nowak A</dc:creator>
          <dc:creator>Boesch L</dc:creator>
          <dc:creator>Andres E</dc:creator>
          <dc:creator>Battegay E</dc:creator>
          <dc:creator>Hornemann T</dc:creator>
          <dc:creator>Schmid C</dc:creator>
          <dc:creator>Bischoff-Ferrari HA</dc:creator>
          <dc:creator>Suter PM</dc:creator>
          <dc:creator>Krayenbuehl PA</dc:creator>
          <dc:date>2016</dc:date>
          <dc:description xml:lang="en">BACKGROUND
Vitamin D deficiency is frequent and has been associated with fatigue in uncontrolled trials.


METHODS
This is the first double-blind placebo-controlled clinical trial to investigate the efficacy of per os vitamin D3 (cholecalciferol) in treating fatigue among otherwise healthy persons with low serum 25-hydroxyvitamin D (25(OH)D) levels. We enrolled 120 individuals (mean age 29 ± 6 years, 53% women) presenting with fatigue and vitamin D deficiency (serum 25(OH)D &lt; 20 μg/L). Participants were randomized to a single oral dose of 100,000 units of vitamin D or placebo. The primary endpoint was intra-individual change in the fatigue assessment scale (FAS) at 4 weeks after treatment.


RESULT
The mean age of the participants was 29 ± 6 years, 53% were women. Mean FAS decreased significantly more in the vitamin D group (-3.3 ± 5.3; 95% confidence interval [CI] for change -14.1 to 4.1) compared with placebo (-0.8 ± 5.3; 95% CI for change -9.0 to 8.7); (P = 0.01). Amelioration of fatigue was reported more frequently in vitamin D than in placebo group (42 [72%] vs. 31 [50%]; P = 0.01; odds ratio [OR] 2.63, 95% CI for OR 1.23-5.62). Among all participants, improvement in fatigue score correlated with the rise in 25(OH)D level (R = -0.22, P = 0.02).


CONCLUSION
Vitamin D treatment significantly improved fatigue in otherwise healthy persons with vitamin D deficiency.This study was registered at the www.ClinicalTrials.gov Protocol ID NCT02022475.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/11534</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1097/MD.0000000000005353</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/28033244</dc:relation>
          <dc:source>Medicine. - 2016</dc:source>
          <dc:subject xml:lang="en">Administration, Oral</dc:subject>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Cholecalciferol</dc:subject>
          <dc:subject xml:lang="en">Double-Blind Method</dc:subject>
          <dc:subject xml:lang="en">Fatigue</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Self Report</dc:subject>
          <dc:subject xml:lang="en">Vitamin D</dc:subject>
          <dc:subject xml:lang="en">Vitamin D Deficiency</dc:subject>
          <dc:subject xml:lang="en">Vitamins</dc:subject>
          <dc:subject xml:lang="en">Young Adult</dc:subject>
          <dc:title xml:lang="en">Effect of vitamin D3 on self-perceived fatigue: A double-blind randomized placebo-controlled trial.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:11477</identifier>
        <datestamp>2025-10-24T20:43:29Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Steiner, Luzius A</dc:creator>
          <dc:identifier>https://sonar.ch/global/documents/11477</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.3410/f.3594960.3304059</dc:relation>
          <dc:source>Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature. - Faculty Opinions Ltd. - 2010</dc:source>
          <dc:title xml:lang="en">Faculty Opinions recommendation of Conscious sedation versus general anesthesia during endovascular therapy for acute anterior circulation stroke: preliminary results from a retrospective, multicenter study.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:11497</identifier>
        <datestamp>2025-10-24T20:43:32Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Kyburz, Diego</dc:creator>
          <dc:identifier>https://sonar.ch/global/documents/11497</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.3410/f.5022.462509</dc:relation>
          <dc:source>Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature. - Faculty Opinions Ltd. - 2006</dc:source>
          <dc:title xml:lang="en">Faculty Opinions recommendation of Febuxostat compared with allopurinol in patients with hyperuricemia and gout.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:11498</identifier>
        <datestamp>2025-10-24T20:43:33Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Körner, Christian</dc:creator>
          <dc:identifier>https://sonar.ch/global/documents/11498</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.3410/f.1011517.372034</dc:relation>
          <dc:source>Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature. - Faculty Opinions Ltd. - 2006</dc:source>
          <dc:title xml:lang="en">Faculty Opinions recommendation of The response of heterotrophic CO2 flux to soil warming.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:11640</identifier>
        <datestamp>2025-10-24T20:44:12Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Rychli K</dc:creator>
          <dc:creator>Wagner EM</dc:creator>
          <dc:creator>Ciolacu L</dc:creator>
          <dc:creator>Zaiser A</dc:creator>
          <dc:creator>Tasara T</dc:creator>
          <dc:creator>Wagner M</dc:creator>
          <dc:creator>Schmitz-Esser S</dc:creator>
          <dc:date>2017</dc:date>
          <dc:description xml:lang="en">The food-borne pathogen Listeria (L.) monocytogenes is able to survive for months and even years in food production environments. Strains belonging to sequence type (ST)121 are particularly found to be abundant and to persist in food and food production environments. To elucidate genetic determinants characteristic for L. monocytogenes ST121, we sequenced the genomes of 14 ST121 strains and compared them with currently available L. monocytogenes ST121 genomes. In total, we analyzed 70 ST121 genomes deriving from 16 different countries, different years of isolation, and different origins-including food, animal and human ST121 isolates. All ST121 genomes show a high degree of conservation sharing at least 99.7% average nucleotide identity. The main differences between the strains were found in prophage content and prophage conservation. We also detected distinct highly conserved subtypes of prophages inserted at the same genomic locus. While some of the prophages showed more than 99.9% similarity between strains from different sources and years, other prophages showed a higher level of diversity. 81.4% of the strains harbored virtually identical plasmids. 97.1% of the ST121 strains contain a truncated internalin A (inlA) gene. Only one of the seven human ST121 isolates encodes a full-length inlA gene, illustrating the need of better understanding their survival and virulence mechanisms.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/11640</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1371/journal.pone.0176857</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/28472116</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>PloS one. - 2017</dc:source>
          <dc:subject xml:lang="en">Genome, Bacterial</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Listeria monocytogenes</dc:subject>
          <dc:subject xml:lang="en">Plasmids</dc:subject>
          <dc:subject xml:lang="en">Virulence</dc:subject>
          <dc:title xml:lang="en">Comparative genomics of human and non-human Listeria monocytogenes sequence type 121 strains.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:11566</identifier>
        <datestamp>2025-10-24T20:43:47Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Ghayor C</dc:creator>
          <dc:creator>Gjoksi B</dc:creator>
          <dc:creator>Dong J</dc:creator>
          <dc:creator>Siegenthaler B</dc:creator>
          <dc:creator>Caflisch A</dc:creator>
          <dc:creator>Weber FE</dc:creator>
          <dc:date>2017</dc:date>
          <dc:description xml:lang="en">N,N-Dimethylacetamide (DMA) is a water-miscible solvent, FDA approved as excipient and therefore widely used as drug-delivery vehicle. As such, DMA should be devoid of any bioactivity. Here we report that DMA is epigenetically active since it binds bromodomains and inhibits osteoclastogenesis and inflammation. Moreover, DMA enhances bone regeneration in vivo. Therefore, our in vivo and in vitro data reveal DMA's potential as an anti-osteoporotic agent via the inhibition of osteoclast mediated bone resorption and enhanced bone regeneration. Our results highlight the potential therapeutic benefits of DMA and the need for reconsideration of previous reports where DMA was used as an 'inactive' drug-delivery vehicle.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/11566</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1038/srep42108</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/28176838</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Scientific reports. - 2017</dc:source>
          <dc:subject xml:lang="en">Acetamides</dc:subject>
          <dc:subject xml:lang="en">Animals</dc:subject>
          <dc:subject xml:lang="en">Anti-Inflammatory Agents</dc:subject>
          <dc:subject xml:lang="en">Bone Density Conservation Agents</dc:subject>
          <dc:subject xml:lang="en">Cell Cycle Proteins</dc:subject>
          <dc:subject xml:lang="en">Cell Line</dc:subject>
          <dc:subject xml:lang="en">Excipients</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Mice</dc:subject>
          <dc:subject xml:lang="en">Nuclear Proteins</dc:subject>
          <dc:subject xml:lang="en">Osteogenesis</dc:subject>
          <dc:subject xml:lang="en">Protein Binding</dc:subject>
          <dc:subject xml:lang="en">Rats, Sprague-Dawley</dc:subject>
          <dc:subject xml:lang="en">Transcription Factors</dc:subject>
          <dc:title xml:lang="en">N,N Dimethylacetamide a drug excipient that acts as bromodomain ligand for osteoporosis treatment.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:11641</identifier>
        <datestamp>2025-10-24T20:44:00Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Xu Z</dc:creator>
          <dc:creator>Lay B</dc:creator>
          <dc:creator>Oexle N</dc:creator>
          <dc:creator>Drack T</dc:creator>
          <dc:creator>Bleiker M</dc:creator>
          <dc:creator>Lengler S</dc:creator>
          <dc:creator>Blank C</dc:creator>
          <dc:creator>Müller M</dc:creator>
          <dc:creator>Mayer B</dc:creator>
          <dc:creator>Rössler W</dc:creator>
          <dc:creator>Rüsch N</dc:creator>
          <dc:date>2019</dc:date>
          <dc:description xml:lang="en">AIMS
Compulsory admission can be experienced as devaluing and stigmatising by people with mental illness. Emotional reactions to involuntary hospitalisation and stigma-related stress may affect recovery, but longitudinal data are lacking. We, therefore, examined the impact of stigma-related emotional reactions and stigma stress on recovery over a 2-year period.


METHOD
Shame and self-contempt as emotional reactions to involuntary hospitalisation, stigma stress, self-stigma and empowerment, as well as recovery were assessed among 186 individuals with serious mental illness and a history of recent involuntary hospitalisation.


RESULTS
More shame, self-contempt and stigma stress at baseline were correlated with increased self-stigma and reduced empowerment after 1 year. More stigma stress at baseline was associated with poor recovery after 2 years. In a longitudinal path analysis more stigma stress at baseline predicted poorer recovery after 2 years, mediated by decreased empowerment after 1 year, controlling for age, gender, symptoms and recovery at baseline.


CONCLUSION
Stigma stress may have a lasting detrimental effect on recovery among people with mental illness and a history of involuntary hospitalisation. Anti-stigma interventions that reduce stigma stress and programs that enhance empowerment could improve recovery. Future research should test the effect of such interventions on recovery.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/11641</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1017/S2045796018000021</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/29382403</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Epidemiology and psychiatric sciences. - 2019</dc:source>
          <dc:subject xml:lang="en">Coercion</dc:subject>
          <dc:subject xml:lang="en">compulsory admission</dc:subject>
          <dc:subject xml:lang="en">empowerment</dc:subject>
          <dc:subject xml:lang="en">recovery</dc:subject>
          <dc:subject xml:lang="en">stigma stress</dc:subject>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Emotions</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Hospitalization</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Involuntary Treatment</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Mental Disorders</dc:subject>
          <dc:subject xml:lang="en">Outcome Assessment, Health Care</dc:subject>
          <dc:subject xml:lang="en">Psychiatric Status Rating Scales</dc:subject>
          <dc:subject xml:lang="en">Self Concept</dc:subject>
          <dc:subject xml:lang="en">Shame</dc:subject>
          <dc:subject xml:lang="en">Social Stigma</dc:subject>
          <dc:subject xml:lang="en">Stereotyping</dc:subject>
          <dc:subject xml:lang="en">Stress, Psychological</dc:subject>
          <dc:subject xml:lang="en">Switzerland</dc:subject>
          <dc:subject xml:lang="en">Young Adult</dc:subject>
          <dc:title xml:lang="en">Involuntary psychiatric hospitalisation, stigma stress and recovery: a 2-year study.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:11613</identifier>
        <datestamp>2025-10-24T20:44:08Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Jentzsch T</dc:creator>
          <dc:creator>Geiger J</dc:creator>
          <dc:creator>König MA</dc:creator>
          <dc:creator>Werner CM</dc:creator>
          <dc:date>2017</dc:date>
          <dc:description xml:lang="en">STUDY DESIGN
A retrospective study.


OBJECTIVE
Our study opted to clarify the remaining issues of lumbar lordosis (LL) with regard to (1) its physiological values, (2) age, (3) sex, and (4) facet joint (FJ) arthritis and orientation using computed tomography (CT) scans.


SUMMARY OF BACKGROUND DATA
Recent studies have questioned whether LL really decreases with age, but study sample sizes have been rather small and mostly been based on x-rays. As hyperlordosis increases the load transferred through the FJs, it seems plausible that hyperlordosis may lead to FJ arthritis at the lower lumbar spine.


METHODS
We retrospectively analyzed the CT scans of 620 individuals, with a mean age of 42.5 (range, 14-94) years, who presented to our traumatology department and underwent a whole-body CT scan, between 2008 and 2010. LL was evaluated between the superior endplates of L1 and S1. FJs of the lumbar spine were evaluated for arthritis and orientation between L2 and S1.


RESULTS
(1) The mean LL was 49.0 degrees (SD 11.1 degrees; range, 11.4-80.1 degrees). (2) LL increased with age and there was a significant difference in LL in our age groups (30 y and below, 31-50, 51-70, and ≥71 y and above) (P=0.02). (3) There was no significant difference in LL between females and males (50 and 49 degrees) (P=0.17). (4) LL showed a significant linear association with FJ arthritis [P=0.0026, OR=1.022 (1.008-1.036)] and sagittal FJ orientation at L5/S1 (P=0.001). In a logistic regression analysis, the cutoff point for LL was 49.4 degrees.


CONCLUSIONS
This is the largest CT-based study on LL and FJs. LL significantly increases with age. As a novelty finding, hyperlordosis is significantly associated with FJ arthritis and sagittal FJ orientation at the lower lumbar spine. Thus, hyperlordosis may present with back pain and patients may benefit from surgical correction, for example, in the setting of trauma.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/11613</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1097/BSD.0b013e3182aab266</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/28323692</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Clinical spine surgery. - 2017</dc:source>
          <dc:subject xml:lang="en">Adolescent</dc:subject>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Aged</dc:subject>
          <dc:subject xml:lang="en">Aged, 80 and over</dc:subject>
          <dc:subject xml:lang="en">Analysis of Variance</dc:subject>
          <dc:subject xml:lang="en">Arthritis</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Lordosis</dc:subject>
          <dc:subject xml:lang="en">Lumbar Vertebrae</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Retrospective Studies</dc:subject>
          <dc:subject xml:lang="en">Tomography Scanners, X-Ray Computed</dc:subject>
          <dc:subject xml:lang="en">Young Adult</dc:subject>
          <dc:subject xml:lang="en">Zygapophyseal Joint</dc:subject>
          <dc:title xml:lang="en">Hyperlordosis is Associated With Facet Joint Pathology at the Lower Lumbar Spine.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:11635</identifier>
        <datestamp>2025-10-24T20:44:10Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Gerber PA</dc:creator>
          <dc:creator>Nikolic D</dc:creator>
          <dc:creator>Rizzo M</dc:creator>
          <dc:date>2017</dc:date>
          <dc:description xml:lang="en">PURPOSE OF REVIEW
In this review, we summarize the latest findings on small, dense LDL (sdLDL) atherogenic particles, including their associations with other biomarkers.


RECENT FINDINGS
Increased sdLDL levels have been reported not only in different metabolic disorders such as diabetes, obesity and metabolic syndrome, but also in patients with rheumatoid and psoriatic arthritis as well as hypothyroidism. A wide range of lipid-lowering, as well as other drug classes, including novel antidiabetic agents and nutraceuticals, exert favourable effects on these atherogenic particles. The 'gold standard' methodology for the assessment of sdLDL has not been established yet. However, the association between sdLDL and several biomarkers could facilitate their assessment.


SUMMARY
Estimation of sdLDL in daily clinical practice may help with the identification of patients at high cardiovascular risk and further contribute in directing specific interventions to prevent and/or decrease such risk.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/11635</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1097/HCO.0000000000000410</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/28426445</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Current opinion in cardiology. - 2017</dc:source>
          <dc:subject xml:lang="en">Atherosclerosis</dc:subject>
          <dc:subject xml:lang="en">Biomarkers</dc:subject>
          <dc:subject xml:lang="en">Cardiovascular Diseases</dc:subject>
          <dc:subject xml:lang="en">Cholesterol, LDL</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Metabolic Syndrome</dc:subject>
          <dc:subject xml:lang="en">Particle Size</dc:subject>
          <dc:subject xml:lang="en">Risk Factors</dc:subject>
          <dc:title xml:lang="en">Small, dense LDL: an update.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:11621</identifier>
        <datestamp>2025-10-24T20:44:09Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Jaremko JL</dc:creator>
          <dc:creator>Azmat O</dc:creator>
          <dc:creator>Lambert RG</dc:creator>
          <dc:creator>Bird P</dc:creator>
          <dc:creator>Haugen IK</dc:creator>
          <dc:creator>Jans L</dc:creator>
          <dc:creator>Weber U</dc:creator>
          <dc:creator>Winn N</dc:creator>
          <dc:creator>Zubler V</dc:creator>
          <dc:creator>Maksymowych WP</dc:creator>
          <dc:date>2017</dc:date>
          <dc:description xml:lang="en">OBJECTIVE
To assess feasibility and reliability of scoring bone marrow lesions (BML) on knee magnetic resonance imaging (MRI) in osteoarthritis using the Outcome Measures in Rheumatology Knee Inflammation MRI Scoring System (KIMRISS), with a Web-based interface and online training with real-time iterative calibration.


METHODS
Six readers new to the KIMRISS (3 radiologists, 3 rheumatologists) scored sagittal T2-weighted fat-saturated MRI in 20 subjects randomly selected from the Osteoarthritis Initiative data, at baseline and 1-year followup. In the KIMRISS, the reader moves a transparent overlay grid within a Web-based interface to fit bones, then clicks or touches each region containing BML per slice, to score 1 if BML is present. Regional and total scores are automatically calculated. Outcomes include the interreader intraclass correlation coefficients (ICC) and the smallest detectable change (SDC).


RESULTS
Scoring took 3-12 min per scan and all readers rated the process as moderately to very user friendly. Despite a low BML burden (average score 2.8% of maximum possible) and small changes, interobserver reliability was moderate to high for BML status and change in the femur and tibia (ICC 0.78-0.88). Four readers also scored the patella reliably, whereas 2 readers were outliers, likely because of image artifacts. SDC of 1.5-5.6 represented 0.7% of the maximum possible score.


CONCLUSION
We confirmed feasibility of knee BML scoring by new readers using interactive training and a Web-based touch-sensitive overlay system, finding high reliability and sensitivity to change. Further work will include adjustments to training materials regarding patellar scoring, and study in therapeutic trial datasets with higher burden of BML and larger changes.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/11621</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.3899/jrheum.161102</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/28365581</dc:relation>
          <dc:source>The Journal of rheumatology. - 2017</dc:source>
          <dc:subject xml:lang="en">BONE MARROW LESION</dc:subject>
          <dc:subject xml:lang="en">KNEE JOINT</dc:subject>
          <dc:subject xml:lang="en">MRI</dc:subject>
          <dc:subject xml:lang="en">OMERACT</dc:subject>
          <dc:subject xml:lang="en">OSTEOARTHRITIS</dc:subject>
          <dc:subject xml:lang="en">SCORING METHODS</dc:subject>
          <dc:subject xml:lang="en">Aged</dc:subject>
          <dc:subject xml:lang="en">Bone Marrow</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Femur</dc:subject>
          <dc:subject xml:lang="en">Follow-Up Studies</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Inflammation</dc:subject>
          <dc:subject xml:lang="en">Knee Joint</dc:subject>
          <dc:subject xml:lang="en">Magnetic Resonance Imaging</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Osteoarthritis</dc:subject>
          <dc:subject xml:lang="en">Reproducibility of Results</dc:subject>
          <dc:subject xml:lang="en">Severity of Illness Index</dc:subject>
          <dc:subject xml:lang="en">Tibia</dc:subject>
          <dc:title xml:lang="en">Validation of a Knowledge Transfer Tool for the Knee Inflammation MRI Scoring System for Bone Marrow Lesions According to the OMERACT Filter: Data from the Osteoarthritis Initiative.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:11643</identifier>
        <datestamp>2025-10-24T20:44:00Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Revilla-León M</dc:creator>
          <dc:creator>Fountain J</dc:creator>
          <dc:creator>Piedra-Cascón W</dc:creator>
          <dc:creator>Özcan M</dc:creator>
          <dc:creator>Zandinejad A</dc:creator>
          <dc:date>2020</dc:date>
          <dc:description xml:lang="en">A digital workflow for fabricating a fiber-reinforced composite prosthesis is described. A facial scanner and an intraoral scanner were used to gather records, and dental and open-source software programs were used to elaborate a diagnostic waxing and design a 4-piece additively manufactured clear silicone index. Advantages of the index design included precise translation of the diagnostic waxing, optimal composite resin stratification, and minimal clinical time.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/11643</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.prosdent.2020.02.030</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/32376030</dc:relation>
          <dc:source>The Journal of prosthetic dentistry. - 2020</dc:source>
          <dc:subject xml:lang="en">Oral Surgery</dc:subject>
          <dc:title xml:lang="en">Workflow of a fiber-reinforced composite fixed dental prosthesis by using a 4-piece additive manufactured silicone index: A dental technique.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:11576</identifier>
        <datestamp>2025-10-24T20:43:50Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Hilfiker PR</dc:creator>
          <dc:creator>Weishaupt D</dc:creator>
          <dc:creator>Schmid M</dc:creator>
          <dc:creator>Dubno B</dc:creator>
          <dc:creator>Hodler J</dc:creator>
          <dc:creator>Debatin JF</dc:creator>
          <dc:date>1999</dc:date>
          <dc:description xml:lang="en">The purpose of this study was to evaluate interactive MR-guided joint puncture with intra-articular application of contrast agent. MR-guided arthrography of the shoulder joint was successfully performed in three patients using an interactive guidance system implemented in an open-configuration MR system. Visualization of the needle pathway and contrast inflow was comparable to that with conventional X-ray fluoroscopy. The position of the intra-articular needle tip was accurately confirmed and subsequent MR arthrography was diagnostic in all cases.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/11576</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1007/s003300050655</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/10101638</dc:relation>
          <dc:source>European radiology. - 1999</dc:source>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Aged</dc:subject>
          <dc:subject xml:lang="en">Arthrography</dc:subject>
          <dc:subject xml:lang="en">Contrast Media</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Gadolinium DTPA</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Image Processing, Computer-Assisted</dc:subject>
          <dc:subject xml:lang="en">Injections, Intra-Articular</dc:subject>
          <dc:subject xml:lang="en">Joint Diseases</dc:subject>
          <dc:subject xml:lang="en">Magnetic Resonance Imaging</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Punctures</dc:subject>
          <dc:subject xml:lang="en">Reproducibility of Results</dc:subject>
          <dc:subject xml:lang="en">Shoulder Joint</dc:subject>
          <dc:title xml:lang="en">Real-time MR-guided joint puncture and arthrography: preliminary results.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:11610</identifier>
        <datestamp>2025-10-24T20:44:07Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Brändle E</dc:creator>
          <dc:date>1971</dc:date>
          <dc:description xml:lang="en">1. All axial regions of the gonozoid and the medusa buds ofPodocaryne carnea M. Sars incorporate3H-thymidine. Medusa buds grow by mitosis and by migration of cells from the colony into the buds. 2. Stolonization inhibits the formation and differentiation of medusa buds: non stolonizing chimerae formed by a gonozoid and an autozoid produce more buds than stolonizing ones. 3. When isolated gonozoids and likewise isolated budding regions are not connected with an nutritive autozoid, the formation and differentiation of medusa buds are restricted. Young medusa buds (stage 3, Frey, 1968) transplanted onto autozoids may differentiate into medusae, while isolated buds of the same stage are transformed into stolons. 4. If the hypostome of the gonozoid is separated from the subhypostomal budding region by ligature and does not regenerate, the young buds already present are resorbed and no new ones are formed. 5. Heads of gonozoids transplanted onto cauli of adult autozoids may induce the formation of medusa buds in the subtentacular axial region. These buds differentiate into normal medusae. 6. Isolated adult autozoids, treated with extract taken from hypostomes of gonozoids, form medusa buds which complete normal differentiation. 7. Treatment of autozoid colonies with extract from gonozoids brings about a standstill of colony growth and resorption of autozoids. After transfer to normal sea-water a compensatory increase in growth and head formation takes place. 8. The results are discussed. It is suggested that an "activator" substance is produced in the hypostome of the gonozoid which induces and maintains the budding region in the subtentacular zone. Furthermore, budding would be dependent on the nutritional state of the gonozoid, food being supplied by the autozoid, and on the extent of inhibition by intensive stolonization.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/11610</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1007/BF00650034</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/28304674</dc:relation>
          <dc:source>Wilhelm Roux' Archiv fur Entwicklungsmechanik der Organismen. - 1971</dc:source>
          <dc:title xml:lang="en">[Significance of the colonial components for the medusa formation and differentiation inPodocoryne carnea M. Sars].</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12782</identifier>
        <datestamp>2025-10-24T20:49:11Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Lepore M</dc:creator>
          <dc:creator>Kalinichenko A</dc:creator>
          <dc:creator>Kalinicenko A</dc:creator>
          <dc:creator>Colone A</dc:creator>
          <dc:creator>Paleja B</dc:creator>
          <dc:creator>Singhal A</dc:creator>
          <dc:creator>Tschumi A</dc:creator>
          <dc:creator>Lee B</dc:creator>
          <dc:creator>Poidinger M</dc:creator>
          <dc:creator>Zolezzi F</dc:creator>
          <dc:creator>Quagliata L</dc:creator>
          <dc:creator>Sander P</dc:creator>
          <dc:creator>Newell E</dc:creator>
          <dc:creator>Bertoletti A</dc:creator>
          <dc:creator>Terracciano L</dc:creator>
          <dc:creator>De Libero G</dc:creator>
          <dc:creator>Mori L</dc:creator>
          <dc:date>2014</dc:date>
          <dc:description xml:lang="en">Mucosal-associated invariant T (MAIT) cells are abundant in humans and recognize conserved bacterial antigens derived from riboflavin precursors, presented by the non-polymorphic MHC class I-like molecule MR1. Here we show that human MAIT cells are remarkably oligoclonal in both the blood and liver, display high inter-individual homology and exhibit a restricted length CDR3β domain of the TCRVβ chain. We extend this analysis to a second sub-population of MAIT cells expressing a semi-invariant TCR conserved between individuals. Similar to 'conventional' MAIT cells, these lymphocytes react to riboflavin-synthesizing microbes in an MR1-restricted manner and infiltrate solid tissues. Both MAIT cell types release Th0, Th1 and Th2 cytokines, and sCD40L in response to bacterial infection, show cytotoxic capacity against infected cells and promote killing of intracellular bacteria, thus suggesting important protective and immunoregulatory functions of these lymphocytes.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12782</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1038/ncomms4866</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/24832684</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Nature communications. - 2014</dc:source>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Gene Rearrangement, beta-Chain T-Cell Antigen Receptor</dc:subject>
          <dc:subject xml:lang="en">Genes, T-Cell Receptor alpha</dc:subject>
          <dc:subject xml:lang="en">Genes, T-Cell Receptor beta</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">RNA, Messenger</dc:subject>
          <dc:subject xml:lang="en">Receptors, Antigen, T-Cell, alpha-beta</dc:subject>
          <dc:subject xml:lang="en">Sequence Analysis, Protein</dc:subject>
          <dc:subject xml:lang="en">T-Lymphocyte Subsets</dc:subject>
          <dc:subject xml:lang="en">T-Lymphocytes</dc:subject>
          <dc:subject xml:lang="en">Young Adult</dc:subject>
          <dc:title xml:lang="en">Parallel T-cell cloning and deep sequencing of human MAIT cells reveal stable oligoclonal TCRβ repertoire.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12741</identifier>
        <datestamp>2025-10-24T20:49:07Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Maier PJ</dc:creator>
          <dc:creator>Zemoura K</dc:creator>
          <dc:creator>Acuña MA</dc:creator>
          <dc:creator>Yévenes GE</dc:creator>
          <dc:creator>Zeilhofer HU</dc:creator>
          <dc:creator>Benke D</dc:creator>
          <dc:date>2014</dc:date>
          <dc:description xml:lang="en">Cerebral ischemia frequently leads to long-term disability and death. Excitotoxicity is believed to be the main cause for ischemia-induced neuronal death. Although a role of glutamate receptors in this process has been firmly established, the contribution of metabotropic GABAB receptors, which control excitatory neurotransmission, is less clear. A prominent characteristic of ischemic insults is endoplasmic reticulum (ER) stress associated with the up-regulation of the transcription factor CCAAT/enhancer-binding protein-homologous protein (CHOP). After inducing ER stress in cultured cortical neurons by sustained Ca(2+) release from intracellular stores or by a brief episode of oxygen and glucose deprivation (in vitro model of cerebral ischemia), we observed an increased expression of CHOP accompanied by a strong reduction of cell surface GABAB receptors. Our results indicate that down-regulation of cell surface GABAB receptors is caused by the interaction of the receptors with CHOP in the ER. Binding of CHOP prevented heterodimerization of the receptor subunits GABAB1 and GABAB2 and subsequent forward trafficking of the receptors to the cell surface. The reduced level of cell surface receptors diminished GABAB receptor signaling and, thus, neuronal inhibition. These findings indicate that ischemia-mediated up-regulation of CHOP down-regulates cell surface GABAB receptors by preventing their trafficking from the ER to the plasma membrane. This mechanism leads to diminished neuronal inhibition and may contribute to excitotoxicity in cerebral ischemia.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12741</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1074/jbc.M114.550517</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/24668805</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>The Journal of biological chemistry. - 2014</dc:source>
          <dc:subject xml:lang="en">CHOP</dc:subject>
          <dc:subject xml:lang="en">Cell Surface</dc:subject>
          <dc:subject xml:lang="en">Cerebral Ischemia</dc:subject>
          <dc:subject xml:lang="en">Endoplasmic Reticulum (ER)</dc:subject>
          <dc:subject xml:lang="en">Endoplasmic Reticulum Stress</dc:subject>
          <dc:subject xml:lang="en">G Protein-coupled Receptors (GPCR)</dc:subject>
          <dc:subject xml:lang="en">GABA Receptors</dc:subject>
          <dc:subject xml:lang="en">Neurons</dc:subject>
          <dc:subject xml:lang="en">Trafficking</dc:subject>
          <dc:subject xml:lang="en">Animals</dc:subject>
          <dc:subject xml:lang="en">Brain Ischemia</dc:subject>
          <dc:subject xml:lang="en">Cell Membrane</dc:subject>
          <dc:subject xml:lang="en">Cells, Cultured</dc:subject>
          <dc:subject xml:lang="en">Down-Regulation</dc:subject>
          <dc:subject xml:lang="en">Endoplasmic Reticulum Stress</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Gene Expression</dc:subject>
          <dc:subject xml:lang="en">Glucose</dc:subject>
          <dc:subject xml:lang="en">HEK293 Cells</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Microscopy, Confocal</dc:subject>
          <dc:subject xml:lang="en">Neurons</dc:subject>
          <dc:subject xml:lang="en">Oxygen</dc:subject>
          <dc:subject xml:lang="en">Protein Binding</dc:subject>
          <dc:subject xml:lang="en">Rats</dc:subject>
          <dc:subject xml:lang="en">Rats, Wistar</dc:subject>
          <dc:subject xml:lang="en">Receptors, GABA-B</dc:subject>
          <dc:subject xml:lang="en">Reverse Transcriptase Polymerase Chain Reaction</dc:subject>
          <dc:subject xml:lang="en">Transcription Factor CHOP</dc:subject>
          <dc:title xml:lang="en">Ischemia-like oxygen and glucose deprivation mediates down-regulation of cell surface γ-aminobutyric acidB receptors via the endoplasmic reticulum (ER) stress-induced transcription factor CCAAT/enhancer-binding protein (C/EBP)-homologous protein (CHOP).</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12777</identifier>
        <datestamp>2025-10-24T20:49:10Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Csomor PA</dc:creator>
          <dc:creator>Preller KH</dc:creator>
          <dc:creator>Geyer MA</dc:creator>
          <dc:creator>Studerus E</dc:creator>
          <dc:creator>Huber T</dc:creator>
          <dc:creator>Vollenweider FX</dc:creator>
          <dc:date>2014</dc:date>
          <dc:description xml:lang="en">Despite advances in the treatment of schizophrenia spectrum disorders with atypical antipsychotics (AAPs), there is still need for compounds with improved efficacy/side-effect ratios. Evidence from challenge studies suggests that the assessment of gating functions in humans and rodents with naturally low-gating levels might be a useful model to screen for novel compounds with antipsychotic properties. To further evaluate and extend this translational approach, three AAPs were examined. Compounds without antipsychotic properties served as negative control treatments. In a placebo-controlled, within-subject design, healthy males received either single doses of aripiprazole and risperidone (n=28), amisulpride and lorazepam (n=30), or modafinil and valproate (n=30), and placebo. Prepulse inhibiton (PPI) and P50 suppression were assessed. Clinically associated symptoms were evaluated using the SCL-90-R. Aripiprazole, risperidone, and amisulpride increased P50 suppression in low P50 gaters. Lorazepam, modafinil, and valproate did not influence P50 suppression in low gaters. Furthermore, low P50 gaters scored significantly higher on the SCL-90-R than high P50 gaters. Aripiprazole increased PPI in low PPI gaters, whereas modafinil and lorazepam attenuated PPI in both groups. Risperidone, amisulpride, and valproate did not influence PPI. P50 suppression in low gaters appears to be an antipsychotic-sensitive neurophysiologic marker. This conclusion is supported by the association of low P50 suppression and higher clinically associated scores. Furthermore, PPI might be sensitive for atypical mechanisms of antipsychotic medication. The translational model investigating differential effects of AAPs on gating in healthy subjects with naturally low gating can be beneficial for phase II/III development plans by providing additional information for critical decision making.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12777</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1038/npp.2014.102</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/24801767</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. - 2014</dc:source>
          <dc:subject xml:lang="en">Acoustic Stimulation</dc:subject>
          <dc:subject xml:lang="en">Amisulpride</dc:subject>
          <dc:subject xml:lang="en">Antipsychotic Agents</dc:subject>
          <dc:subject xml:lang="en">Aripiprazole</dc:subject>
          <dc:subject xml:lang="en">Auditory Perception</dc:subject>
          <dc:subject xml:lang="en">Benzhydryl Compounds</dc:subject>
          <dc:subject xml:lang="en">Brain</dc:subject>
          <dc:subject xml:lang="en">Double-Blind Method</dc:subject>
          <dc:subject xml:lang="en">Electroencephalography</dc:subject>
          <dc:subject xml:lang="en">Electromyography</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Lorazepam</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Modafinil</dc:subject>
          <dc:subject xml:lang="en">Piperazines</dc:subject>
          <dc:subject xml:lang="en">Prepulse Inhibition</dc:subject>
          <dc:subject xml:lang="en">Psychometrics</dc:subject>
          <dc:subject xml:lang="en">Psychotropic Drugs</dc:subject>
          <dc:subject xml:lang="en">Quinolones</dc:subject>
          <dc:subject xml:lang="en">Risperidone</dc:subject>
          <dc:subject xml:lang="en">Sensory Gating</dc:subject>
          <dc:subject xml:lang="en">Sulpiride</dc:subject>
          <dc:subject xml:lang="en">Valproic Acid</dc:subject>
          <dc:subject xml:lang="en">Young Adult</dc:subject>
          <dc:title xml:lang="en">Influence of aripiprazole, risperidone, and amisulpride on sensory and sensorimotor gating in healthy 'low and high gating' humans and relation to psychometry.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12738</identifier>
        <datestamp>2025-10-24T20:49:06Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Müller M</dc:creator>
          <dc:creator>Schlagenhauf P</dc:creator>
          <dc:date>2014</dc:date>
          <dc:description xml:lang="en">OBJECTIVES
Since the initial discovery of Plasmodium knowlesi in Malaysia, cases have been reported from several neighbouring countries. Tourism has also resulted in an increasing number of cases diagnosed in Europe, America, and Oceania. In this review we focus on the risk of the travel-associated acquisition of P. knowlesi malaria.


METHODS
A search of the literature in PubMed was carried out to identify articles and literature on the distribution of P. knowlesi infections in Southeast Asia and details of its acquisition and importation by travellers to other continents. The cut-off date for the search was December 1, 2013. Search words used were: "Plasmodium knowlesi", "Plasmodium knowlesi infections", "Plasmodium knowlesi travellers", "Plasmodium knowlesi prevalence", "Plasmodium knowlesi host", "Plasmodium knowlesi vector" "Plasmodium knowlesi RDT", and "Plasmodium knowlesi Malaysia". Traveller numbers to Malaysia were obtained from the Tourism Malaysia website.


RESULTS
A total of 103 articles were found. Using a selection of these and others identified from the reference lists of the papers, we based our review on a total of 66 articles.


RESULTS
P. knowlesi malaria appears to be the most common malaria species in Malaysian Borneo and is also widely distributed on the Malaysian mainland. Furthermore, locally transmitted cases of P. knowlesi malaria have been reported in Thailand, the Philippines, Vietnam, Singapore, Myanmar, Indonesian Borneo, and Cambodia. Two cases have been reported from non-endemic countries in Asia (Japan and Taiwan) in people with a history of travel to Malaysia and the Philippines. Twelve cases were imported to their home countries by travellers from other continents: two from the USA, two from the Netherlands, two from Germany, and one each from Spain, France, Sweden, Finland, Australia, and New Zealand. In most cases, the infection was associated with a trip to or near forested areas. The symptoms were fever (n=12), headache (n=6), chills (n=6), nausea (n=4), myalgia (n=3), back pain (n=3), abdominal problems (n=1), anorexia (n=2), fatigue (n=2), malaise (n=1), arthralgia (n=1), sore throat (n=1) vomiting (n=2), and jaundice (n=1). All patients were treated successfully with currently available antimalaria treatments. The identification of the pathogen by microscopy can be problematic due to the morphological similarity of P. knowlesi to Plasmodium malariae.


CONCLUSION
P. knowlesi appears to be a threat not only to the local population in Malaysia, but also to the estimated 25 million annual tourists and occupational travellers to Malaysia, especially those who visit rural, forested areas of the country. The P. knowlesi risk is not limited to Malaysia, and travellers from Southeast Asia presenting with possible malaria should be considered for a diagnostic work-up that includes P. knowlesi.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12738</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.ijid.2013.12.016</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/24631521</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. - 2014</dc:source>
          <dc:subject xml:lang="en">Malaysia</dc:subject>
          <dc:subject xml:lang="en">Plasmodium knowlesi</dc:subject>
          <dc:subject xml:lang="en">Southeast Asia</dc:subject>
          <dc:subject xml:lang="en">Travellers</dc:subject>
          <dc:subject xml:lang="en">Adult</dc:subject>
          <dc:subject xml:lang="en">Animals</dc:subject>
          <dc:subject xml:lang="en">Antimalarials</dc:subject>
          <dc:subject xml:lang="en">Asia, Southeastern</dc:subject>
          <dc:subject xml:lang="en">Child</dc:subject>
          <dc:subject xml:lang="en">Diagnosis, Differential</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Macaca fascicularis</dc:subject>
          <dc:subject xml:lang="en">Malaria</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Plasmodium knowlesi</dc:subject>
          <dc:subject xml:lang="en">Plasmodium malariae</dc:subject>
          <dc:subject xml:lang="en">Travel</dc:subject>
          <dc:title xml:lang="en">Plasmodium knowlesi in travellers, update 2014.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12732</identifier>
        <datestamp>2025-10-24T20:49:06Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Beyer C</dc:creator>
          <dc:creator>Huang J</dc:creator>
          <dc:creator>Beer J</dc:creator>
          <dc:creator>Zhang Y</dc:creator>
          <dc:creator>Palumbo-Zerr K</dc:creator>
          <dc:creator>Zerr P</dc:creator>
          <dc:creator>Distler A</dc:creator>
          <dc:creator>Dees C</dc:creator>
          <dc:creator>Maier C</dc:creator>
          <dc:creator>Munoz L</dc:creator>
          <dc:creator>Krönke G</dc:creator>
          <dc:creator>Uderhardt S</dc:creator>
          <dc:creator>Distler O</dc:creator>
          <dc:creator>Jones S</dc:creator>
          <dc:creator>Rose-John S</dc:creator>
          <dc:creator>Oravecz T</dc:creator>
          <dc:creator>Schett G</dc:creator>
          <dc:creator>Distler JH</dc:creator>
          <dc:date>2015</dc:date>
          <dc:description xml:lang="en">OBJECTIVES
To investigate the role of liver X receptors (LXRs) in experimental skin fibrosis and evaluate their potential as novel antifibrotic targets.


METHODS
We studied the role of LXRs in bleomycin-induced skin fibrosis, in the model of sclerodermatous graft-versus-host disease (sclGvHD) and in tight skin-1 (Tsk-1) mice, reflecting different subtypes of fibrotic disease. We examined both LXR isoforms using LXRα-, LXRβ- and LXR-α/β-double-knockout mice. Finally, we investigated the effects of LXRs on fibroblasts and macrophages to establish the antifibrotic mode of action of LXRs.


RESULTS
LXR activation by the agonist T0901317 had antifibrotic effects in bleomycin-induced skin fibrosis, in the sclGvHD model and in Tsk-1 mice. The antifibrotic activity of LXRs was particularly prominent in the inflammation-driven bleomycin and sclGvHD models. LXRα-, LXRβ- and LXRα/β-double-knockout mice showed a similar response to bleomycin as wildtype animals. Low levels of the LXR target gene ABCA-1 in the skin of bleomycin-challenged and control mice suggested a low baseline activation of the antifibrotic LXR signalling, which, however, could be specifically activated by T0901317. Fibroblasts were not the direct target cells of LXRs agonists, but LXR activation inhibited fibrosis by interfering with infiltration of macrophages and their release of the pro-fibrotic interleukin-6.


CONCLUSIONS
We identified LXRs as novel targets for antifibrotic therapies, a yet unknown aspect of these nuclear receptors. Our data suggest that LXR activation might be particularly effective in patients with inflammatory disease subtypes. Activation of LXRs interfered with the release of interleukin-6 from macrophages and, thus, inhibited fibroblast activation and collagen release.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12732</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1136/annrheumdis-2013-204401</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/24618263</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>Annals of the rheumatic diseases. - 2015</dc:source>
          <dc:subject xml:lang="en">Fibroblasts</dc:subject>
          <dc:subject xml:lang="en">Systemic Sclerosis</dc:subject>
          <dc:subject xml:lang="en">Treatment</dc:subject>
          <dc:subject xml:lang="en">Animals</dc:subject>
          <dc:subject xml:lang="en">Antibiotics, Antineoplastic</dc:subject>
          <dc:subject xml:lang="en">Bleomycin</dc:subject>
          <dc:subject xml:lang="en">Disease Models, Animal</dc:subject>
          <dc:subject xml:lang="en">Fibroblasts</dc:subject>
          <dc:subject xml:lang="en">Fibrosis</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Hydrocarbons, Fluorinated</dc:subject>
          <dc:subject xml:lang="en">Interleukin-6</dc:subject>
          <dc:subject xml:lang="en">Liver X Receptors</dc:subject>
          <dc:subject xml:lang="en">Macrophages</dc:subject>
          <dc:subject xml:lang="en">Mice</dc:subject>
          <dc:subject xml:lang="en">Mice, Knockout</dc:subject>
          <dc:subject xml:lang="en">Orphan Nuclear Receptors</dc:subject>
          <dc:subject xml:lang="en">Scleroderma, Diffuse</dc:subject>
          <dc:subject xml:lang="en">Skin</dc:subject>
          <dc:subject xml:lang="en">Skin Diseases</dc:subject>
          <dc:subject xml:lang="en">Sulfonamides</dc:subject>
          <dc:title xml:lang="en">Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12624</identifier>
        <datestamp>2025-10-24T20:48:56Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Wolfram L</dc:creator>
          <dc:creator>Fischbeck A</dc:creator>
          <dc:creator>Frey-Wagner I</dc:creator>
          <dc:creator>Wojtal KA</dc:creator>
          <dc:creator>Lang S</dc:creator>
          <dc:creator>Fried M</dc:creator>
          <dc:creator>Vavricka SR</dc:creator>
          <dc:creator>Hausmann M</dc:creator>
          <dc:creator>Rogler G</dc:creator>
          <dc:date>2013</dc:date>
          <dc:description xml:lang="en">The chaperone function of the ER-residing heat shock protein gp96 plays an important role in protein physiology and has additionally important immunological functions due to its peptide-binding capacity. Low amounts of gp96 stimulate immunity; high quantities induce tolerance by mechanisms not fully understood. A lack of gp96 protein in intestinal macrophages (IMACs) from Crohn`s disease (CD) patients correlates with loss of tolerance against the host gut flora, leading to chronic inflammation. Since gp96 shows dose-dependent direction of immunological reactions, we studied primary IMACs and developed cell models to understand the regulation of gp96 expression. Induction of gp96-expression was higher in in vitro differentiated dendritic cells (i.v.DCs) than in in vitro differentiated macrophages (i.v.MACs), whereas monocytes (MOs) expressed only low gp96 levels. The highest levels of expression were found in IMACs. Lipopolysaccharide (LPS), muramyl dipeptide (MDP), tumour necrosis factor (TNF), and Interleukin (IL)-4 induced gp96-expression, while IL12, IL-17, IL-23 and interferon (IFN)-γ were not effective indicating that Th1 and Th17 cells are probably not involved in the induction of gp96. Furthermore, gp96 was able to induce its own expression. The ER-stress inducer tunicamycin increased gp96-expression in a concentration- and time-dependent manner. Both ulcerative colitis (UC) and CD patients showed significantly elevated gp96 mRNA levels in intestinal biopsies which correlated positively with the degree of inflammation of the tissue. Since gp96 is highly expressed on the one hand upon stress induction as during inflammation and on the other hand possibly mediating tolerance, these results will help to understand the whether gp96 plays a role in the pathophysiology of inflammatory bowel disease (IBD).</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12624</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1371/journal.pone.0076350</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/24146856</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>PloS one. - 2013</dc:source>
          <dc:subject xml:lang="en">Acetylmuramyl-Alanyl-Isoglutamine</dc:subject>
          <dc:subject xml:lang="en">Biopsy</dc:subject>
          <dc:subject xml:lang="en">Case-Control Studies</dc:subject>
          <dc:subject xml:lang="en">Cell Differentiation</dc:subject>
          <dc:subject xml:lang="en">Cell Wall</dc:subject>
          <dc:subject xml:lang="en">Cells, Cultured</dc:subject>
          <dc:subject xml:lang="en">Dendritic Cells</dc:subject>
          <dc:subject xml:lang="en">Endoplasmic Reticulum Stress</dc:subject>
          <dc:subject xml:lang="en">Gene Expression Regulation</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Ileum</dc:subject>
          <dc:subject xml:lang="en">Immunity, Innate</dc:subject>
          <dc:subject xml:lang="en">Inflammatory Bowel Diseases</dc:subject>
          <dc:subject xml:lang="en">Lipopolysaccharides</dc:subject>
          <dc:subject xml:lang="en">Macrophages</dc:subject>
          <dc:subject xml:lang="en">Membrane Glycoproteins</dc:subject>
          <dc:subject xml:lang="en">Monocytes</dc:subject>
          <dc:subject xml:lang="en">RNA, Messenger</dc:subject>
          <dc:subject xml:lang="en">Tumor Necrosis Factor-alpha</dc:subject>
          <dc:subject xml:lang="en">Up-Regulation</dc:subject>
          <dc:title xml:lang="en">Regulation of the expression of chaperone gp96 in macrophages and dendritic cells.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12660</identifier>
        <datestamp>2025-10-24T20:48:58Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Scharl M</dc:creator>
          <dc:creator>Frei P</dc:creator>
          <dc:creator>Frei SM</dc:creator>
          <dc:creator>Biedermann L</dc:creator>
          <dc:creator>Weber A</dc:creator>
          <dc:creator>Rogler G</dc:creator>
          <dc:date>2014</dc:date>
          <dc:description xml:lang="en">Anal adenocarcinomas arising from perianal fistulae represent a rare complication in Crohn's disease (CD) patients. We have previously demonstrated the involvement of an epithelial-to-mesenchymal transition (EMT) in the pathogenesis of CD-associated fistulae. Although EMT has also been implicated in the development of colorectal and anal carcinoma, the molecular link from fistula to carcinoma is unclear. We present a case of a 48-year-old White woman who developed a mucinous anal adenocarcinoma originating from a perianal, CD-associated fistula 24 years after being diagnosed with CD. To characterize the expression of EMT-associated molecules in fistula and carcinoma tissue, immunohistochemical analysis for Snail1, Slug, β-catenin and E-cadherin was performed. A mucinous anal adenocarcinoma developed on a perianal fistula in a patient with long-standing CD. After neoadjuvant radiochemotherapy, the fistula-associated tumour was resected and the patient is presently in remission. Using immunohistochemical analysis, we detected a remarkable staining of the Slug transcription factor in transitional cells lining the fistula tract. This observation is unique to this 'carcinoma'-fistula: we had previously shown Slug expression in cells surrounding the fistula tract but not in transitional cells. Expression of Snail1, β-catenin and E-cadherin in this case was comparable with our previous findings. We describe a rare case of a CD fistula-associated adenocarcinoma within an area of squamous epithelium of the perianal area and an unusual expression pattern of EMT markers in this fistula. This case seems to underline the relevance of our previous findings demonstrating that EMT plays an important role for fistula pathogenesis and likely carcinogenesis in CD patients.</dc:description>
          <dc:format>application/pdf</dc:format>
          <dc:identifier>https://sonar.ch/global/documents/12660</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1097/MEG.0b013e32836371a2</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/24284372</dc:relation>
          <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
          <dc:source>European journal of gastroenterology &amp; hepatology. - 2014</dc:source>
          <dc:subject xml:lang="en">Adenocarcinoma, Mucinous</dc:subject>
          <dc:subject xml:lang="en">Antigens, CD</dc:subject>
          <dc:subject xml:lang="en">Anus Neoplasms</dc:subject>
          <dc:subject xml:lang="en">Biomarkers, Tumor</dc:subject>
          <dc:subject xml:lang="en">Cadherins</dc:subject>
          <dc:subject xml:lang="en">Chemoradiotherapy, Adjuvant</dc:subject>
          <dc:subject xml:lang="en">Colonoscopy</dc:subject>
          <dc:subject xml:lang="en">Crohn Disease</dc:subject>
          <dc:subject xml:lang="en">Endosonography</dc:subject>
          <dc:subject xml:lang="en">Epithelial-Mesenchymal Transition</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Magnetic Resonance Imaging</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Neoadjuvant Therapy</dc:subject>
          <dc:subject xml:lang="en">Rectal Fistula</dc:subject>
          <dc:subject xml:lang="en">Snail Family Transcription Factors</dc:subject>
          <dc:subject xml:lang="en">Transcription Factors</dc:subject>
          <dc:subject xml:lang="en">Treatment Outcome</dc:subject>
          <dc:subject xml:lang="en">beta Catenin</dc:subject>
          <dc:title xml:lang="en">Epithelial-to-mesenchymal transition in a fistula-associated anal adenocarcinoma in a patient with long-standing Crohn's disease.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12670</identifier>
        <datestamp>2025-10-24T20:49:00Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Gerschütz A</dc:creator>
          <dc:creator>Heinsen H</dc:creator>
          <dc:creator>Grünblatt E</dc:creator>
          <dc:creator>Wagner AK</dc:creator>
          <dc:creator>Bartl J</dc:creator>
          <dc:creator>Meissner C</dc:creator>
          <dc:creator>Fallgatter AJ</dc:creator>
          <dc:creator>Al-Sarraj S</dc:creator>
          <dc:creator>Troakes C</dc:creator>
          <dc:creator>Ferrer I</dc:creator>
          <dc:creator>Arzberger T</dc:creator>
          <dc:creator>Deckert J</dc:creator>
          <dc:creator>Riederer P</dc:creator>
          <dc:creator>Fischer M</dc:creator>
          <dc:creator>Tatschner T</dc:creator>
          <dc:creator>Monoranu CM</dc:creator>
          <dc:date>2014</dc:date>
          <dc:description xml:lang="en">The hallmarks of sporadic Alzheimer's disease (AD) are extracellular amyloid deposits, intracellular neurofibrillary tangles (NFTs), and neuronal death. Hyperphosphorylation of tau is a key factor in the generation of NFTs. Mitogen activated protein kinase 1 (MAPK1) and protein kinase C beta (PRKCB) are thought to play a role in hyperphosphorylation, and PRCKB is thought to be involved in hypoxic stress and vascular dysfunction, and to trigger MAPK phosphorylation pathways. We performed single-cell analyses of neurons with different vulnerabilities to AD-related changes. Using quantitative PCR (qPCR), we measured the levels of MAPK1 and PRKCB transcript in CA1 (high vulnerability), CA2 pyramidal cells from the hippocampus, granule cells from the cerebellum (low vulnerability), and neurons from the brain stem (nucleus tractus spinalis nervi trigemini, characterized by early neurophysiological deficits) at progressive Braak stages compared to age-matched controls. The highly vulnerable CA1 pyramidal neurons were characterized by age- and disease-unrelated increases in PRCKB levels and by age- and disease-related increases in MAPK1 levels. In contrast, low PRKCB levels were found in CA2 pyramidal neurons, and MAPK1 levels were elevated in controls and intermediate AD stages. Both PRKCB and MAPK1 were increased in the late AD stages. MAPK1 and PRKCB levels were low in the brainstem and cerebellum. We propose that alterations in the expression of these two genes occur early in the pathogenesis of AD in a region-specific manner. In addition, multiple signal transduction pathways need to be affected to result in AD instead of physiological aging.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/12670</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.3233/JAD-131280</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/24334724</dc:relation>
          <dc:source>Journal of Alzheimer's disease : JAD. - 2014</dc:source>
          <dc:subject xml:lang="en">Alzheimer's disease</dc:subject>
          <dc:subject xml:lang="en">MAPK1</dc:subject>
          <dc:subject xml:lang="en">PRKCB</dc:subject>
          <dc:subject xml:lang="en">neurodegeneration</dc:subject>
          <dc:subject xml:lang="en">selective vulnerability</dc:subject>
          <dc:subject xml:lang="en">signal transduction pathway</dc:subject>
          <dc:subject xml:lang="en">Age Factors</dc:subject>
          <dc:subject xml:lang="en">Aged</dc:subject>
          <dc:subject xml:lang="en">Aged, 80 and over</dc:subject>
          <dc:subject xml:lang="en">Alzheimer Disease</dc:subject>
          <dc:subject xml:lang="en">Brain</dc:subject>
          <dc:subject xml:lang="en">Female</dc:subject>
          <dc:subject xml:lang="en">Gene Expression Regulation</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Laser Capture Microdissection</dc:subject>
          <dc:subject xml:lang="en">Male</dc:subject>
          <dc:subject xml:lang="en">Middle Aged</dc:subject>
          <dc:subject xml:lang="en">Mitogen-Activated Protein Kinase 1</dc:subject>
          <dc:subject xml:lang="en">Neurons</dc:subject>
          <dc:subject xml:lang="en">Protein Kinase C beta</dc:subject>
          <dc:subject xml:lang="en">RNA, Messenger</dc:subject>
          <dc:subject xml:lang="en">Signal Transduction</dc:subject>
          <dc:title xml:lang="en">Neuron-specific alterations in signal transduction pathways associated with Alzheimer's disease.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <record>
      <header>
        <identifier>oai:sonar.ch:12686</identifier>
        <datestamp>2025-10-24T20:49:02Z</datestamp>
      </header>
      <metadata>
        <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:creator>Roesslein M</dc:creator>
          <dc:creator>Froehlich C</dc:creator>
          <dc:creator>Jans F</dc:creator>
          <dc:creator>Piegeler T</dc:creator>
          <dc:creator>Goebel U</dc:creator>
          <dc:creator>Loop T</dc:creator>
          <dc:date>2014</dc:date>
          <dc:description xml:lang="en">AIMS
Dobutamine is cytoprotective when applied before a subsequent stress. However, the underlying molecular mechanism is unknown. Dobutamine also inhibits nuclear factor (NF)-κB in human T lymphocytes. Other inhibitors of NF-κB induce a so-called heat shock response. We hypothesized that dobutamine mediates protection from apoptotic cell death by the induction of a heat shock response.


MAIN METHODS
Jurkat T lymphoma cells were preincubated with dobutamine (0.1, 0.5 mM) before the induction of apoptosis (staurosporine, 2 μM). DNA-binding of heat shock factor (HSF)-1 was analyzed by electrophoretic mobility shift assay, mRNA-expression of heat shock protein (hsp)70 and hsp90 by Northern Blot, activity of caspase-3 by fluorogenic caspase activity assay and cleavage of pro-caspase-3 by Western Blot. Apoptosis was assessed by flow cytometry after annexin V-fluorescein isothiocyanate staining. Hsp70 and hsp90 were inhibited using N-formyl-3,4-methylenedioxy-benzylidene-gamma-butyrolaetam and 17-allylamino-17-demethoxygeldana-mycin, respectively. All data are given as median and 25/75% percentile.


KEY FINDINGS
Pre-incubation with dobutamine inhibited staurosporine-induced annexin V-fluorescence (28 [20-32] % vs. 12 [9-15] % for dobutamine 0.1 mM and 7 [5-12] % for dobutamine 0.5 mM, p&lt;0.001), cleavage of pro-caspase-3 as well as caspase-3-like activity (0.46 [0.40-0.48] vs. 0.32 [0.27-0.39] for Dobutamine 0.1 mM and 0.20 [0.19-0.23] for Dobutamine 0.5 mM, p&lt;0.01). Dobutamine induced DNA-binding of HSF-1 and mRNA-expression of hsp70 and hsp90. While inhibition of Hsp90 had no effect, inhibition of Hsp70 increased the number of annexin V-positive cells (33 [32-36] % vs. 18 [16-24] %) and caspase-3-like activity (0.21 [0.19-0.23] vs. 0.16 [0.13-0.17], p&lt;0.05).


SIGNIFICANCE
Dobutamine protects from apoptotic cell death via the induction of Hsp70.</dc:description>
          <dc:identifier>https://sonar.ch/global/documents/12686</dc:identifier>
          <dc:language>eng</dc:language>
          <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.lfs.2014.01.005</dc:relation>
          <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/24447628</dc:relation>
          <dc:source>Life sciences. - 2014</dc:source>
          <dc:subject xml:lang="en">Apoptosis</dc:subject>
          <dc:subject xml:lang="en">Dobutamine</dc:subject>
          <dc:subject xml:lang="en">Dobutamine hydrochloride (PubChem CID: 65324)</dc:subject>
          <dc:subject xml:lang="en">Heat shock protein 70</dc:subject>
          <dc:subject xml:lang="en">Heat shock response</dc:subject>
          <dc:subject xml:lang="en">Protection</dc:subject>
          <dc:subject xml:lang="en">Adrenergic beta-1 Receptor Agonists</dc:subject>
          <dc:subject xml:lang="en">Apoptosis</dc:subject>
          <dc:subject xml:lang="en">Blotting, Northern</dc:subject>
          <dc:subject xml:lang="en">Cell Line, Tumor</dc:subject>
          <dc:subject xml:lang="en">Cytoprotection</dc:subject>
          <dc:subject xml:lang="en">Dobutamine</dc:subject>
          <dc:subject xml:lang="en">Electrophoresis, Polyacrylamide Gel</dc:subject>
          <dc:subject xml:lang="en">Flow Cytometry</dc:subject>
          <dc:subject xml:lang="en">Gene Expression Regulation</dc:subject>
          <dc:subject xml:lang="en">HSP70 Heat-Shock Proteins</dc:subject>
          <dc:subject xml:lang="en">Humans</dc:subject>
          <dc:subject xml:lang="en">Protein-Serine-Threonine Kinases</dc:subject>
          <dc:subject xml:lang="en">RNA, Messenger</dc:subject>
          <dc:subject xml:lang="en">Real-Time Polymerase Chain Reaction</dc:subject>
          <dc:title xml:lang="en">Dobutamine mediates cytoprotection by induction of heat shock protein 70 in vitro.</dc:title>
          <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
        </oai_dc:dc>
      </metadata>
    </record>
    <resumptionToken expirationDate="2026-08-02T10:57:20Z" cursor="0" completeListSize="324118">.eJytzM9ugjAcAOB36ZkstNIsJfGwP5ZoAipQsFxM4VfR0IoRjDrju89s980D3wN8N9RpDch3XygmI0Jcxhgl3itlDjqoWiOfOKg5q2PdIf-GrO4VqF4tjnqzuyAftWq3hgrdHdRVx9aY9e6RIR6YkyQXXATZRhJ2giDzgDMMuWk-9xwXqxnNgq0pm8JAELUf74UHzTbOU04Un3UJARvavk1JliXuYfT2Qyz4eZKnX7FX5pEILU1C0Xta8IleVS64fASXZ5_lQM90oCcc6BEDPfK_J5U5m8sEzwWONktivFJEuBQ0lQ2Nfx9o3VOVRwG2qTXTJeFJecVSrHgMe36NbaSef-q_n_N4jO7fZu7lSA.am8iVA.lHlMaigMuJOHJd6J8h_Xb0Q8BsI</resumptionToken>
  </ListRecords>
</OAI-PMH>
